

US00RE45968E

(19) **United States**  
 (12) **Reissued Patent**  
 Minenkova et al.

(10) **Patent Number:** **US RE45,968 E**  
 (45) **Date of Reissued Patent:** **Apr. 12, 2016**

(54) **VECTOR FOR EFFICIENT SELECTION  
 AND/OR MATURATION OF AN ANTIBODY  
 AND USES THEREOF**

WO 2005/118647 12/2005  
 WO 2007/074496 7/2007  
 WO 2012/001004 1/2012

## OTHER PUBLICATIONS

(71) Applicant: **SIGMA TAU INDUSTRIE  
 FARMACEUTICHE RIUNITE S.p.A.**,  
 Rome (IT)

Restriction Requirement issued for U.S. Appl. No. 12/097,876, filed Jun. 17, 2008, in the name of Olga Minenkova et al., mailed on Oct. 28, 2009.

(72) Inventors: **Olga Minenkova**, Montecompatri (IT);  
**Emiliano Pavoni**, Grottaferrata (IT)

Non-Final Office Action issued for U.S. Appl. No. 12/097,876, filed Jun. 17, 2008, in the name of Olga Minenkova et al., mailed on Jun. 3, 2010.

(73) Assignee: **SIGMA TAU INDUSTRIE  
 FARMACEUTICHE RIUNITE S.P.A.**,  
 Rome (IT)

Final Office Action issued for U.S. Appl. No. 12/097,876, filed Jun. 17, 2008, in the name of Olga Minenkova et al., mailed on Jan. 18, 2011.

(21) Appl. No.: **13/831,258**

Notice of Allowance issued for U.S. Appl. No. 12/097,876, filed Jun. 17, 2008, in the name of Olga Minenkova et al., mailed on May 13, 2011.

(22) Filed: **Mar. 14, 2013**

Barbas, C.F. III et al., *Phage-display vectors* in Phage Display: A Laboratory Manual Cold Spring Harbor Laboratory Press, 2001, pp. 2.1-2.19, ISSN: 0-87969-546-3.

## Related U.S. Patent Documents

Reissue of:

(64) Patent No.: **8,003,383**  
 Issued: **Aug. 23, 2011**  
 Appl. No.: **12/097,876**  
 PCT Filed: **Dec. 27, 2006**  
 PCT No.: **PCT/IT2006/000876**  
 § 371 (c)(1),  
 (2) Date: **Jun. 17, 2008**  
 PCT Pub. No.: **WO2007/074496**  
 PCT Pub. Date: **Jul. 5, 2007**

Barbas, CF., et al., Phage Display: A Laboratory Manual 2001, Cold Spring Harbor Laboratory Press, New York, pp. IV-XVI, 1.1.

Hansen, M.H. et al., *The tumor-infiltrating B cell response in medullary breast cancer is oligoclonal and directed against the autoantigen actin exposed on the surface of apoptotic cancer cells*, PNAS vol. 98, No. 22, pp. 12659-12664 (Oct. 23, 2001).

Bernstein et al., Defective humoral immunity in pediatric immune deficiency syndrome acquired, J. Pediatrics 1985, 107: 352-357.

Clark et al., Bacterial viruses as human vaccines, Expert Rev. Vaccines 2004, 3: 463-476.

Clark et al., Bacterial Pathogenesis Part B: Interaction of Pathogenic Bacteria with Host Cells, Methods in Enzymology 1994, 236: 211-231.

Dente et al., Monoclonal antibodies that recognize filamentous phage: tools for phage: display technology, Gene 1994, 148: 7-13.

Esposito et al., Immunogenicity and therapeutic efficacy of phage-displayed beta-amyloid epitopes, Mol. Immuno. 2008, 45: 1056-1062.

Hawkins et al., Selection of phage antibodies by binding affinity mimicking affinity maturation, J. Mol. Biol. 1992, 226: 889-896.

Hooton et al., Diagnosis and treatment of uncomplicated urinary tract infection, Infectious Disease Clinics of North America 1997, 11: 551-581.

Hopkins et al., Vaginal Mucosal Vaccine for Recurrent Urinary Tract Infections in Women: Results of a Phase 2 Clinical Trial, J. Urology 2007, 177: 1349-1353.

Hopkins et al., Induction of Urinary Tract Infection by Intraurethral Inoculation with *Escherichia coli*: Refining the Murine Model, JID 1995, 171: 462-465.

Krieg, A., Lymphocyte activation by CpG dinucleotide motifs in prokaryotic DNA, Trends in Microbiol. 1996, 4: 73-77.

Langermann et al., Prevention of Mucosal *Escherichia coli* Infection by FimH-Adhesin-Based Systemic Vaccination, Science 1997, 276: 607-611.

Lidqvist et al., Phage display for site-specific immunization and characterization of high-risk human papillomavirus specific E7 monoclonal antibodies, J. Immunol. Methods 2008, 337: 88-96.

(Continued)

## (30) Foreign Application Priority Data

Dec. 27, 2005 (EP) ..... 05 028 501

(51) **Int. Cl.**  
**C07H 21/04** (2006.01)  
**C12P 21/08** (2006.01)  
**C12N 15/85** (2006.01)

(52) **U.S. Cl.**  
 CPC ..... **C12N 15/85** (2013.01)

(58) **Field of Classification Search**  
 None  
 See application file for complete search history.

## (56) References Cited

## U.S. PATENT DOCUMENTS

3,663,684 A 5/1972 Freedman et al.  
 6,856,208 B2 2/2005 Lee et al.  
 8,003,383 B2 8/2011 Minenkova et al.  
 2008/0241169 A1 10/2008 Solomon et al.  
 2008/0286274 A1\* 11/2008 Minenkova et al. .... 424/138.1

## FOREIGN PATENT DOCUMENTS

CA 2 286 301 5/2001  
 EP 1 452 599 9/2004  
 EP 1803814 7/2007  
 JP 2002/532058 10/2002  
 WO 90/11092 10/1990  
 WO 92/01047 1/1992  
 WO 93/11236 6/1993  
 WO 97/45544 12/1997  
 WO 01/36433 5/2001  
 WO 2005/042578 5/2005

Primary Examiner — Michael Burkhart

(74) Attorney, Agent, or Firm — Steinfl & Bruno LLP

## (57) ABSTRACT

It is described a vector suitable for efficient selection and/or maturation of a recombinant antibody characterized in that it contains at least one element able to reduce the expression level and/or has an improved efficiency of display of said recombinant antibody.

21 Claims, 19 Drawing Sheets

(56)

## References Cited

## OTHER PUBLICATIONS

Marvin, D.A., X-Ray Diffraction and Electron Microscope Studies on the Structure of the Small Filamentous Bacteriophage fd, *J. Mol. Biol.* 1966, 15: 8-17.

Das, P., Vaginal vaccine for recurrent urinary-tract infections, *The Lancet* 2002, 2: 68.

Parr et al., Immunity to vaginal infection by herpes simplex virus type 2 in adult mice: characterization of the immunoglobulins in vaginal mucus, *J. Reproductive Immunology* 1998, 38: 15-30.

Roy et al., Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy, *Nat. Med.* 1999, 4: 387-39.

Sambrook et al., *Molecular Cloning: A Laboratory Manual* 1989, Cold Spring Harbor Lab Press, pp. 1-3.

Sato et al., Immunostimulatory Dna sequences necessary for effective intradermal gene immunization, *Science* 1996, 273: 352-354.

Schulman et al., Oral immunotherapy of recurrent urinary tract infections: A double-blind placebo-controlled multicenter study, *J. Urology* 1993, 150: 917-921.

Stamm, W., Urinary tract infections, *Infectious Disease Clinics of North America* 2003, xiii-xiv.

Vieira et al., Production of Single-stranded Plasmid DNA, *Methods in Enzymology* 1987, 1253: 3-11.

Wedgwood et al., The recognition and classification of immunodeficiency disease with  $\phi$ X 174, *Birth Defects: Original Article Series* 1975, XI: 331-338.

Willis et al., Immunological properties of foreign peptides in multiple display on a filamentous bacteriophage, *Gene* 1993, 128: 79-83.

International Search Report for PCT Application PCT/EP2011/060839 filed on Jun. 28, 2011 in the name of Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Mail date: Aug. 12, 2011.

Written Opinion for PCT Application PCT/EP2011/060839 filed on Jun. 28, 2011 in the name of Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Mail date: Aug. 12, 2011.

Japanese Office Action for Japanese Patent Application No. 2008-548090 filed in the name of Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. Mail date: Apr. 26, 2013 (English Translation & Japanese Original).

Krebber, A. et al., Inclusion of an upstream transcriptional terminator in phage display vectors abolishes background expression of toxic fusions with coat protein g3p, *Gene*, vol. 178 1996, pp. 71-74.

Beekwilder, J. et al., A phagemid vector using the *E. coli* phage shock promoter facilitates phage display of toxic proteins, *Gene*, vol. 228 1999, pp. 23-31.

Schimmele, B. et al. Ribosome display of mammalian receptor domains. *Protein Engineering Design & Selection*, vol. 18 (6), 2005, pp. 285-294.

Sletta, H. et al. Broad-host-range plasmid pJB658 can be used for Industrial-Level Production of a Secreted Host-Toxic Single-Chain Antibody Fragment in *Escherichia coli*. *Applied and Environmental Microbiology*, Vol., vol. 70 (12), Dec. 2004, pp. 7033-7039.

Kotlan, B. et al. A scFv phage display mini library generated from the immunoglobulin repertoire of breast medullary carcinoma infiltrating B lymphocytes. *Disease Markers*, vol. 16, 2000, pp. 25-27.

Carlos F. Barbas et al. "Assembly of combinatorial antibody libraries on phage surfaces: The gene III site", *Proc Natl. Acad. Sci. USA* vol. 88, pp. 7978-7982 (Sep. 1991).

Franco Felici, et al. "Selection of antibody ligands from a large library of oligopeptides expressed on a multivalent exposition vector", *J. Mol. Bio.* 222, pp. 301-310 (1991).

Sten Hammarstrom, "The carcinoembryonic antigen (CEA) family: structures, suggested functions and expression in normal and malignant tissues," *Seminars in Cancer Biology*, vol. 9, pp. 67-81 (1999).

Margit H. Hansen et al. "Translocation of an intracellular antigen to the surface of medullary breast cancer cells early in apoptosis allows for antigen-driven antibody response elicited by tumor-infiltrating B Cells", *The Journal of Immunology* 169, pp. 2701-2711 (2002).

Satoru Imahayashi et al., "Tumor Infiltrating B-Cell-Derived IgG Recognizes Tumor Components in Human Lung Cancer", *Cancer Investigation* 18(6), pp. 530-536 (2000).

Erik S. Kass et al., "Carcinoembryonic antigen as a target for specific antitumor immunotherapy of head and neck cancer", *Cancer Research* 62, pp. 5049-5057 (Sep. 1, 2002).

Beatrix Kotlan et al., "Novel ganglioside antigen identified by B cells in human medullary breast carcinomas: The proof of principle concerning tumor infiltrating B lymphocytes", *The Journal of Immunology* 175, pp. 2278-2285 (2005).

Olga Minenkova et al., "Identification of Tumor-Associated Antigens by Screening Phage-Displayed Human cDNA Libraries with Sera From Tumor Patients", *Int. J. Cancer*, 2003, vol. 106, pp. 534-544.

Lucien Perey et al., "Effects of Differentiating Agents on Cell Surface Expression of the Breast Carcinoma-Associated DF3-P Epitope", *Cancer Research* 52, pp. 6365-6370 (Nov. 15, 1992).

John B. B. Ridgway et al. "Identification of a Human Anti-CD55 Single-Chain Fv by Subtractive Panning of a Phage Library Using Tumor and Nontumor Cell Lines", *Cancer Research* 59, pp. 2718-2723 (Jun. 1, 1999).

Rob C. Roovers et al. "Evidence for a bias toward intracellular antigens in the local humoral antitumor immune response of a colorectal cancer patient revealed by phage display", *Int. J. Cancer* 93, pp. 832-840 (2001).

A. Rothe et al. "Construction of phage display libraries from reactive lymph nodes of breast carcinoma patients and selection for specifically binding human single chain Fv on cell lines", *International Journal of Molecular Medicine*, vol. 14, pp. 729-735 (2004).

Brigitte Sanzey, "Modulation of Gene Expression by Drugs Affecting Deoxyribonucleic Acid Gyrase", *Journal of Bacteriology* vol. 138, No. 1, pp. 40-47 (Apr. 1979).

Mohsen Shadidi et al., "An Anti-leukemic single chain Fv antibody selected from a synthetic human phage antibody library", *Biochemical and Biophysical Research Communications* 280, pp. 548-552 (2001).

K. Sikora et al. "Human hybridomas from malignant gliomas", *The Lancet* vol. 1, Issue 8262, pp. 11-14(1982).

Donald B. Smith et al. "Single-step purification of polypeptides expressed in *Escherichia coli* as fusions with glutathione S-transferase", *Gene* 67, pp. 31-40 (1988).

Herbert D. Soule et al. "Isolation and characterization of a spontaneously immortalized human epithelial cell line, MCF-10", *Cancer Research* 50, pp. 6075-6086 (Sep. 15, 1990).

John A. Thompson et al. "Carcinoembryonic antigen gene family: Molecular biology and clinical perspectives", *Journal of Clinical Laboratory Analysis* 5, pp. 344-366 (1991).

Ming-Yan Xu et al., "Production of a human single chain-variable fragment antibody against esophageal carcinoma", *World J. Gastroenterol* 10(18), pp. 2619-2623 (2004).

Luciano Zardi et al., "Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon." *The EMBO Journal* vol. 6, No. 8, pp. 2337-2342 (1987).

Hua Zhang et al. "A human monoclonal antimelanoma single-chain Fv derived from tumor-infiltrating lymphocytes", *Cancer Research* 55, pp. 3584-3591 (Aug. 15, 1995).

European Search Report issued for European Application No. EP05028501.4 filed Dec. 27, 2005 in the name of Sigma-Tau. Mailed Aug. 18, 2006.

O'Connor, C., et al., Highly repressible expression system for cloning genes that specify potentially toxic proteins, *Journal of Bacteriology* 1987, 169: 4457-4462.

Kimata, K., et al., cAMP receptor protein-cAMP plays a crucial role in glucose-lactose diauxie by activating the major glucose transporter gene in *Escherichia coli*, *PNAS* 1997, 94: 12914-12919.

Richard J. Simpson, Chapter title "Characterization of protein complexes" in *Proteins and proteomics: A Laboratory Manual*, 2002, pp. 705.

Barbas III, CF., et al., *Phage Display: A Laboratory Manual* 2001, Cold Spring Harbor Laboratory Press, New York, pp. IV-XVI, 1.1.

PCT International Search Report for PCT/IT2006/000876 filed on Dec. 27, 2006 in the name of Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. et al. Mailed Nov. 13, 2007.

Jamie K. Scott et al., "Phage-display vectors" in *Phage Display: A Laboratory Manual* Cold Spring Harbor Laboratory Press; pp. 2.1-2.19, 2001 ISSN: 0-87969-546-3.

(56)

## References Cited

## OTHER PUBLICATIONS

- Emiliano Pavoni et al., "Identification of a panel of tumor-associated antigens from breast carcinoma cell lines, solid tumors and testis cDNA libraries displayed on lambda phage" in *BMC Cancer*, 4:78; Nov. 12, 2004.
- Germaine Fuh et al., "Efficient phage display of polypeptides fused to the carboxy-terminus of the M13 gene-3 minor coat protein" in *FEBS Letters*, vol. 480, pp. 231-234; 2000.
- Gregory A. Weiss et al. "Design and evolution of artificial M13 coat proteins" in *Journal of Molecular Biology*, vol. 300, No. 1, pp. 213-219, Jun. 30, 2000.
- Heike A. Held et al., "Comprehensive mutational analysis of the M13 major coat protein: improved scaffolds for C-terminal phage display" in *Journal of Molecular Biology*, vol. 340, No. 3, pp. 587-597, Jul. 9, 2004.
- S.G. Park et al. "Affinity maturation of natural antibody using a chain shuffling technique and the expression of recombinant antibodies in *Escherichia coli*" in *Biochem. Biophys. Res. Commun.*, 2000, vol. 275, No. 2, pp. 553-557; (Abstract).
- D. O'Connell et al. "Phage versus Phagemid Libraries for Generation of Human Monoclonal Antibodies" in *J. Molec. Biol.*, 2002, vol. 321, No. 1, pp. 49-56.
- International Preliminary Report on Patentability issued on Jul. 1, 2008, for PCT Application No. PCT/IT2006/000876 filed Dec. 27, 2006 in the name of Sigma-Tau.
- R.S. Williams et al., "Introduction of foreign genes into tissues of living mice by DNA-coated microprojectiles", *Proc. Natl. Acad. Sci. USA*, vol. 88, pp. 2726-2730, 1991.
- E.F. Fynan et al., "DNA vaccines: Protective immunizations by parenteral, mucosal, and gene-gun inoculations", *Proc. Natl. Acad. Sci. USA*, vol. 90, pp. 11478-11482, 1993.
- C.M. Bearden et al., "Rituximab inhibits the in vivo primary and secondary antibody response to a neoantigen, bacteriophage phiX174." *Am J Transplant*. Jan. 2005;5(1):50-7.
- C.K. Garofalo et al, "*Escherichia coli* from urine of female patients with urinary tract infections is competent for intracellular bacterial community formation." *Infect Immun*. Jan. 2007; 75(1):52-60.
- M.J. McCluskie et al., "CpG DNA is a potent enhancer of systemic and mucosal immune responses against hepatitis B surface antigen with intranasal administration to mice." *J Immunol*. Nov. 1, 1998; 161(9):4463-6.
- O.O. Minenkova, et al., "Design of specific immunogens using filamentous phage as the carrier." *Gene*. 1993; 128(1):85-8.
- I.U. Mysorekar, et al., "Mechanisms of uropathogenic *Escherichia coli* persistence and eradication from the urinary tract." *Proc Natl Acad Sci US A*. Sep. 19, 2006; 103(38):14170-5.
- K.G. Naber et al., "Immunoactive prophylaxis of recurrent urinary tract infections: a meta-analysis." *Int J Antimicrob Agents*. Feb. 2009; 33(2): 111-9.
- H.D. Ochs et al., "Immunologic responses to bacteriophage phi-X 174 in immunodeficiency diseases." *J Clin Invest*. Dec. 1971; 50(12):2559-68.
- T.V. Poggio et al., "Intranasal immunization with a recombinant truncated FimH adhesin adjuvanted with CpG oligodeoxynucleotides protects mice against uropathogenic *Escherichia coli* challenge." *Can J Microbiol*. 2006; 52(11):1093-102.
- C.S. Reigstad et al., "Functional genomic studies of uropathogenic *Escherichia coli* and host urothelial cells when intracellular bacterial communities are assembled." *J Biol Chem*. Jul. 20, 2007; 282(29):21259-67.
- V. Tchesnokova et al., "Integrin-like allosteric properties of the catch bond-forming FimH adhesin of *Escherichia coli*." *J Biol Chem*. Mar. 21, 2008;283(12):7823-33. Epub Jan. 3, 2008.
- K. Thankavel et al. "Localization of a domain in the FimH adhesin of *Escherichia coli* type 1 fimbriae capable of receptor recognition and use of a domain-specific antibody to confer protection against experimental urinary tract infection." *J Clin Invest*. Sep. 1, 1997;100(5): 1123-36.
- J. Clark et al., "Bacteriophages and biotechnology: vaccines, gene therapy and antibacterials." *Trends in Biotechnology*, May 2006, LNKd-PUBMED:16567009, vol. 24, No. 5; pp. 212-218.
- S. Langermann et al, "Vaccination utilizing the FimCH complex as a strategy to prevent *Escherichia coli* urinary tract infections." *The Journal of Infectious Diseases*, Mar. 1, 2001, LNKD-PUBMED:11171023, vol. 183 Suppl 1, pp. S84-S86.
- Sambrook J. et al. *Molecular cloning: A laboratory manual*, vol. 1, 2nd edition. Cold Spring Harbor: Cold Spring Harbor Laboratory Press; 1989: 4.17.
- Scott, J.K. et al. et al., "Phage-display vectors" in *Phage Display: A Laboratory Manual*, Cold Spring Harbor Press; pp. 2.1-2.19, 2001.
- Restriction Requirement mailed on Jun. 14, 2013 for U.S. Appl. No. 13/806,609, filed Jan. 30, 2013 in the name of Rita De Santis et al.
- Non-Final Office Action mailed on Jun. 14, 2013 for U.S. Appl. No. 13/806,609, filed Jan. 30, 2013 in the name of Rita De Santis et al.
- Greenspan, N.S. et al. "Defining epitopes: It's not as easy as it seems." *Nature Biotechnology*. vol. 17. Oct. 1999, pp. 936-937.
- Bowie, J.U. et al. "Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions." *Science*, New Series. vol. 247 (4948). Mar. 1990, pp. 1306-1310.
- Goldsmith, M.E. And Konigsberg, W.H. "Adsorption Protein of the Bacteriophage fd: Isolation, Molecular Properties, and Location in the Virus." *Biochemistry*, vol. 16, No. 12, pp. 2686-2694. 1977.
- Non-Final Office Action issued for U.S. Appl. No. 13/806,609, filed Jan. 30, 2013 in the name of Rita De Santis et al. Mail date: Dec. 27, 2013.
- Final Office Action issued for U.S. Appl. No. 13/806,609, filed Jan. 30, 2013 in the name of Rita De Santis et al. Mail date: Oct. 23, 2014.
- Marciano, D.K. et al. "An Aqueous Channel for Filamentous Phage Export." *Science*, vol. 284, pp. 1516-1519. May 1999.
- Scott et al. (Phage Display: A Laboratory Manual, Cold Spring Harbor Lab. Press, p. 2.1-2.19 (2001)).\*
- Park et al. (Biochem. Biophys. Res. Commun. Aug. 28, 2000;275(2):553-7; Abstract).\*
- O'Connell et al. (J. Molec. Biol. Aug. 2, 2002; 321(1):49-56).\*
- Carlos F. Barbas et al. "Assembly of combinatorial antibody libraries on phage surfaces: The gene III site", *Proc. Natl. Acad. Sci. USA* vol. 88, pp. 7978-7982 (Sep. 1991).
- J. Beekwilder et al. "A phagemid vector using the *E. coli* phage shock promoter facilitates phage display of toxic proteins", *GENE* 228, pp. 23-31 (1999).
- Elisa Beghetto et al. "Discovery of novel *Streptococcus pneumoniae* antigens by screening a whole genome-display library", *FEMS Microbiol Lett*. 262, pp. 14-21 (2006).
- S. B. Brown et al. "Catalytic activity of iron (III)-centered catalysts", *Biochem J*. 117, pp. 741-744 (1970).
- M. A. Clark et al. "Isolation of human anti-c-erbB-2 Fabs from a lymph node-derived phage display library", *Clin. Exp. Immunol* 109, pp. 166-174 (1997).
- Julia A. Coronella et al. "Antigen-driven oligoclonal expansion of tumor-infiltrating B cells in infiltrating ductal carcinoma of the breast", *The Journal of Immunology* 169, pp. 1829-1836 (2002).
- Julia A. Coronella et al. "Evidence for an antigen-driven humoral immune response in medullary ductal breast cancer", *Cancer Research* 61, pp. 7889-7899 (Nov. 1, 2001).
- Julia A. Coronella-Wood et al. "Naturally occurring B-cell responses to breast cancer", *Cancer Immunol Immunother* 52, pp. 715-738 (2003).
- J. O. Drife et al. "Immunoglobulin synthesis in the "resting" breast", *British Medical Journal* 2, pp. 503-506 (1976).
- Pat Edelmann et al. "Nonsense suppression context effects in *Escherichia coli* bacteriophage T4", *Mol. Gen. Genet*. 207, pp. 517-518 (1987).
- Franco Felici, "Selection of antibody ligands from a large library of oligopeptides expressed on a multivalent exposition vector", *J. Mol. Bio*. 222, pp. 301-310 (1991).
- Sten Hammarstrom, "The carcinoembryonic antigen (CEA) family" *Cancer Biology*, vol. 9, pp. 67-81 (1999).
- Margit H. Hansen, "Translocation of an intracellular antigen to the surface of medullary breast cancer cells early in apoptosis allows for antigen-driven antibody response elicited by tumor-infiltrating B Cells", *The Journal of Immunology* 169, pp. 2701-2711 (2002).

(56)

## References Cited

## OTHER PUBLICATIONS

- Margit H. Hansen et al. "The tumor-infiltrating B cell response in medullary breast cancer is oligoclonal and directed against the autoantigen actin exposed on the surface of apoptotic cancer cells", PNAS vol. 98, No. 22, pp. 12659-12664 (Oct. 23, 2001).
- Satoru Imahayashi et al., "Tumor infiltrating C-cell-derived IgG recognizes tumor components in human lung cancer", Cancer Investigation 18(6), pp. 530-536 (2000).
- Erik S. Kass et al., "Carcinoembryonic antigen as a target for specific antitumor immunotherapy of head and neck cancer", Cancer Research 62, pp. 5049-5457 (Sep. 1, 2001).
- Beatrix Kotlan et al., "Novel gangoslide antigen identified by B cells in human medullary breast carcinomas: The proof of principle concerning tumor infiltrating B lymphocytes", The Journal of Immunology 175, pp. 2278-2285 (2005).
- Titus Kretzschmar et al., "Evaluation of antibodies fused to minor coat protein III and major coat protein VIII of bacteriophage M13", GENE 155, pp. 61-65 (1995).
- Michael A. McGuckin et al. "Prognostic Significance of MUC1 Epithelial Mucin Expression in Breast Cancer", Human Pathology vol. 26, No. 4 pp. 432-439 (1995).
- Jeffrey H. Miller et al. "Effects of Surrounding Sequence on the Suppression of nonsense codons", J. Mol. Bio. 164, pp. 59-71 (1983).
- Philippa M. O'Brien, "Immunoglobulin genes expressed by B-lymphocytes infiltrating cervical carcinomas show evidence of antigen-driven selection", Cancer Immunol Immunother 50, pp. 523-532 (2001).
- Emilian Pavoni et al., "New display vector reduces biological bias for expression of antibodies in *E. coli*", GENE 391, pp. 120-129 (2007).
- Emilian Pavoni et al., "Selection, affinity maturation, and characterization of human scFv antibody against CEA protein", BMC Cancer 6:41 (2006).
- Lucien Perey et al., "Effects of differentiating agents on cell surface expression of the breast carcinoma-associated DF3-P epitope", Cancer Research 52, pp. 6367-6370 (Nov. 15, 1992).
- Alessandro Pini et al. "Design and use of a phage display library", The Journal of Biological Chemistry, vol. 273, pp. 21769-21776 (1998).
- Cornelis J. A. Punt et al. "Anti-tumor antibody produced by human tumor-infiltrating and peripheral blood B lymphocytes", Cancer Immunol Immunother 38, pp. 225-232 (1994).
- John B. B. Ridgway et al. "Identification of a human anti-CD55 Single-chain Fv by subtractive panning of a phage library using tumor and nontumor cell lines", Cancer Research 59, pp. 2718-2723 (Jun. 1, 1999).
- Rob C. Foovers et al. "Evidence for a bias toward intracellular antigens in the local humoral anti-tumor immune response of a colorectal cancer patient revealed by phage display", Int. J. Cancer 93, pp. 832-840 (2001).
- A. Rothe et al. "Construction of phage display libraries from reactive lymph nodes of breast carcinoma patients and selection for specifically binding human single chain Fv on cell lines", International Journal of Molecular Medicine 14, pp. 729-735 (2004).
- Brigitte Sanzey, "Modulation of Gene Expression by Drugs Affecting Deoxyribonucleic Acid Gyrase", Journal of Bacteriology vol. 138, No. 1, pp. 40-47 (Apr. 1979).
- Mohsen Shadid et al., "An Anti-leukemic single chain Fv antibody selected from a synthetic human phage antibody library", Biochemical and Biophysical Research Communications 280, pp. 548-552 (2001).
- K. Sikora et al. "Human hybridomas from patients with malignant disease", Br. J. Cancer 47, pp. 135-145 (1983).
- K. Sikora et al. "Human hybridomas from malignant gliomas", The Lancet vol. 1, Issue 8262, pp. 1-14(1982).
- Donald B. Smith et al. "Single-step purification of polypeptides expressed in *Escherichia coli* as fusions with glutathione S-transferase", GENE 67, pp. 31-40 (1988).
- Herbert Soule et al. "Isolation and characterization of a spontaneously immortalized human epithelial cell line, MCF-10", Cancer Research 50, pp. 6075-6086 (Sep. 15, 1990).
- John A. Thompson et al. "Carcinoembryonic antigen gene family: Molecular biology and clinical perspectives", Journal of Clinical Laboratory Analysis 5, pp. 244-366 (1991).
- Katherine P. Topping et al., "Isolation of human colorectal tumor reactive antibodies using phage display technology", International Journal of Oncology 16, pp. 187-195 (2000).
- Herren Wu et al., "Cloning, isolation and characterization of human tumor in situ monoclonal antibodies", Cancer Immunol Immunother 51, pp. 79-90 (2002).
- Ming-Yanh Xu et al., "Production of a human single chain-variable fragment antibody against esophageal carcinoma", World J. Gastroenterol 10(18), pp. 2619-2623 (2004).
- Manabu Yasuda et al. "Tumor-infiltrating B lymphocytes as a potential source of identifying tumor antigen in human lung cancer", Cancer Research 62, pp. 1751-1756 (Mar. 15, 2002).
- Luciano Zardi et al., "Transformed human cells produce a new fibronectin isoform by preferential alternative splicing of a previously unobserved exon." The EMBO Journal vol. 6, No. 8, pp. 2337-2342 (1987).
- Hu Zhang et al. "A human monoclonal antimelanoma single-chain Fv derived from tumor-infiltrating lymphocytes", Cancer Research 55, pp. 3584-3591 (Aug. 15, 1995).
- J. McCafferty et al., "Antibody Engineering: A Practical Approach" (soft cover) Oxford University Press, 1996, ISBN 0-19-963592-7.
- PCT International Search Report for PCT/IT2006/000876 filed on Dec. 27, 2006 in the name of Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. et al.
- Jamie K. Scott et al., "Phage-display vectors" in Phage Display: A Laboratory Manual Cold Spring Harbor Laboratory Press; pp. 2.1-2.19, 2001 ISSN: 0-87969-546-3.
- Emiliano Pavoni et al., "Identification of a panel of tumor-associated antigens from breast carcinoma cell lines, solid tumors and testis cDNA libraries displayed on lambda phage" in BMC Cancer, p. 78; Nov. 12, 2004.
- S. Thirion et al., "Mono- and bispecific single-chain antibody fragments for cancer therapy" in European Journal of Cancer Prevention, vol. 5, No. 6, pp. 507-511, Dec. 1996.
- Olga Minenkova et al., "Identification of tumor-associated antigens by screening phage-displayed human cDNA libraries with sera from tumor patients" in International Journal of Cancer, vol. 106, No. 4, pp. 534-544, Sep. 10, 2003.
- Gabriella Garufi et al., "Display libraries on bacteriophage lambda capsid" in Biotechnology Annual Review; vol. 11, pp. 153-190, Oct. 7, 2005.
- Germaine Fuh et al., "Efficient phage display of polypeptides fused to the carboxy-terminus of the M13 gene-3 minor coat protein" in FEBS Letters, vol. 480 No. 2-3; Sep. 1, 2000.
- Gregory A. Weiss et al. "Design and evolution of artificial M13 coat proteins" in Journal of Molecular Biology, London, vol. 300, No. 1, pp. 213-219, Jun. 30, 2000.
- Heike A. Held et al., "Comprehensive mutational analysis of the M13 major coat protein: improved scaffolds for C-terminal phage display" in Journal of Molecular Biology, London, vol. 340, No. 3, pp. 587-597, Jul. 9, 2004.
- Emiliano Pavoni et al., "New display vector reduces biological bias for expression of antibodies in *E. coli*" in Gene, vol. 391, No. 1-2, pp. 120-129, Apr. 15, 2007.
- European Search Opinion issued for European Application No. EP05028501.4 filed Dec. 27, 2005 in the name of SIGMA-TAU.
- Crissman, J., et al., Gene-III protein of filamentous phages: evidence for a carboxyl-terminal domain with a role in morphogenesis, Virology 1984, 132: 445-455.
- Dickson, R., et al., Genetic Regulation: the lac control region, Science 1975, 187: 27-35.
- O'Connor, C., et al., Highly repressible expression system for cloning genes that specify potentially toxic proteins, Journal of Bacteriology 1987, 169:4457-4462.

(56)

**References Cited**

OTHER PUBLICATIONS

Parker, J., Errors and alternatives in reading the universal genetic code, *Microbiological reviews* 1989, 53: 273-298.  
Kimata, K., et al., cAMP receptor protein-cAMP plays a crucial role in glucose-lactose diauxie by activating the major glucose transporter gene in *Escherichia coli*, *PNAS* 1997, 94: 12914-12919.

Simpson, Characterization of protein complexes, *Science* 2002, 705.  
Viti, F., et al., Design and use of phage display libraries for the selection of antibodies and enzymes, *Methods in Enzymology* 2000, 326: 480-505.

Barbas, CF., et al., *Phage Display: A Laboratory Manual* 2001, Cold Spring Harbor Laboratory Press, New York, pp. IV-XVI, 1.1;.

\* cited by examiner




Fig. 1

```

1  GCCCAATACG CAAACCGCCT CTCCCSCGCG GTTGGDCGAT TCATTAATG
                                     >Plac<
                                     C
51  AGCTGGCAGG ACAGGTTTCC CACTCGAAA SCGGGCAGTG AGCGCAACGC
101 AATTAATGTG AGTTAGCTCA CTCATTAGGC ACCCCAGGCT TTACACTTGA
151 TGCTTCCGGC TCGTATGTTG TSTGGA
                                     <Plac<
                                     ATTG TGAGCGGATA ACAATTCAC
201 ACAAGATCTA GCTATTCCTAG AATATA
                                     >alpha-peptide<
                                     CGCC AAGCCCC
                                     >fl.seg>
                                     GTA TTITAACCGT
251 TTAATGS
                                     M K Q S T I A L A L L
AAGCTT ATAAGGAGGAAATCCFC ATG AAA TAG AGC ACC ATC GCA CTG GCA CTG TTA
HindIII RBS amb
                                     -1 +1
P L L P T P V T K A R T M V S L A
CCG TTA CTG TTC ACC CCG GTT ACC AAA GCA CGT ACC ATG GTT TCC CTT GCG
                                     NcoI
A A G D Y K D D D D K
GCC GCA GGA GAC TAC AAA GAC GAC GAC GAC AAA GAA TTC
NotI EcoRI
                                     >gpIII (C-terminal part)
                                     C TCCCTCAACC TCCTGTCAAT
436 GCIGCCGGCG GCTCTGGTGG TGSTTCTGTF GCGGCTCTG AGGSTECCGG
476 CTCTGAGGGT GCGGTTTCTG ASGSTECCGG CTCTGAGGGT GCGGTTTCCG
536 GTGGCGGCTC CGGTPCCGGT GATTTTGAAT ATGAAAAAAT GCCAACCCTT
576 AATAAGGGGG CTATGACCGA AAATGCCGAT GAAACGCGC TACAGTCTGA
626 CACTAALGGC AACTTERTT CTCTCGCTAC TGATTACGGT GCTGCTATCG
676 ATGTTTCTAT TGCTGACGTT TCGGCTTGG CTAAATGATA TGSTGCTACT
736 GGTGATTTTG CTGGCTCTAA TCCCAAATG GCTCAAGTCG GTGACGGTGA
776 TATTTCACCT TTAATGATA ATTTCCGTCG ATATTACCT TCTTSCCTC
826 AGTCGGTTCG ATGTCGCCCC TATGTCTTGG GCGCTGATA ACCATATGAA
876 TTTTCTATG ATTTGACAAA AATAACTTA TTCCGTSETG TCTTSCCTT
926 TCTTTTATAT GPTGCRACCT TTAGTATAT ATTTTCGACG TTTGCTAACA
                                     gpIII end>
976 TACTGCGTAA TAAGGAGTCT TAAGGATCC
                                     BamHI

```

Fig. 2a

```

>gpIV
                                     TAATA TTGTTCTGGA TATTACCAGC
1030 AAGGCCGATA GTTTGAGTTC TTCTACTCAG GCAAGTGATG TTATTACTAA
1080 TCAAAGAAGT ATTGCCACAA CGGTAATTT GCGTGATGGA CAGACTCTTT
1130 TACTCGGTGG CCTCACTGAT TATAAAAACA CTTCTCAGGA TTCTGGCGTA
1180 CCGTTCCTGT CTAAAATCCC TTTAATCGGC CTCTCTTTA GCTCCCGCTC
1230 TGATTCTAAC GAGCAAAGCA CGTTATACGT GCTCGTCAA GCAACCATAG
      end gpIV stop >fl-ori
1260 TACGCGCCCT GTAGCGGCGC ATTAAGCGCG GCGGGTGTGG TGGTTACGCG
1330 CAGGDTGACC GGTACACTTG CCAGGCCCCT AGCGCCCCCT CTTTTCGCTT
1380 TCTTCCCTTC CTTTCTCGCC ACGTTGCGCG GCTTTCCTCC TCAAGCTCTA
1430 AATCGGGGGC TCCCTTTAGG GTTCDGATTT AGTGCTTTAC GGCACCTCGA
1480 CCCCAGAAAA CTTGATTTGG GTGATGTTTT ACCTAGTGGG CCATCGCCCT
1530 GATAGACGGT TTTTCGCCCC TTGACGTTGG AGTCCACGTT CTTAATAGT
1580 GGACTCTTGT TCCAAACTGG AACACACTTC AACCCATCT CCGTCTATTC
1630 TTTTGATTTA TAAGGGATTT TSCCGATTTG GGCCTATTTG TTAAGAAATG
1680 AGCTGATTTA ACAAAAATTT AACGCGAATT TTAACAAAAT ATTAACGTTT
1730 ACAATTTAAA TATTTGCTTA TACAATCTTC CTGTTTFTTG GGCTTTTCTG
      <fl-ORI<
1780 ATTATCAACC GGGGTACAT
      gpII start
      A TGATTGACAT GCTAGTTTTA CGATTACCGT
1830 TCATCGCAGG TGGCACTTTF CGGGGAAATG TCGCGCGGAC CCTATTFTGT
1880 TTATTTTCTT AAATACATTC AAATATGTAT CCGCTCATGA GACAATAACC
1930 CTGATAAATG CTTCAATAAT ATTGAAAAAG GAAGAGTATG AGTATTCAAC
1980 ATTTCCGTGT CGCCCTTATF CCGTTTTTTS CGGCATTTTG CPTTCTGTFT
2030 TTGCT
      >beta-lactamase>
      CACC CAGAAACGCT GGTGAAAGTA AAAGATGCTG AAGATCAGTT
2080 GGGTGCACGA GTGGSTTACA TCGAACEGGA TCTCAACAGC GGTAAAGATCC
2130 TTGAGAGTTT TCGCCCGGAA GAACSTTTTC CAATGATGAG CACTTTTAA
2180 GTTCTGCTAT GTGGCGCGGT ATTATCCCGT ATTGACGCGG GGCAGAGCA
2230 ACTCGGTGCG CCGATACACT ATTCCTCAGAA TCACTTGGTT GACTACTCAC
2280 CRGTCACAGA AAAGCATCTT ACGGATGGCA TGACAGTAAG AGAATTATGC
2330 AGTGCTGCCA TAACCATGAG TGATFAACTT GCGGCCAACT TACTTCTGAC
    
```

Fig. 2b








Fig. 3




Fig. 4




Fig. 5




Fig. 6




Fig. 7




Fig. 8




Fig. 9




Fig. 10




Fig. 11




Fig. 12






Fig. 13




Fig. 14

**B92 heavy chain**

VH	number of clones	CDR1	CDR2	CDR3
B92-A	8	SNSAAWS	TRYRISKWYNDYALSVKS	WKAFTAVAGPNYYGMDV
B92-B1	5	SYYS	RIYASGRPKYNPSLKS	VYSSSLTDFDYYYGLDV
B92-B2	1	-----	-----	-C-----
B92-C1	2	GSSNYWG	SIHYIGTTYNPSFKS	RTRWCWFDP
B92-C2	1	-----	-T-----	-----

**B93 heavy chain**

VH	number of clones	CDR1	CDR2	CDR3
B93-A1	5	NYSLN	AISSSGTYRFYADSLRG	DLGDLEWLHSPDP
B93-A2	1	---F-	---R-----	-----D-----
B93-B1	5	SYWID	IIYPDDSDTRYSPSQG	RGDSGTLWGD
B93-B2	1	N----	-----	-----
B93-C	1	SYAMN	SISGSGIGTYIANSVOG	DELNQLPGYYFDY

Fig. 15




Fig. 16




Fig. 17




Fig. 18

average	HFF	MCF10-2A	MCF7	MDA-MB468
mix 7	0.119	0.192	0.490	0.383
mix 8	0.462	0.548	2.241	1.149
mix 11	0.254	0.350	0.424	0.507
mix 12	0.282	0.291	0.673	0.414
mix 17	0.118	0.179	0.606	0.435
mix 23	0.157	0.223	0.585	0.393
mix 25	0.236	0.318	0.622	0.382
mix 39	0.168	0.237	1.527	0.497
B96/4F	0.222	1.711	0.497	0.376
B96/11L	0.142	0.206	1.148	0.501
αSP2	0.110	0.192	0.149	0.183

Fig. 19




Fig. 20




Fig. 21




Fig. 22



**VECTOR FOR EFFICIENT SELECTION  
AND/OR MATURATION OF AN ANTIBODY  
AND USES THEREOF**

**Matter enclosed in heavy brackets [ ] appears in the original patent but forms no part of this reissue specification; matter printed in italics indicates the additions made by reissue; a claim printed with strikethrough indicates that the claim was canceled, disclaimed, or held invalid by a prior post-patent action or proceeding.**

CROSS REFERENCE TO RELATED  
APPLICATIONS

*Two reissue applications have been filed for the reissue of U.S. Pat. No. 8,003,383: this application and a reissue continuation application, U.S. application Ser. No. 14/998,264 filed on Dec. 23, 2015. This application is a reissue of U.S. Pat. No. 8,003,383, which was filed as U.S. application Ser. No. 12/097,876 on Jun. 17, 2008, which, in turn, is the national phase of International Application PCT/IT2006/000876 filed on Dec. 27, 2006 which, in turn, claims priority to European Patent Application 05028501.4 filed on Dec. 27, 2005.*

The present invention relates to a method of improving the antibody selection capacity in phage-display library, in which said improvement is obtained through the reduction of the expression levels of the antibodies produced in said library.

FIELD OF THE INVENTION

Recombinant DNA technology provides a cheap and useful alternative to monoclonal antibody production. Display of recombinant antibodies on bacteriophage capsid, known as phage-display, not only allows generation of human antibody libraries for selection of specific binders, providing antibodies useful for therapy not inducing a harmful immune response in patients, but also facilitates affinity maturation of antibodies through construction of mutant antibody libraries, giving clones with a higher affinity.

The possibility of finding high-affinity binders in a recombinant antibody library characterizes its quality, which depends on several factors like library size, diversity and source of immunoglobulin genes.

It is known that various lymphoid tissues from immunized or non-immunized donors, such as peripheral blood lymphocytes, spleen and bone marrow and even metastasized or drained lymph node tissue from individuals affected by tumors may serve as a source of specific antibody repertoire.

Although naïve antibody libraries are more diverse and lead to isolation of broad antibody specificities, it is reasonable to suggest that construction of a recombinant antibody library from Ig repertoire of a patient affected by specific disease can provide antibody fragments of higher binding affinity against particular antigens.

Several published studies describe construction of recombinant antibody libraries from tumor-associated lymph nodes (Clin. Exp. Immunol. 1997 109(1):166-74; Int. J. Mol. Med. 2004 14(4):729-35; World J. Gastroenterol. 2004 10(18):2619-23). These studies are based on the general idea that lymph node tissue from cancer patients are infiltrated with activated B cells, which may serve as source of tumor-specific antibodies.

It is quite difficult to obtain metastasized or drained lymph nodes from breast cancer patients as fresh surgical material. According to recent medical practice the surgeon removes

only a sentinel lymph node or a small cluster of nodes (sentinel node and those closest to it), thus performing less invasive surgery and reducing side effects, instead of removing dozen of lymph nodes according to previous surgery technique. After sentinel lymph node dissection, practically the entire node is studied for presence of micrometastasis or single cancer cells. Therefore, in breast cancer surgery the metastasized node is practically unavailable as discarded surgical material.

The evidence that tumor-infiltrating B lymphocyte (TIL-B)-derived antibodies may also recognize tumor cells was obtained by producing human hybridomas, obtained from TIL, able to secrete tumor-specific antibodies (Lancet. 1982 1(8262):11-4; Br. J. Cancer, 1983 47(1):135-45); by B cell expansion of TIL from human tumor biopsies (Cancer Immunol. Immunother. 1994 38(4):225-32), by B cell expansion of melanoma-derived TIL and following cloning the scFv antibody from single B cell clone with specific melanoma reactivity (Cancer Res. 1995 55:3584-91); and by subcutaneous transplantation of human lung cancer tissue in immunodeficient mice producing human antibodies derived from TIL-B, which recognized two tumor-specific proteins (Cancer Invest. 2000; 18(6):530-6; Cancer Res. 2002 62(6):1751-6), thus suggesting a specific function of TIL-B in the tumor.

Recently, cervical carcinoma and a rare type of breast cancer, classified as medullary carcinoma (MCB) have been shown to be characterized by lymphoplasmacytic infiltrates that correlate with improved prognosis and patient survival. These diseases, were investigated to understand the nature of tumor-infiltrated B lymphocytes (TIL-B) by using also phage-display methods. Study of the molecular structure of variable antibody regions gave evidence of antigen-driven humoral immune responses in medullary breast carcinomas, as well as in cervical tumors. Oligoclonal predominance found in antibody genes derived from TIL indicated possible clonal selection of the Ig molecules against specific neoantigens overexpressed, or specifically expressed, in tumor tissue (Cancer Immunol. Immunother. 2001 50(10):523-32; Cancer Res. 2001 61(21):7889-99; Proc. Natl. Acad. Sci. U.S.A. 2001 98(22):12659-64; J. Immunol. 2002 169(5):2701-11).

Despite the very strong above-mentioned indications that tumor tissue is infiltrated with activated B cells, which may serve as a source of tumor-specific antibodies, several research groups, in the panning experiments performed with TIL-derived phage-display libraries against purified known tumor antigens, or living tumor cells, or frozen tissue sections, failed to select either a specific antibody discriminating between tumor and normal cells, or one reactive with cell-surface tumor antigens (Cancer Res. 2001 61(21):7889-99; Proc. Natl. Acad. Sci. U.S.A. 2001 98(22):12659-64; Int. J. Cancer 2001 93:832-40). Only later, two different groups managed to identify specific antibodies recognizing tumor cells from this kind of phage-display libraries (J. Immunol. 2002 169:1829-36; J Immunol. 2005 175(4):2278-85).

An alternative approach, based on a phage-expression tumor-derived library and direct plaque screening protocols, that avoided limitations of phage display system, allowed Wu and colleagues (Cancer Immunol Immunother. 2002 51(2):79-90) to isolate multiple antibodies that specifically bound cultured tumor cells. This study indicates that the observed difficulties in selection of anti-tumor antibodies from TIL-derived phage-display libraries result from imperfection of display vectors known in the art. However, the direct screening is also not an excellent method for selection of recombinant antibodies from large libraries. Indeed it is a laborious procedure demanding large expenses of time and means, as compared to the phage display technology.

Applicant performed a screening of recombinant antibody phage-display libraries derived from TIL-B by utilizing novel phagemid vector pKM19 and demonstrated efficient selection of tumor-specific antibodies against desirable tumor antigens as well as against living breast carcinoma cells.

## SUMMARY OF INVENTION

The authors have found that it is possible to improve the efficiency of selection and/or maturation of recombinant antibodies from libraries by using the phage-display system, upon suitable modifications of prior art vectors. Prior art vectors are, i.e., phagemid vectors as in "Antibody Engineering—A practical approach (McCafferty, J. Hoogenboom, H. & Chiswell D., eds), pp. 325, Oxford University Press, 1996)".

Therefore it is an object of the instant invention a vector, suitable for efficient selection and/or maturation of a recombinant antibody, characterized in that it contains at least one element able to reduce the expression level and/or has an improved efficiency of display of said recombinant antibody.

In the instant invention a recombinant antibody includes: ScFv, active fragments of Abs, or any other derivatives of Abs known in the art, including humanized sequences of Abs.

The vector of the invention may be a plasmid, a phagemid, a phage, or any other vectors known to the skilled in the art.

In one preferred aspect the element able to reduce the expression level of the recombinant antibody belongs to the group of: a) a suppressed stop codon inside either the leader peptide or the antibody coding sequence; b) a low-efficient promoter driving transcription of said antibody coding sequence; c) an inhibitor of the promoter driving transcription of said antibody coding sequence.

Low-efficient promoters are known in the art and are exemplified in *Biochem J.* 1970 117: 741-746). Suitable inhibitors for promoters are known in the art and are exemplified in *J. Bacteriol.* 1979, 138(1):40-7.

In one preferred aspect the improved efficiency of display of said recombinant antibody is obtained by: a) fusing the recombinant, antibody coding sequence to a sequence coding for the carboxy-terminal part of the pIII protein; and/or b) using as leader peptide of the recombinant antibody the leader peptide of the alkaline phosphatase of *E. coli*; and/or c) eliminating any amber codon between the recombinant antibody coding sequence and the pIII coding sequence.

It is a further object of the present invention a phagemid vector having the nucleotide sequence of SEQ ID NO: 1.

This vector, named pKM19, is designed for the display of recombinant antibodies in single-chain format on the surface of filamentous phage.

It is a further object of the invention a phage display-antibody library obtained by cloning cDNAs into the vector of the invention. Preferably the library is obtained by cloning in the vector of the invention cDNAs from antibody producing cells, more preferably Tumor Infiltrating Lymphocytes (TILs) or Peripheral Blood Lymphocytes (PBLs). In a preferred aspect such antibody producing cells are isolated from a tumor affected subject, preferably from a breast cancer affected subject. Alternatively the library consists of synthetic or semi-synthetic antibody libraries, also mutated for affinity maturation of antibodies.

It is within the scope of the invention an antibody selected from the library of the invention, and method for selecting the same, able to recognize an antigen or a complex multi-component biological structure, preferably a cell or a cell membrane, more preferably selected from the group comprising:

MUC1 tumor antigen, CEA (carcino-embryonic antigen), MCF7 breast carcinoma cells. Said antibodies may be in single or double-format.

In a particular aspect the MUC1 tumor antigen antibody is the MB5 scFv antibody consisting essentially of the amino acid sequence of SEQ ID NO: 3, preferably coded by the nucleotide sequence of SEQ ID NO: 2. Alternatively the MUC1 tumor antigen antibody is the MB5/C'1 scFv antibody, consisting essentially of the amino acid sequence of SEQ ID NO: 5, preferably coded by the nucleotide sequence of SEQ ID NO: 4. Alternatively the MUC1 tumor antigen antibody is the MB5/C'3 scFv antibody, consisting essentially of the amino acid sequence of SEQ ID NO: 7, preferably coded by the nucleotide sequence of SEQ ID NO: 6.

In a particular aspect the CEA tumor antigen antibody is the CB37 scFv antibody consisting essentially of the amino acid sequence of SEQ ID NO: 9, preferably coded by the nucleotide sequence of SEQ ID NO: 8. Alternatively the CEA tumor antigen antibody is the CB37/9C scFv antibody, consisting essentially of the amino acid sequence of SEQ ID NO: 13, preferably coded by the nucleotide sequence of SEQ ID NO: 12. Alternatively the MUC1 tumor antigen antibody is the CB37/3B scFv antibody, consisting essentially of the amino acid sequence of SEQ ID NO: 11, preferably coded by the nucleotide sequence of SEQ ID NO: 10.

In a particular aspect the MCF7 breast carcinoma cells antibody is the B96/11L scFv antibody consisting essentially of the amino acid sequence of SEQ ID NO: 15, preferably coded by the nucleotide sequence of SEQ ID NO: 14. Alternatively the MCF7 breast carcinoma cells antibody is the mix7 scFv antibody, consisting essentially of the amino acid sequence of SEQ ID NO: 17, preferably coded by the nucleotide sequence of SEQ ID NO: 16. Alternatively the MCF7 breast carcinoma cells antibody is the mix17 scFv antibody, consisting essentially of the amino acid sequence of SEQ ID NO: 19, preferably coded by the nucleotide sequence of SEQ ID NO: 18. Alternatively the MCF7 breast carcinoma cells antibody is the mix39 scFv antibody, consisting essentially of the amino acid sequence of SEQ ID NO: 21, preferably coded by the nucleotide sequence of SEQ ID NO: 20.

The antibodies selected from the libraries of the invention may be advantageously utilized for therapeutic, diagnostic, immunogenic or research purposes. Conveniently they may be utilized for preparing suitable pharmaceutical compositions comprising as active ingredient one or more recombinant antibody of the invention and optionally one or more excipients or diluents pharmaceutically acceptable and known in the art.

The antibodies of the invention may be also utilized for obtaining so-called maturation libraries wherein single Variable Heavy chains (VH) coding sequences are co-transfected with Variable Light chain (VL) coding sequences, and recombinant antibodies selected for affinity.

Moreover the antibodies may be utilized for selecting recombinant and/or synthetic peptides able to mimic the native antigen. Tumor surface antigens can be selected by using novel anti-tumor antibodies recognizing tumor cells through: (i) immunoprecipitation of unknown target proteins from tumor cell extracts (*Antibodies. A laboratory manual.* Ed Harlow, David Lane, Cold Spring Harbor, N.Y.: Cold Spring Harbor Laboratory Press, 1988); or (ii) developing the immunoreactions with tumor cell extract, separated by two-dimensional PAGE (*Proteins and proteomics: A laboratory manual.* Richard J. Simpson, pp. 705, Science 2002) and transferred onto nitrocellulose membrane (Sambrook J,

## 5

Fritsch E F, Maniatis T. Molecular cloning: A laboratory manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 1989);

Such recombinant and/or synthetic peptides able to mimic the native antigen so obtained may be utilized for producing vaccines, diagnostic reagents or in the research field. Conveniently they may be utilized for preparing suitable pharmaceutical compositions comprising as active ingredient one or more disease-specific antigen above mentioned, and optionally one or more excipients or diluents pharmaceutically acceptable and known in the art.

It is a further object of the present invention a nucleic acid encoding for the recombinant antibody obtained by the library of the invention.

Preferably the nucleic acid encodes for a MUC1 tumor antigen antibody, more it has the nucleotide sequence of SEQ ID NO: 2. Alternatively it has the nucleotide sequence of SEQ ID NO: 4. Alternatively it has the nucleotide sequence of SEQ ID NO: 6.

Preferably the nucleic acid encodes for a CEA tumor antigen antibody, more preferably it has the nucleotide sequence of SEQ ID NO: 8. Alternatively it has the nucleotide sequence of SEQ ID NO: 10. Alternatively it has the nucleotide sequence of SEQ ID NO: 12.

Preferably the nucleic acid encodes for a MCF7 breast carcinoma cells antibody, more preferably it has the nucleotide sequence of SEQ ID NO: 14. Alternatively it has the nucleotide sequence of SEQ ID NO: 16. Alternatively it has the nucleotide sequence of SEQ ID NO: 18. Alternatively it has the nucleotide sequence of SEQ ID NO: 20.

It is a further object of the present invention a host cell transformed with the vector of the invention able to express the antibody.

It is another object of the invention a method for improving the selection and/or maturation of a recombinant antibody comprising the step of using as cloning and expression vector the vector of the invention as above described.

The invention will be now described by means of non limiting examples referring to the following figures:

## DETAILED DESCRIPTION OF THE DRAWINGS

FIG. 1. It is schematically described the essential elements of pKM16 plasmid useful for the production of soluble antibodies in scFv format and the essential elements of pKM17, pKM18 and pKM19 plasmids useful for production of phage-displayed antibodies. These plasmids direct antibody expression under control of pLac promoter. The unique NcoI and NotI cloning sites allow insertion of an antibody gene to express single-chain antibodies with a leader peptide of the bacterial periplasmic enzyme, alkaline phosphatase (PhoA leader). Plasmid pKM17 encodes the entire protein pIII (406 aa) and plasmids pKM18 and pKM19 encode the carboxy-terminal part of pIII (197 aa). Plasmid pKM19 contains amber codon in PhoA leader.

FIGS. 2a, 2b, 2c. It is described the detailed structure of pKM19 phagemid vector (SEQ ID NO: 1). The specific modification made are reported in the figure and described in the text.

FIG. 3. Soluble scFv production by using pKM16 plasmid. Three independent clones obtained by cloning scFv anticarcino-embryonic antigen (CEA) gene in pKM16 were tested for soluble scFv production (gel lines 1-3). Periplasmic protein fractions were purified from bacteria by freeze and thaw method. The protein size marker is included. Western blot membrane was developed with an anti-FLAG AP-conjugated secondary antibody. Bands corresponding to soluble scFv

## 6

antibodies (expected molecular weight 26 kDa) migrate between 24.5 and 35.9 kDa bands.

FIG. 4. Display efficiency of pKM17, pKM18 and pKM19 plasmids in comparison with a classic phagemid system. Anti-CEA scFv antibodies displayed by the three different plasmids, were assayed by ELISA against CEA protein and compared with MA39 phage (anti-CEA/pDN322). The helper phage, M13K07, that does not display antibody fragments, was included as negative control. Data reported are the average values of assays performed in duplicate. The highest phage concentration, labeled by asterisk, corresponds to the  $10^{11}$  TU for all phages and  $3 \times 10^{10}$  TU for anti-CEA/pKM17. The ELISA was performed by using the anti-M13 (panel A), or alternatively, the anti-FLAG secondary antibody (panel B).

FIG. 5. Filtration of phage samples. About  $2 \times 10^{11}$  TU/well of each preparation or the corresponding quantity of filtrate samples were tested in ELISA and developed either with anti-M13 (panel A) or anti-FLAG (panel B) secondary antibodies. Data reported are the average values of assays performed in duplicate. The data show reactivity of filtrates against CEA as percentage of original reactivity of non-filtrated samples (100%).

FIG. 6. Competition with soluble anti-CEA scFv. Freshly prepared supernatants of MA39 (10  $\mu$ L) and anti-CEA/pKM19 (5  $\mu$ L) phages competed with various amounts of the purified soluble anti-CEA antibody. The data are expressed as percentage of reactivity of the supernatants without competitors. The irrelevant soluble anti-SP2 scFv was used as negative control.

FIG. 7. Competition with phage supernatant filtrates. Freshly prepared supernatants of MA39 (10  $\mu$ L) and anti-CEA/pKM19 (5  $\mu$ L) phages were competed with 10  $\mu$ L or 50  $\mu$ L of filtrates of the same phage supernatants. The data are expressed as percentage of reactivity of the supernatants without competitors.

FIG. 8. Western blot of PEG-purified recombinant phages. Protein extracts from about  $5 \times 10^9$  PFU of phages MA39, anti-CEA/pKM18 and anti-CEA/pKM19, and  $1 \times 10^9$  PFU of anti-CEA/pKM17 were fractionated by SDS-PAGE and transferred onto a nitrocellulose membrane. The membrane strips were developed with an anti-FLAG AP-conjugated antibody. The protein size marker is included (last strip). The scFv-pIII (66.1 kDa) and scFv- $\Delta$ pIII (45.2 kDa) proteins migrate as higher molecular weight bands because of an anomalous moiety of the pIII protein described earlier (Goldsmith and Konigsberg, 1977).

FIG. 9. Selection against SP2-GST protein. Reactivity of the phage pools derived from first and second rounds of panning of the scFvEC23 library is shown. GST (glutathione S-transferase), milk and streptavidin, present in the selection system, are included as negative controls. Data reported are the average values of assays performed in duplicate. Phage input was normalized since  $3 \times 10^9$  TU per single well of each preparation were tested in ELISA.

FIG. 10 Affinity selection of matured anti-CEA gene from a maturation library. In this assay, positive immunoreactions were developed by an anti-FLAG AP-conjugated secondary antibody, in order to moderate positive signals and make visible the increasing reactivity during the selection process. The helper phage, M13K07, that does not display antibody fragments, was included as negative control. The reactivity of the original anti-CEA antibody in pKM19 (anti-CEA/pKM19), maturation library (Lib.), pools of phage after first and second round of selection (I round, II round) and single clones (c1.1, c1.2) from the phage pool after second round of affinity selection, tested on CEA and irrelevant GST protein, are shown. Data reported are the average values of

assays performed in duplicate. Phage input was normalized. About  $3 \times 10^{10}$  TU per single well of each preparation were tested in ELISA.

FIG. 11. ELISA reactivity of soluble matured scFvs. Various amounts of soluble antibodies were assayed on CEA-coated plates. Bound scFvs were developed by using an anti-FLAG secondary antibody. Data reported are the average values of assays performed in duplicate. The irrelevant anti-SP2 antibody and matured anti-CEA ES antibody, obtained earlier (Pavoni et al., 2006), were included as controls.

FIG. 12. Specificity of matured clones. About 250 ng per well of original and matured antibodies in soluble form were assayed with CEA and various irrelevant proteins. The irrelevant anti-SP2 antibody was included as negative control. Data reported are the average values of assays performed in duplicate.

FIG. 13. V(D)J analysis of TIL-derived antibody genes. A. SMART cDNAs derived from 10 different tumor samples (patients B84, B85, B87, B89, B90, B91, B92, B93, B95, B96), from normal breast, normal testis and lymphocytes from four healthy donors (L1, L2, L3, L4), were used, as template for amplification of V(D)J antibody regions. Samples of the cDNAs were normalized by amplification of  $\beta$ -actin housekeeping gene. V(D)J fragments were amplified well from all templates excluding normal testis cDNA. B. The same PCR products were fractionated by PAGE giving a higher resolution for DNA bands.

FIG. 14. Antibody subclass distributions. PCR-amplified normal breast and B84 cDNA samples, not showing oligoclonal bands in the V(D)J test, have prevalence of IgA bands in comparison to IgG1 and IgG2 (left panel), while three samples, showing strong oligoclonal bands in previous test (B91, B92 and B93), have IgG1 or both IgG1 and IgG2 bands prevalence in comparison with IgA (right panel).

FIG. 15. Amino acid sequences of variable regions of 30 random clones obtained by cloning  $\gamma$ -chain antibody genes derived from B92 (SEQ ID NO: 54 to SEQ ID NO:64) and B93 (SEQ ID NO: 65 to SEQ ID NO: 77) cDNAs. Peptide sequence is reported in single-letter code. Identical amino acids in similar clones are represented by a dash.

FIG. 16. Selection on ED-B, MUC1 and CEA proteins. Reactivity of phage pools derived from second and third rounds of panning in comparison with original libraries were tested. GST is included as a negative control. Additional negative control, protein D possessing 6His tail as a target protein used in the selection was used in case of ED-B panning. Data reported are the average values of assays performed in duplicate. Library ScFvEC23 derives from PBL. MixTIL is a mixture of 4 TIL-derived libraries (ScFvB87, ScFvB95, ScFvB96 and ScFvmix) as indicated in table 1.

FIG. 17. ELISA reactivity of single phage clones displayed scFv antibodies. Reactivity of single phage clones selected against ED-B (clones EDE1, EDE3, EDE5, EDB5, table 5), MUC1 (clones ME 1, ME2, MB5, table 5) and CEA (clones CB3, CB37, CB40, CB41, CB53, CB60, table 5) after third round of selection was tested using respective proteins. Data reported are the average values of assays performed in duplicate. Several irrelevant proteins and an anti-SP2 irrelevant phage antibody are included as negative controls.

FIG. 18. Cell-based panning reactivity against fixed breast carcinoma (MCF7) and human fibroblast (HFF) cells of phage pools derived from fourth and fifth rounds of panning in comparison with original libraries, were tested. Data reported are the average values of assays performed in triplicate. Libraries scFvB96 and mixLIB are defined in Table 2.

FIG. 19. Cell-ELISA reactivity against fixed cells of single phage clones. Data reported are the average values of assays

performed in triplicate. Cell developing with irrelevant anti-SP2 antibody is included as negative control. MCF7 and MDA-MB-468: fixed breast carcinoma cells; HFF: human fibroblast and MCF10-2A: normal breast epithelium cells.

FIG. 20. Origin of anti-MCF7 scFv antibodies. One  $\mu$ L of each scFv phage library was amplified by PCR by using oligonucleotide primers specific for analyzed antibody genes. Corresponding PEG-purified phage was used as positive control (last line). The irrelevant anti-SP2 antibody gene of known origin, selected earlier from scFvEC23 library; derived from PBL, was also tested. Anti-MUC1 MB5 antibody and anti-CEA CB37 antibody were selected from mixture of TIL-derived libraries. Mix 11, mix 12, mix17 and mix39 antibodies were selected from mixture of TIL-derived and PBL-derived libraries Antibodies are defined in Table 5.

FIG. 21. Fluorescent staining of non-permealized breast carcinoma MCF7 and normal breast epithelium MCF10-2A fixed cells by phage-displayed scFv antibodies (mix17 (A), mix7 (B)).

FIG. 22. A. Fluorescent staining of breast carcinoma cells MCF7, SkBr3 expressing MUC1 tumor antigen and normal breast epithelium cells MCF 10-2A by using phage-displayed anti-MUC1 MB5 scFv antibody; B. Staining of colorectal adenocarcinoma cells LoVo expressing CEA by phage-displayed anti-CEA CB37 scFv antibody. Staining of negative control MCF10-2A cells is included.

The following examples illustrates the invention.

#### Example 1

##### Construction of Novel pKM19 Phagemid Vector for Display of Single-Chain Antibodies on Filamentous Phage

###### Introduction

This work describes construction of a novel pKM19 phagemid vector for the display of single-chain antibodies on filamentous phage. This vector is characterized by several differences compared to canonical systems.

###### a) Amber Codon

The classic phagemids contain an amber codon between the scFv and gpIII genes, thus directing production of free scFvs and scFv-pIII fusion antibodies in suppressor bacteria, such as TG1, or DH5 $\alpha$ F', or XL1-Blue, generally used for phage amplification. These bacterial strains, carrying the supE mutation, are glutamine-inserting suppressors with suppression efficiency dependent on the codon following the TAG (J. Mol. Biol. 1983 164(1):59-71; Mol. Gen. Genet. 1987 207(2-3):517-518). In such system, the produced free soluble scFv antibodies are secreted into the periplasm and then leak from the periplasm into the medium. Under standard phage purification protocol by PEG/NaCl, the free scFv antibodies are co-precipitated with phage particles. As a result, the concentration of free antibodies in phage suspension may be five to ten times higher than the concentration of scFv-pIII-fused proteins assembled in the phage particle. In a subsequent selection, the abundant free antibodies compete with phage-displayed antibodies for target binding. This interferes with panning efficiency and delays the selection process, specially:

- i) when antigen concentration is limited (e.g. biopanning on living cells, ex-vivo cells),
- ii) in later panning rounds, where concentration of specific phage is relatively high, or
- iii) in maturation libraries, containing many relative antibodies with the same specificity.

Therefore classic phagemids need to be modified for an improved selection and/or maturation of antibodies.

As expected from literature data, the presence of an amber codon positioned in a sequence encoding for a phosphatase alkaline leader peptide in pKM19, leads to a relatively low expression level of recombinant antibodies in the amber-suppressor bacteria harboring this plasmid.

It was shown (Gene 1999 228: 23-31) that inhibition of lac promoter only by catabolic repression with glucose is not sufficient to equilibrate growth rates of different clones with or without stop codons. The lower scFv expression achieved using pKM49, reduces the toxicity of recombinant antibodies for the bacterial host and has no influence on display efficacy.

Using pKM19 the authors demonstrated:

(i) that the present level of antibody expression is sufficient to produce highly reactive phage antibodies, giving a similar signal in ELISA test as compared to pKM18 phage without amber codon;

(ii) that specific antibodies can be easily isolated from an scFv library constructed from peripheral blood lymphocytes of a patient with antibodies against a target protein after only two selection rounds;

(iii) that maturation of anti-CEA antibody leads to isolation of improved scFv clones without stop codons in comparison with maturation performed by using canonical vector (BMC Cancer 2006 6:41).

#### b) Gene III Protein

The pKM19 vector allows the cloning of scFv fragments as amino terminal fusion of the deleted gene III protein.

Commonly used phage display vectors for scFv lead to incorporation into the phage particles of the entire pIII fused to the antibody fragment (in Antibody Engineering—A practical approach: McCafferty, J. Hoogenboom, H. & Chiswell D., eds, pp. 325, Oxford University Press, 1996), while in the case of pComb3 plasmid utilized for Fab display (Proc. Natl. Acad. Sci. USA 1991 88(18):7978-7982), the antibody fragment is fused to the carboxy terminal half of the pIII. Infectivity of such recombinant phages is obtained during their propagation, since superinfection with a helper phage provides the native gene III protein.

According to the present data, fusion of the single-chain antibody to the C-terminal part of pIII improves phage production and display efficiency of an antibody in comparison with wt pIII protein fusion. These data are in agreement with Kretzschmar's earlier data (Gene 1995 155(1):61-65). The improved display efficiency in combination with elimination of free scFv antibodies from the incubation mixture facilitates affinity selection and results in faster enrichment of the phage pools for specific clones. This may also contribute to reduction of stop codons in selected clones since a lower number of panning/amplification rounds are necessary to complete selection. Rapidly growing defective clones have less chance of being isolated.

#### c) PhoA Leader Peptide

In bacteria harboring the pKM19 vector, after synthesis of recombinant protein, the PhoA leader peptide is cleaved off by leader peptidase upon membrane translocation, and scFv-pIII is assembled into the phage particle. In this way, the entire cleavage site of the alkaline phosphatase, a genuine periplasmic protein of *E. coli*, is preserved to guarantee efficient and correct processing and antibody assembly. As a result, the mature protein contains two additional amino acids at the N-terminus of scFv. In the described system, it is necessary to reclone the antibody gene in the appropriate plasmid for the subsequent production of soluble antibodies. At this stage, the additional amino acids can be conserved or eliminated according to specific requirements.

In conclusion, the combination of relatively low expression of displayed antibodies by introducing the amber codon before antibody gene with improved display efficiency makes the novel pKM19 phagemid useful both for selection of the recombinant scFv antibodies against desired targets from large libraries, as for their affinity maturation. The plasmid guarantees efficient display and allows reduction of biological bias against "difficult" antibodies in the delicate initial selection step. Moreover, this vector is particularly useful for the affinity maturation of antibodies, since high expression levels may increase avidity of phage particles displaying Ab, leading to selection of antibodies with only modest affinity.

#### Methods

##### Bacterial Strains and Phages

Bacterial strain DH5 $\alpha$ F' (supE44  $\Delta$ lacU169 (100 lacZ $\Delta$ M15) hsdR17 recA1 endA1 gyrA96 thi-1 re1A1 F' [traD36 proAB<sup>+</sup> lacI<sup>q</sup>lacZ $\Delta$ M15]) was used for soluble and phage antibody production. Helper phage M13 KO7 (Sambrook J, Fritsch E F, Maniatis T. Molecular cloning: A laboratory manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 1989) was used for phage preparation.

The anti-CEA phage antibody, MA39 (BMC Cancer 2006 6: 41), in pDN322 plasmid (J. Biol. Chem. 1998 273(34): 21169-21776) was used as source of anti-CEA antibody gene.

##### Construction of Plasmids

The pC89 plasmid (J. Mol. Biol. 1991 222(2): 301-310) was amplified by inverse PCR with the KM161, I(M162 oligonucleotides, containing HindIII and NotI sites (underlined) (KM161 5'-GAGG AAGCTTCCATTAAACGGGTAAAATAC-3' (SEQ ID 78); KM162 5'-TGCAATG GCGGCCGCTAATATTGTTCTGGATATTACCAGC-3' [SEQ ID 79]). In inverse PCR a Taq polymerase mixture with Pfu DNA polymerase was used to increase fidelity of DNA synthesis. Twenty-five cycles of amplification (95° C.-30 sec, 55° C.-30 sec, 72° C.-20 min) were done. The PCR product was digested with HindIII and NotI endonucleases and ligated with a KM163-KM164 oligonucleotide duplex encoding FLAG peptide and His-tail (KM163 5'-AGCTTC-CTCATG TAG GCG GCC GCA GGA GAC TAC AAA GAC GAC GAC GAC AAA CAC CAC CAT CAC CAC CAT TAA-3' [SEQ ID 80]; KM164 5'-GGCC TTA ATG GTG GTG ATG GTG GTG TTT GTC GTC GTC GTC TTT GTA GTC TCC TGC GGC CGC CTA CAT GAGGA-3' [SEQ ID 81]). The cloned DNA duplex contained an internal NotI site, upstream of FLAG peptide encoding sequence, while the NotI site, used for cloning of the duplex, was not restored. The resulting pKM15 plasmid was newly digested with HindIII, NotI endonucleases and ligated with KM175-KM176 duplex encoding the leader sequence and the first two amino acids of the PhoA bacterial protein, containing the NcoI cloning site (KM175 5'-AGC TTA TAA AGG AGG AAA TCC TCA TGA AAC AGA GCA CCA TCG CAC TGG CAC TGT TAC CGT TAC TGT TCA CCC CGG TTA CCA AAG CAC GTA CCA TGG TTT CCC TTGC-3' [SEQ ID 82]; KM176 5'-GGC CGC AAG GGA AAC CAT GGT ACG TGC TTT GGT AAC CGG GGT GAA CAG TAA CGG TAA CAG TGC CAG TGC GAT GGT GCT CTG TTT CAT GAG GAT TTC CTC CTT TATA-3' [SEQ ID 83]). This new pKM16 plasmid was destined for soluble single-chain antibody production (FIG. 1).

The plasmid pKM16 was amplified by inverse PCR with the KM181, KM182 oligonucleotides, presenting EcoRI and BamHI restriction sites, respectively (KM181 5'-GTG GTG ATG GAATTC TTT GTC GTC GTC GTC TTT GTA GTC-3' [SEQ ID 84]; KM182 5'-CAC CAT TAA GGATCC TAA TAT TGT TCT GGA TAT TAC CAG C-3' [SEQ ID 85]). The

full-length gene III (Accession number V00604) and the 3' part of the gene encoding the last 197 aa of the pIII were amplified by using the oligonucleotides KM183-KM185 or KM184-KM185 containing BamHI and EcoRI sites (underlined) and ligated into digested pKM16, giving the new plasmids pKM17 and pKM18, respectively (KM183 5'-TC TAT TCT GAATTC GCT GAA ACT GTT GAA AGT TGT TTA GC-3' [SEQ ID 86]; KM184 5'-GC CAA TCG GAA TTC CTG CCT CAA CCT CCT GTC AAT GCT-3' [SEQ ID 87]; KM185 5'-GAA CTG GGA TCC TTA AGA CTC CTT ATT ACG CAG TAT G-3' [SEQ ID 88]).

A short fragment of the pKM18 plasmid encoding the leader sequence was PCR-amplified with KM186-KM180 primers, introducing an amber mutation in PhoA leader peptide gene (KM186 5'-ACC CGT AAG CTT ATA AAG GAG GAA ATC CTC ATG AAA TAG AGC ACC ATC GC-3' [SEQ ID 89]; KM180 5'-TAG CCC CCT TAT TAG CGT TTG-3' [SEQ ID 90]). The resulting PCR product was digested with HindIII and NotI and cloned into pKM18, digested with HindIII and NotI and purified from agarose, to construct the pKM19 plasmid.

#### Soluble Antibody Production

A single colony was inoculated into 50 mL of LB containing 100 µg/mL Ap and 2% glucose. The culture was grown at 37° C. for 2-3 h up to O.D.=0.8. The cells recovered by centrifugation were resuspended in 50 mL of LB with Ap and 1 mM IPTG and incubated overnight at 30-32° C. Cell pellet was resuspended in 500 µL of PBS. After three cycles of freeze and thaw, cell debris was pelleted by centrifugation. The resulting supernatant was used for ELISA or for Western blot.

#### Purification of Lymphocytes from Peripheral Blood and cDNA Synthesis

The lymphocytes were isolated from 10 mL of fresh peripheral blood from patient EC23 (with advanced stage of breast cancer) with an anticoagulant using Ficoll-Paque Plus (Amersham Pharmacia Biotech, Sweden) according to manufacturer's instructions. mRNA was isolated from lymphocytes by using Dynabeads mRNA DIRECT Kit (Dyna, Norway). The mRNA was isolated from lymphocytes by using Dynabeads mRNA DIRECT Kit (Dyna, Oslo, Norway). One µg of the poly(A)<sup>+</sup> RNA from the lymphocytes was used to synthesize full-length cDNA by using SMART cDNA Library Construction Kit (Clontech, Palo Alto, Calif.).

#### ScFv Library Construction

The antibody gene repertoire was amplified using a set of primers designed for amplification of VH and VL antibody domains, while entire scFv fragments were assembled in vitro as it was described in [Pope, A. R., Embleton, M. J. & Mer-naugh R. (1996) Construction and use of antibody gene repertoires. In: Antibody Engineering—A practical approach (McCafferty, J., Hoogenboom, H. & Chiswell D., eds), pp. 325, Oxford University Press]. The latter were then amplified by PCR with appropriate extension primers, incorporating NcoI, NotI restriction sites, and allowing the cloning of scFv genes into a pKM19 vector. The resulting PCR products were purified on 1% low-melting agarose gel (NuSieve 3:1 agarose, Rockland, Me.), cut with NcoI/NotI and inserted into digested plasmid. The transformed library scFvEC23 contained  $1.77 \times 10^7$  independent clones with full-length scFv insert. The scFvEC23 library derives from PBL obtained from a single patient EC23 with advanced stage of breast cancer.

#### Construction of Mutated Anti-CEA scFv Library

The maturation library for the anti-CEA scFv was constructed as earlier described (BMC Cancer 2006 6:41). Briefly, mutated scFv gene fragments were generated by PCR

amplification with primers: KM144-KM143 (KM143, 5'-GT-CATCGTCGGAATCGTCATCTGC-3' [SEQ ID 91]; KM144, 5'-TGTGCGAAA AGTAATGAGTTTCTTTT GACTACTGGGGC-3' [SEQ ID 92]) and KM148-KM145 (KM148, 5'-CTATTGCCTACGGCAGCCGCTGGA-3' [SEQ ID 93]; KM145, 5'-TCCGCCGAATACCAC ATAGGGCAACCACGGATAAGAGGAGTTACAGTAAT AGT CAGCC-3' [SEQ ID 94]) introducing random mutations in CDR3 regions of heavy or light chains with low frequency. Each underlined base of KM144 and KM145 oligonucleotides was replaced with mixture of G/A/T/C with a frequency of 10%. Missing scFv antibody gene parts were amplified with KM148-KM157 and KM158-KM143 primers for HC and LC, respectively (KM157 5'-TTT CGC ACA GTA ATA TAC GG-3' [SEQ ID 95]; KM158 5'-TAT GTG GTA TTC GGC GGA-3' [SEQ ID 96]). In order to reconstruct the entire gene, the corresponding fragments were combined and amplified in a PCR-like process without oligonucleotide primers. The resulting product was utilized to amplify the entire gene with external primers KM148, KM143. The final DNA fragment was agarose-purified, digested with restriction enzymes NcoI and NotI, and ligated with the digested plasmid pKM19. The resulting library contained  $2.2 \times 10^6$  mutated antibody clones.

#### Competition with Soluble scFv

ELISA plates were coated, blocked and washed as above. Various quantities of anti-CEA soluble antibody MA39 (BMC Cancer 2006 6: 41) in 100 µL of blocking buffer were added to the wells and incubated for 30 min at 37° C. Then, 10 µL ( $4.5 \times 10^9$  TU) of MA39 phage supernatant or 5 µL ( $3 \times 10^8$  TU) of anti-CEA/pKM19 supernatant were added to the wells and incubated for another 1 h at 37° C. The plates were washed and the bound phage detected by an anti-M13 HRP-conjugated antibody. An irrelevant soluble anti-SP2 scFv (Table 5), was used at a high concentration (400 ng/well) as negative control. A lower quantity of the anti-CEA/pKM19 phage, as compared to MA39, was used to moderate ELISA reactivity of this phage.

In the case of competition with filtrates of phage supernatants, 10 µL or 50 µL of the MA39 or pKM19/anti-CEA filtrates in 100 µL of blocking buffer were used as competitors. The phage filtrates were obtained from freshly prepared phage supernatant by using filtration column Microcon 100. Western Blot of PEG-Purified Phages

Phage was purified according to standard PEG/NaCl precipitation (Sambrook J, Fritsch E F, Maniatis T. Molecular cloning: A laboratory manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 1989). Protein extracts from phage samples were fractionated by SDS-PAGE and transferred onto a nitrocellulose membrane. The membrane strips were developed with an anti-FLAG AP-conjugated antibody. Phage ELISA

Multiwell plates (Immunoplate Maxisorb, Nunc, Roskilde, Denmark) were coated ON at 4° C. with a protein solution at a concentration of 10 mg/mL in 50 mM NaHCO<sub>3</sub>, pH 9.6. After discarding coating solution, plates were blocked for 1 h at 37° C. with ELISA blocking buffer (5% non-fat dry milk, 0.05% Tween-20 in PBS). Plates were washed several times with washing buffer (0.05% Tween-20 in PBS). PEG-purified phage in blocking buffer (1:1) was added to each well and incubated for 1 h at 37° C. The plates were washed and the bound phage was detected by an anti-M13 HRP-conjugated (27-9421-01, Amersham Biosciences, Uppsala, Sweden), or anti-FLAG HRP-conjugated (A9044, Sigma, St. Louis, Mo.), or anti-FLAG AP-conjugated (A9469, Sigma) secondary antibody. In the case of HRP-conjugates, the immunoreaction

was developed by incubation with TMB liquid substrate (Sigma) for 15 min and stopped by the addition of 25  $\mu$ L 2 M  $H_2SO_4$ . The results were expressed as the difference between absorbances at 450 and 620 nm, determined by an automated ELISA reader. The AP-conjugated antibody was detected by incubation with 1 mg/mL solution of p-nitrophenyl phosphate in substrate buffer (10% diethanolamine buffer, 0.5 mM  $MgCl_2$ , pH 9.8) for 60 min. The results were expressed as the difference between absorbances at 405 and 620 nm.

Antibodies are defined in table 5.

### Results

The pKM16 plasmid (FIG. 1) used for production of soluble antibodies in scFv configuration is constructed as described above. This plasmid directs protein expression under the control of lacP promoter. The unique NcoI and NotI cloning sites allow insertion of an antibody gene able to express single-chain antibodies with a leader peptide of the bacterial periplasmic enzyme, alkaline phosphatase (AP), and with the first two amino acids of the mature AP protein, at the antibody's amino-terminus; and FLAG/His-tail at carboxyl-terminus of antibody. In order to confirm the plasmid's practical qualities, a gene of a single-chain antibody of known specificity, the anti-CEA MA39, was amplified by PCR and cloned into the pKM16 vector. The authors then analyzed freeze-thaw purified periplasmic proteins in Western blot developed with an anti-FLAG secondary antibody (FIG. 3). Single-chain antibody bands migrated as proteins with the expected molecular weight. N-terminal protein sequencing by Edman degradation confirms the correct processing of the leader peptide.

### Phagemids for Display of scFv Antibody

A classic phagemid (pDN322) displaying the anti-CEA single-chain antibody, MA39, was compared with pKM17, pKM18 and pKM19 vectors displaying the same antibody, for phage particle production and display efficiency. The pKM17 and pKM18 plasmids (FIG. 1) allow display of antibody fragments on a phage particle by fusion to, respectively, the entire pIII (1-406 aa) or the carboxy terminal domain only (210-406 aa) of the protein. The pKM19 plasmid, derivative of pKM18, harbors an amber codon in leader sequence, thus leading to lower production of scFv-pIII fusion proteins as compared to pKM18. This is in agreement with data showing that in supE bacteria, suppression efficiency of this TAG codon, which depends on nucleotide context, is about 10-15% (J. Mol. Biol. 1983 164(1): 59-71; Mol. Gen. Genet. 1987 207(2-3): 517-518).

The authors performed functional tests by cloning the anti-CEA single-chain antibody gene into the three novel plasmids and confronting them with the original MA39 clone (anti-CEA in pDN322).

Three single colonies for each clone were incubated in 10 mL of media and phage was amplified as described in Example 2. After phagemid rescue the supernatants were titered. The authors obtained a range between 5 to  $1 \times 10^{11}$  TU/mL for MA39, pKM18 and pKM19, displaying the anti-CEA antibody, while anti-CEA/pKM17 generated five to ten times lower titers (Table 1).

TABLE 1

Phage production by different phagemid vectors encoding the same anti-CEA gene.					
Phage	Clone	Titer	Phage	Clone	Titer
MA39	1	$1.5 \times 10^{11}$	anti-CEA/pKM18	1	$2.52 \times 10^{11}$
	2	$2.55 \times 10^{11}$		2	$2.5 \times 10^{11}$
	3	$5.1 \times 10^{11}$		3	$1.75 \times 10^{11}$

TABLE 1-continued

Phage production by different phagemid vectors encoding the same anti-CEA gene.					
Phage	Clone	Titer	Phage	Clone	Titer
anti-CEA/pKM17	1	$6 \times 10^{10}$	anti-CEA/pKM19	1	$3 \times 10^{11}$
	2	$4.1 \times 10^{10}$		2	$1.8 \times 10^{11}$
	3	$1.95 \times 10^{10}$		3	$2.8 \times 10^{11}$

Phage preparations were tested in ELISA, where developing was performed by using the anti-M13, or alternatively, the anti-FLAG secondary antibody. Applying different amounts of the phage per ELISA well, the authors demonstrated higher display efficiency for pKM18 and pKM19 phages in comparison with pKM17 and much higher as compared to MA39 (FIG. 4). It is interesting that the MA39 clone, which produces a higher level of antibodies than anti-CEA/pKM17, as shown by developing with anti-FLAG antibody (FIG. 4B), has a weaker signal when ELISA is developed with the anti-M13 secondary antibody (FIG. 4A).

This indicates that free scFvs, produced by the classic phagemid system, leak into the medium and coprecipitate with phage particles, consequently competing with phage-displayed antibodies for target binding. This phenomenon is due to the presence of an amber codon between scFv and pIII genes.

In order to verify this hypothesis, the authors filtered fresh preparations of MA39 and anti-CEA/pKM19 phage by using Microcon 100 Centrifugal Filter Devices (Millipore Corporation, Bedford, Mass.), able to retain large phage particles and pass through soluble scFvs. The ELISA test of phage preparations, before and after filtration, developed with anti-M13 or anti-FLAG antibodies, shows that:

- (i) filtrates from both MA39 and pKM19 practically lose antibodies displayed on the phage particles, as expected;
- (ii) the free antibodies are present in both preparations (FIG. 5).

However, the level of free antibodies in the anti-CEA/pKM19 sample is markedly lower. The free antibodies in this sample are the result of antibody shedding, inevitable during phage preparation and which might increase as a result of contact with components of the filtration system; while the free antibodies in MA39 samples are the result of free antibody expression and leakage into medium together with shedding.

To test the competitive ability of free antibodies in phage supernatants we had the phage supernatants of the MA39 and anti-CEA/pKM19 phages compete either with the soluble anti-CEA antibody of known concentration (FIG. 6) or with different quantities of supernatant filtrates of both phages (FIG. 7). These two experiments show that the free scFvs efficiently compete with the phage antibodies. Ten  $\mu$ L of the MA39 filtrate already competes with 10  $\mu$ L of its own phage supernatant and 5  $\mu$ L of anti-CEA/pKM19 supernatant, while the same quantity of anti-CEA/pKM19 filtrate has no effect. Marked competition is observed only by a ten-fold excess of anti-CEA/pKM19 filtrate with the same phage supernatant (50  $\mu$ L of filtrate to 5  $\mu$ L of supernatant). Western blot analysis (FIG. 8) of various PEG-purified phages developed with an anti-FLAG antibody detects: (i) the upper band in each sample corresponding to scFv-pIII fusion in case of MA39 and anti-CEA/pKM17 phages, and scFv- $\Delta$ pIII in case of anti-CEA/pKM18 or anti-CEA/pKM19; (ii) a notable presence of free antibodies in MA39 sample; (iii) presence of

degradation products in the phage samples as previously described (Gene 1995 155(1):61-65).

Generation of scFv Antibody-Displayed Library and Isolation of Binding Specificities Using New pKM19 Plasmid

The pKM19 plasmid, a derivative of pKM18, harboring amber codon in leader sequence was used for generation of scFv library to study whether low production of fused antibodies allows efficient selection of a specific antibody against a target molecule.

An scFv antibody library was constructed from human peripheral blood lymphocytes as described in Materials and Methods. The library was selected against GST fusion of a 168 aa-long SP2 *Streptococcus pneumoniae* polypeptide (FEMS Microbiol. Lett. 2006 262(1):14-21), which was reactive with the blood sample utilized for the scFv library construction.

A selection procedure was designed to create a high concentration of the target protein in small incubation volume, by using biotinylated protein for panning and streptavidin-coated Dynabeads for isolation of bound phage, as described in Example 2. After completion of two panning rounds, we tested the reactivity of the phage pools in ELISA (FIG. 9). The phage pool, after the second round of affinity selection, was highly reactive with the fusion protein and negative with irrelevant proteins, such as GST, milk and streptavidin, which presented either as protein carrier or components of the selection system and all used as negative controls in ELISA, thus indicating successive selection of specific antibodies.

Finally, the authors isolated and sequenced a number of positive clones to confirm correct scFv sequence. One of the identified scFv genes was cloned in pKM16 for production of soluble anti-SP2 antibody (Table 5), which was used as an irrelevant antibody control in experiments described in FIGS. 6, 11 and 12.

Maturation of Anti-CEA scFv Antibody by Using pKM19 Vector

Affinity selection from a maturation library was carried out as described in BMC Cancer 2006 6:41. FIG. 10 shows that phage reactivity against the CEA protein grows in each successive selection round. Single phage clones with improved reactivity were isolated (FIG. 10). The authors sequenced 19 random clones from the phage pool after the second round of selection. None of the phage pool sequenced clones having increased affinity (0 of 19) presented stop codons in their sequence, whereas 70% (9 of 13) of classic phagemid system clones contained such mutations ( $P=0.00002$ , calculated according to chi square test). Thus, the use of the pKM19 vector for maturation of an anti-CEA antibody significantly improves selection results.

Two antibody genes isolated from maturation library (clones 1 and 2), were cloned in pKM16, and soluble antibodies were produced and compared with the original soluble anti-CEA MA39 and the matured E8 antibody obtained with canonical phagemid (Pavoni et al., 2006). FIG. 11 confirms the higher affinity of the matured antibodies.

The specificity test on newly selected scFvs shows their low background reactivity with irrelevant proteins, comparable with that of the original antibody (FIG. 12).

#### Example 2

##### Construction of the Libraries Derived from TIL and Antibody Selection

###### Introduction

Identification of tumor-specific recombinant antibodies from display libraries derived from lymph nodes of cancer

patients is described in [Clin. Exp. Immunol. 1997 109(1):166-74; Int. J. Mol. Med. 2004 14(4):729-35; World J. Gastroenterol. 2004 10(18):2619-23].

It is known that about 7% of lymph node-derived, and between 18-68% of TIL-derived heavy chain antibody sequences belong to clonal groups (Cancer Immunol. Immunother. 2003 52(12):715-738). This indicates both tumor-draining lymph nodes and tumor-infiltrating lymphocytes are promising sources of tumor-specific antibodies. The authors showed, by PCR amplification of specific antibody gene regions deriving from ten primary breast tumors (none being of the rare MBC histological type) of patients aged between 49-79 years, that 7 of 10 of these samples (70%), have a prominence of IgG antibody expression, as compared with IgA subclass, which correlates with the oligoclonality of the hypervariable region of heavy chain antibodies, suggesting a specific immune response to tumor-expressed antigens. Clonality of tumor-derived antibodies was confirmed by sequencing analysis.

The authors identified a panel of tumor-specific antibodies from described libraries which were reactive with ED-B domain, MUC1, CEA and MCF7 breast carcinoma cells used in respective selections. It is interesting that in performing cell-based selection without subtractive panning step on normal breast epithelium, in contrast with numerous previously described selection protocols [Int J Mol Med. 2004 14(4):729-35; World J Gastroenterol. 2004 10(18):2619-23; Int J Oncol. 2000 16(1):187-95; Cancer Res. 1999 59(11):2718-23; Biochem Biophys Res Commun. 2001 280(2):548-52], the authors isolated only one scFv out of 10 was not tumor-specific and recognized normal breast epithelium as well. This probably indicates that our modest-sized libraries contain a very restricted naturally occurring antibody repertoire provided by TIL-B, rather than a vast antibody repertoire created by antibody chain shuffling. Moreover, antibody selection from a mixture of PBL and TIL-derived libraries clearly shows the latter libraries to be more efficient in cell-based panning. In fact, all isolated anti-MCF7 single-chain antibodies appeared to be derived from tumor-infiltrating lymphocytes. In summary, TIL-derived libraries gave good results in all performed selections, providing a panel of human tumor-specific antibodies, which recognize tumor cell-surface antigens useful for therapy and diagnosis of cancer.

In this study we demonstrated that application of novel improved phage-display vector pKM19 led to the isolation of a large panel of antibodies derived from pieces of tumor tissue removed in tumor surgery, against known tumor antigens and entire tumor cells, and which are potentially useful in therapy of cancer. These results are similar to the results obtained by direct screening of soluble TIL-derived antibody expression libraries (Cancer Immunol. Immunother. 2002 51(2):79-90). The direct screening is an unbiased screening strategy which does not depend from phage amplification steps and results more efficient as compared to affinity selection performed with canonical display vectors, which failed to select tumor-specific antibodies in analogous works (Cancer Res. 2001 61(21):7889-99; Proc. Natl. Acad. Sci. U.S.A. 2001 98(22):12659-64; Int. J. Cancer 2001 93:832-40). Our results indicate that pKM19 vector improves the selection results in comparison with classic display vectors and at the same time, provides possibility to apply affinity selection methodologies, facilitating manipulation with large libraries.

In conclusion, our results indicate that naturally occurring immune responses to tumor-related antigens exist in a majority of patients with breast cancer, not only in histologically-defined MCB. Tumor samples as small as 0.2 g obtained as



surgical material and, can be exploited as an appropriate source for generation of recombinant phage display libraries enriched for tumor-specific antibodies. Isolation of a panel of anti-tumor scFvs through selection against desirable protein targets, as well as against living breast carcinoma cells, shows this approach to be very promising for development of human therapeutic antibodies. Moreover, investigation of the protein targets eliciting production of tumor cell-specific antibodies in a tumor microenvironment may (i) provide important details about individual immunoreactivity of a given patient, affording a prognostic value; (ii) open a large perspective for discovery of novel tumor-specific antigens.

#### Methods

##### Tissue and Blood Samples

Specimens of breast carcinoma and fresh peripheral blood from breast cancer patients (B81-B96, EC23) were obtained from M. G. Vannini Hospital, Rome. All the human biological samples were obtained through informed consent.

##### Cell Lines

The breast carcinoma cell lines MCF-7 (ATCC Number: HTB-22), MDA-MB-468 (ATCC Number: HTB-132) and SkBr3 (ATCC Number: HTB-30), and colon adenocarcinoma cell line LoVo (ATCC Number: CCL-229) were maintained according to manufacturer's instructions. Human foreskin fibroblasts (HFF) were cultivated in DMEM supplemented with 10% FBS and 1% L-glutamine. Immortal breast epithelial cells MCF10-2A (ATCC number CRL-10781) [Cancer Res. 1990 50(18):6075-86] were propagated according to manufacturer's instructions, and used as negative controls in ELISA tests.

##### Purified Tumor Antigen Proteins

Human CEA protein, purified from colon carcinoma and liver metastases, was purchased from USBiological (#C1300-16, United States Biological, Swampscott, Mass.).

Biotinylated recombinant ED-B domain of fibronectin was obtained from Sigma-Tau S.p.A. (Pomezia, Rome).

Recombinant MUC1 protein was obtained in several steps. Two over-lapping oligonucleotides KM358 5'-ACT TCA GCT CCG GAC ACC CGT CCG GCT CCG GGT TCC ACC GCT CCG CCG GCT CAC GGT GTC-3' [SEQ ID 97] and KM359 5'-CGG AGC CGG ACG GGT GTC CGG AGC TGA AGT GAC ACC GTG AGC CGG CGG AGC GGT GGA ACC-3' [SEQ ID 98] encoded for 20-aa MUC1 repeat, were assembled in PCR-like process, in which 25 cycles of PCR amplification were performed with 0.2  $\mu$ M/ $\mu$ L of KM358 and KM359. High-weight DNA band was then cut from agarose gel and ligated with a short adapter, obtained by annealing a KM328 5'-CT AGT TCG TCG GGT TCG TCG GGA-3' [SEQ ID 99] oligonucleotide and a phosphorylated one: KM329 5'-TCC CGA CGA ACC CGA CGA A-3' [SEQ ID 100]. The resulting DNA fragment was purified from adapter excess, phosphorylated and cloned into digested and dephosphorylated pGEX-SN [Int J Cancer. 2003 106(4):534-44], derived from pGEX-3X plasmid [Gene 1988 67:31-40]. GST-fused MUC1 recombinant protein, containing a 107-aa MUC1 sequence, containing 5.3 repeats, was purified according to standard methods [Gene 1988 67:31-40].

##### Purification of Lymphocytes from Peripheral Blood

The lymphocytes were isolated from 10 mL of fresh peripheral blood mixed with anticoagulant by using Ficoll-Paque Plus (Amersham Pharmacia Biotech, Sweden) according to manufacturer's instructions. mRNA was isolated from lymphocytes by using Dynabeads mRNA DIRECT Kit (Dyna, Norway).

##### RNA Extraction and cDNA Synthesis

Tumor specimens of about 200 mg from breast carcinoma patients were obtained as surgical discard samples and imme-

diately frozen in liquid nitrogen. Total RNA was prepared by Total RNA Isolation System (Promega, Madison, Wis.) and purified to poly A<sup>+</sup> RNA using PolyAtract mRNA Isolation Systems (Promega). Five hundred ng of poly(A)<sup>+</sup> RNA from breast carcinomas or 1  $\mu$ g of the poly(A)<sup>+</sup> RNA from the lymphocytes were used to synthesize full-length cDNAs by using SMART cDNA library construction kit (Clontech, Palo Alto, Calif.).

##### Analysis of Antibody Gene Expression by PCR

The hypervariable V(D)J antibody region was amplified by PCR from cDNA templates by using site-specific primers 5'-GGACACGGCT(G/C)TGTATTACTG-3' [SEQ ID 101] and 5'-GCTGAGGAGACGGTGACC-3' [SEQ ID 102] designed in designed in a study by Hansen and colleagues [Proc Natl Acad Sci USA 2001 98(22):12659-64]. IgG1, IgG2 and IgA subclass determination was done as described in [J Immunol. 2002 169(5):2701-11] by individually combining constant region-specific primers for IgG1, IgG2 and IgA genes (CG1d, CG2a and CA1, respectively) with a set of variable heavy chain primers: VH135, VH3a, VH3f, VH4, VH4b. These primers were designed for construction of human Fab libraries [Barbas C F III, Burton DR (1994) Monoclonal antibodies from combinatorial libraries. Cold Spring Harbor Laboratory Course Manual].

##### ScFv Library Construction

Antibody gene repertoire was amplified using set of primers designed for amplification of VH and VL antibody domains [Pope, A. R., Embleton, M. J. & Memaugh R. (1996) Construction and use of antibody gene repertoires. In: Antibody Engineering—A practical approach (McCafferty, J., Hoogenboom, H. & Chiswell D., eds), pp. 325, Oxford University Press] and scFv fragments were assembled in vitro as described earlier [Pope A Ret al., 1996]. The scFv fragments were then amplified by PCR with appropriate extension primers, incorporating NcoI, NotI restriction sites, permitting the cloning of the scFv genes into pKM19 vector. The resulting PCR products were purified on a 1% low-melting agarose gel (NuSieve 3:1 agarose, Rockland, Me.). The DNA fragments were digested with NcoI/NotI and inserted into pKM19 vector. The ligated DNA was used to transform competent bacterial cells DH5 $\alpha$ F' (supE44  $\Delta$ lacU169 ( $\phi$ 80 lacZ $\Delta$ M15) hsdR17 recA1 endA1 gyrA96 thi-1 re1A1 F' [traD36proAB<sup>+</sup> lacI<sup>q</sup>lacZ $\Delta$ M15]) by electroporation. The transformed cells were plated on 20 agar dishes ( $\phi$ 15 cm), containing LB agar, 100  $\mu$ g/mL ampicillin and 1% glucose. After overnight incubation at 37° C., bacterial colonies were scraped from the plates and resuspended in LB, containing 10% of glycerol. Aliquots of this cell suspension were stored at -80° C. and used for phage amplification.

##### Phage Amplification

Forty  $\mu$ L of scraped bacterial cells were incubated in 40 mL of LB containing ampicillin and 1% glucose up to O.D.=0.2. The bacteria were collected by centrifuging and resuspended in 40 mL of LB with ampicillin without glucose. About  $6 \times 10^9$  pfu of helper M13K07 were added to each mL of cell suspension, incubated for 15 min at 37° C. without agitation and a further 2 h in a shaker. Kanamycin was added to final concentration 20  $\mu$ g/mL and cells were incubated ON at 32° C. Phage was purified according to standard PEG/NaCl precipitation [Sambrook J, Fritsch E F, Maniatis T. Molecular cloning: A laboratory manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 1989].

##### Cell-Based Selection of Antibodies from Phage-Displayed Library

MCF-7 semi-confluent cells (about  $2 \times 10^7$ ) were rinsed 3 times with PBS buffer and incubated with 2 mL of 2 mM EDTA in PBS for 15 min at 37° C. Ten mL of PBS containing

10 mM MgCl<sub>2</sub> were added to the cells, they were accurately removed by pipetting. The cells were collected by centrifuging, washed once with 10 mL of PBS/MgCl<sub>2</sub> and finally resuspended in 1 mL of freshly prepared blocking buffer: 4% non-fat dry milk, 0.05% Tween 20, 5×10<sup>11</sup> pfu of fl UV-killed phage. The cells were blocked for 30 min at RT on rotating wheel, then collected and incubated for 1 h at 37° C. on the wheel with about 5×10<sup>11</sup> TU of freshly amplified scFv antibody library in 1 mL of blocking buffer. The cells were washed 5 times with PBS/Tween. The bound phage was eluted by adding 400 μL of 0.1 M HCl, pH 2.2 (adjusted by glycine). Cell suspension was incubated with elution solution for 10 min at RT, neutralized by 40 μL of 2M Tris-HCl, pH 9.6 and used for infection of bacterial cells. The bacteria were plated on two LB agar dishes (ø15 cm), containing 100 μg/mL ampicillin and 1% glucose. Scraped bacteria were used for phage amplification.

#### Affinity Selection on Purified Protein Targets.

CEA and MUC1 were biotinylated as described in [Harlow E. & Lane D. *Antibody: A laboratory manual*. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, 1988]. About 5×10<sup>11</sup> TU of freshly amplified scFv antibody libraries were preincubated with 50 μL of AD202 bacterial extract in blocking buffer for 30 min at 37° C. Twenty γ of a biotinylated protein were added to the reaction mixture and incubated for another h at 37° C. under gentle agitation. The bound phage was captured by using streptavidin-coated Dynabeads M-280 (112.05, Dynal, Oslo, Norway) according to manufacturer's instructions, washed 5-10 times with PBS/Tween, then, eluted and amplified as above.

#### ELISA Experiments

The cells were grown in 96-well plate until almost confluent. After discarding the growth medium, 100 μL of freshly prepared 4% paraformaldehyde (#15710, Electron Microscopy Science, Hatfield, Pa.) in PBS were rapidly added for 10 min. The fixing solution was removed by pipetting and cells were incubated with blocking buffer (5% milk, 0.05% Tween 20 in PBS) for 30 min at RT. PEG purified phage in blocking buffer (1:1) was added to cells and incubated for 1 h at 37° C. under gentle agitation. The cells were washed 3 times and an anti-M13 HRP-conjugated antibody (Pharmacia) was used for developing the reaction. All assays were done in triplicate.

#### Immunofluorescence Staining

The cells were grown in a 24-well plate for cell culture (Nunc, Roskilde, Denmark), fixed as above and blocked with 3% BSA in PBS for 1 h at room temperature. PEG-purified phage in 1% BSA/PBS was added to the cells and incubated for 1 h under gentle agitation at 37° C. The cells were washed three times with 1% BSA/PBS and incubated with an anti-M13 mouse monoclonal antibody (27-9420-01, Amersham Biosciences) for 30 min at 37° C. The cells were washed as above and then incubated with an FITC-conjugated anti-mouse goat polyclonal antibody (554001, BD Biosciences Pharmingen, San Jose, Calif.) at a concentration of 5 μg/mL for 30.1 min at 37° C. under gentle agitation. After the last incubation, cells were washed five times, dried in the dark, mounted with Vectashield medium (Vector Laboratories, Inc. Burlingame, Calif.) and cover glasses, and analyzed using an inverted fluorescence microscope.

All antibodies are defined in table 5.

#### Results

##### Characterization of the Lymphoplasmatic Cell Infiltrate in Breast Tumor Samples

Ten tumor specimens from breast cancer patients (aged 47-79 years) for presence and nature of TIL-B by PCR ampli-

fication of V(D)J antibody segments (CDR3) and by comparison of representation of IgG and IgA antibody classes were examined.

The expression patterns of the antibody fragment genes was analyzed by semi-quantitative PCR from SMART cDNA template. The panel of cDNAs from ten breast carcinomas, from samples of normal breast, normal testis and peripheral blood lymphocytes from healthy donors were normalized by PCR amplification of a housekeeping gene, β-actin and are shown in FIG. 13A.

Hypervariable heavy chain antibody regions (V(D)J) were amplified as described in Materials and Methods. After analysis by agarose gel electrophoresis, the same PCR products were fractionated by high resolving 10% PAGE (FIG. 13B). In applying this technique, the authors observe that 7 out of 10 tumor-deriving samples contain various numbers of discrete bands, characterizing oligoclonality of the immune response in these patients, while the well-amplified normal breast and peripheral lymphocyte DNA fragments do not contain intensive bands and form a smear, consisting of the bands of different length. The observed oligoclonality of the immunoglobulins does not correlate with the age of the patients.

In order to analyze the antibody subclass distributions we amplified Ig genes from breast carcinoma cDNAs and normal breast, using subclass-specific primers. In agreement with previous assay, the 3 cDNA tumor samples, not containing oligoclonal bands in PCR-amplified V(D)J regions, have a prevalence of the IgA band in comparison with IgG1 and IgG2 bands, just as in a sample of normal breast where IgA generally represents the major Ig class (Br. Med. J. 1976 2(6034):503-506). On the other hand, samples showing oligoclonality in the first assay contain IgG1, or both IgG1 and IgG2 as dominant antibody bands, in contrast to normal breast. FIG. 14 shows four more characteristic examples along with normal breast sample.

##### Oligoclonality of TIL-B Derived Antibodies in Breast Cancer Patients was Confirmed by Sequencing

The authors chose two cDNA samples (B92, B93) giving strongest single bands in V(D)J test, for sequencing analysis. The nucleotide sequences of 17 and 13 randomly picked clones containing γ antibody genes deriving from B92 and B93 cDNA, respectively, were determined and their amino acid sequences were deduced. All 30 clones encoded in-frame correct organized heavy chains. More frequently isolated antibodies (B92-A and B93-A1) contained V(D)J regions of the exact length corresponding to the strong bands earlier observed in FIG. 13B (lines with B92 and B93 samples) (FIG. 15), thus indicating that both PCR amplification with variable heavy chain primers and the cloning step do not introduce any particular bias interfering with heavy chain frequencies in the constructed library.

As indicated FIG. 15, six somatic mutations were identified in antibody fragments. These mutations are localized in variable CDRs of γ chain of the same specificity, while only one mutation is found out of variable regions (P=0.0002). Therefore, oligoclonality of antibody repertoire derived from tumor tissue is a natural immune response occurring within tumor tissue driven by tumor antigens, and not an artifact introduced by PCR amplification.

##### Library Construction

Four scFv antibody libraries were constructed using seven cDNAs as template, characterized by oligoclonality of the immune response (see list of libraries in Table 2). Only library scFvEC23 (described in Example 1) was constructed from peripheral blood lymphocytes, obtained from a single patient with advanced stage of breast cancer.

TABLE 2

ScFv-antibody library list.			
Library	Source of Ig genes	Patient (age)	Library complexity
ScFvB87	TIL	B87 (55)	$4.7 \times 10^5$
ScFvB95	TIL	B95 (73)	$1.1 \times 10^7$
ScFvB96	TIL	B96 (72)	$2.6 \times 10^7$
ScFvmix	TIL	B85 (47), B91 (70), B92 (79), B93 (66)	$2.4 \times 10^7$
ScFvEC23	PBL	EC23 (65)	$1.8 \times 10^7$
mixTIL	TIL	—	ScFvB87 + ScFvB95 +
mixLIB	TIL + PBL	—	scFvB87 + scFvB95 + scFvmix + scFvEC23

### Selection of Specific Anti-Tumor Antibodies from Phage Display Libraries Generated from TIL-B and PBL

The authors examined directly the possibility of selecting specific antibody fragments from phage libraries against common cancer antigens including ED-B domain of fibronectin [EMBO J. 1987 6(8):2337-42], MUC1 [Cancer Res. 1992 52(22):6365-70; Hum Pathol. 1995 26(4):432-9], and CEA [J. Clin. Lab. Anal. 5: 344-366; Semin Cancer Biol. 1999 9:67-81; Cancer Res. 2002 62:5049-5057]. Under conditions described in Materials and Methods a mixture of four TIL-derived scFv antibody-displayed libraries (scFvB87, scFvB95, scFvB96 and scFvmix) named mixTIL library (Table 2) and the scFvEC23 library were panned separately against three protein targets in several rounds. In every case we observed that pools of phage were already positive against the selecting antigen after second and third rounds of panning (FIG. 16). Randomly picked clones were tested for binding reactivity against the antigens. Results of the test of random phage clones from third round phage pools are summarized in Table 3. Positive clones were analyzed by fingerprinting using HaeIII and AluI double digestion and unique antibody clones were sequenced. FIG. 17 represents ELISA of single scFv-phages selected on purified antigens. The analyzed single clones strongly bind respective antigens and does not react with irrelevant proteins. This result indicates the pKM19 vector is a suitable tool for selection of anti-tumor antibodies from TIL and PBL-derived libraries.

TABLE 3

Result of selections through the use of three purified tumor antigens.			
Target antigen	Library	Positive clones/ tested clones	Isolated antibody genes
ED-B	mixTIL	10/10	1
	scFvEC23	10/10	3
MUC1	mixTIL	2/16	1
	scFvEC23	6/8	2
CEA	mixTIL	17/20	4
	scFvEC23	15/20	3

### Cell-Based Selection of Tumor-Specific Antibodies

The authors tested functionality of a single TIL-derived library (scFvB96) by selecting breast cancer-specific antibodies through cell-based panning on MCF-7 breast carcinoma cell line. Four libraries, including scFvB87, scFvB95, scFvmix and scFvEC23, were pooled together (library named mixLIB, table 2) and panned on the same type of cells. Four or five selection rounds on MCF-7 cells were necessary for mixLIB or scFvB96 libraries, respectively, in order to enrich the phage pools for specific cell binders (FIG. 18). Then, randomly picked clones were analyzed for entire scFv antibody presence. The full-length scFv-phage clones were tested

by cell-based ELISA, and analyzed by fingerprinting, and various positive clones were sequenced. Amino acid sequences were deduced from DNA sequences, confirming correct, in-frame antibody structures. Clone analysis data are summarized in Table 4.

TABLE 4

Result of selection on intact/living human breast carcinoma MCF7 cells.		
Library	MCF-7 selection	
	scFvB96	mixLIB
Selection round	5	4
Full-length scFv/tested clones	12/40	30/40
Positive clones/full-length tested clones	5/12	22/30
Isolated antibody genes	2	8

The reactivity and specificity of cell-selected antibodies were verified by ELISA on both breast carcinoma cell lines: MCF-7, MDA-MB-468, and normal cells, as negative controls: MCF10-2A (human breast epithelium), HFF (human fibroblasts) (FIG. 19). Among 10 different selected scFv antibodies belonging to 7 specificity groups (mix7, mix12, mix25 antibodies have the same heavy chain sequence and different light chains; mix8 and mix39 antibodies have similar sequences with minor differences), 9 are specific for breast carcinoma cells, while only B96/4F scFv antibody binds normal epithelial cells as well.

### Cell-Selected Antibodies Derive from TIL

Mix11, mix12, mix17, mix23 and mix39 scFv antibodies (Table 4) were selected from a mixture of PBL and TIL-derived libraries. The authors investigated the origin of these antibodies in order to see which type of library works better in equal selection conditions. One  $\mu$ L of each amplified library was used as template for PCR amplification with pair of oligonucleotide primers specific for each antibody (FIG. 20). This analysis shows that the 5 tested scFv antibodies, isolated from a mixture of libraries, belong to TIL-derived antibodies. Antibody genes of mix7 and mix25 antibodies (having the same heavy chain as mix12, table 5), and mix8 (similar to mix39, table 5) are believed to have a similar origin. For irrelevant anti-SP2 antibody, which was selected from the scFvEC23 library, its origin from PBL-derived library was confirmed. Anti-MUC1 MB5 and anti-CEA CB37 antibodies, which were selected from the mixture of four TIL-derived libraries (mixTIL) were shown to derive from the scFvmix and the scFvB96 libraries, respectively.

### Fluorescent Staining of Tumor Cells

Binding specificities of several clones, including mix17, mix7 (FIG. 21), anti-Muc1 antibody MB5 and anti-CEA CB37 (FIG. 22) were assayed by immunofluorescent staining of tumor cells directly with scFvs antibodies displayed on the phage. Mix17 scFv recognizes major part of non-permeabilized MCF7 breast carcinoma cells in this experiment (FIG. 21A), while mix7 stains a low percentage of cells, probably apoptotic cells.

MB5 antibody intensively stains MCF7 cells, known for high MUC1 expression, and reacts well also with another breast carcinoma cell line, SkBr3(FIG. 22). CB37 antibody stains LoVo cells. No background staining for normal breast epithelium was observed for both MB5 and C1337 antibodies.

### Example 3

#### Maturation of Anti-MUC1 and Anti-CEA scFv Antibodies

To increase affinity of tumor specific antibodies CB37 and MB5 we performed affinity maturation of the antibodies in

vitro. The new maturation libraries were created by combination of genes of single VH chains derived from CB37 and MB5, respectively, with various genes of VL chains derived from TIL and PBL of tumor patients. The libraries were constructed as described in Example 1 and 2.

#### Methods

##### Affinity Selection

The affinity selection was performed by using biotinylated proteins as described in Example 2, with the difference that for first round of affinity selection we used 10 µg of the protein and for second only 50 ng. Clones found positive in ELISA were screened by PCR and fingerprinting with restriction enzymes AluI and HaeIII to identify different clones. The

DNA sequence of the clones were determined. The antibody genes from clones having reactivity against target proteins higher than original antibodies were cloned in pKM16 to produce scFvs in soluble form as described in Example 1.

##### 5 Characterization of Maturated Antibodies

The maturated antibody fragments were characterized for antigen binding.

10 The new anti-MUC1 antibodies MB5/C'1 and MB5/C'3 and anti-CEA maturated antibodies CB37/3B and CB37/9C (Table 5) in soluble form were characterized by Surface Plasmon Resonance (Biacore) as described in BMC Cancer 2006 6:41. Results are shown in table 6.

TABLE 5

Selected antibodies. MixTIL and MixLIB are mixture of libraries defined in table 2.			
Anti-body	Anti-gen	Library used for selection	Nucleotide/Amino acid sequence
EDE1	ED-B	scFvEC23	<p>CAGGTGCAGCTGCAGGAGTCTGGGGCTGAGGTGAAGAAG  CCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCTTCTGGA  TACACCTTCACCGGCTACTATATGCACTGGGTGCGACAG  GCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAAC  CCTAACAGTGGTGGCACAACACTATGCACAGAAGTTTCAG  GGCAGGGTCACCATGACCAGGGACACGTCCATCAGCACA  GCCTACATGGAGCTGAGCAGGCTGAGATCTGACGACACG  GCCGTGTATTACTGTGCGAGAGATTGCCACAAAATTGT  ACTAATGGTGTATGCCACCGGGGAGTCATGTCCACTAC  TACGGTATGGACGTCTGGGGCCAAGGCACCCTGGTCACC  GTCTCTTCAGGTGGGGCGGTTGAGCGGAGGTGGCTCT  GGCGGTGGCGGATCGCAGTCTGCCCTGACTCAGCCTGCC  TCCGCGGCCGGTCTCCTGGACAGTCAGTCACCATCTCC  TGCACTGGAACCAGCAGTGATGTTGGTGGTTATAACTAT  GTCTCCTGGTACCAACAGCACCCAGGCAAAGCCCCAAA  CTCATGATTTATGACGTCAATAAGCGGCCCTCAGGGGT  CCTGATCGCTTCTCTGCCCTCAAGTCTGGCAACACGGCC  TCCCTGACCGTCTCTGGGCTCCAGGCTGACGATGAGGCT  GATTACTACTGCGCTTCATATGCAGGCACCTACAGTTAT  GTCTTCGGAAGTGGGACCCAGCTCACCGTTTTAGGTGCG  GCCGAGGAGA [Seq ID 22]</p> <p>QVQLQESGAEVKKPGASVKVSKASGYTFTGYMHVVRQ  APGQGLEWMGWINPNSGGTNYAQKFGQGRVTMTRDTSIST  AYMELSRRLRSDDTAVYYCARDSPQNCTNGVCHRSHVHY  YGMVWVWGQTLVTVSSGGGGSGGGSGGGGSQSALTQPA  SAAGSPGQSVTISCTGTS SDVGGYNYVSWYQHPGKAPK  LMIYDVNKRPSGVPDRFSASKSGNTASLTVSGLQADDEA  DYVCASYAGTYSYVFGTGTQLTVLGAAA [Seq ID 23]</p>
EDE3	ED-B	scFvEC23	<p>GAGGTGCAGCTGTTGCAGTCTGGGGCCGAGGTGAAGAAG  CCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCTTCTGGA  TACACCTTCACCGGCTACTATATGCACTGGGTGCGACAG  GCCCTGGACAAGGGCTTGAGTGGATGGGATGGATCAAC  CCTAACAGTGGTGGCACAACACTATGCACAGAAGTTTCAG  GGCAGGGTCACCATGACCAGGGACACGTCCATCAGCACA  GCCTACATGGAGCTGAGCAGGCTGAGATCTGACGACACG  GCCGTGTATTACTGTGCGAGAGATTGCCACAAAATTGT  ACTAATGGTGTATGCCACCGGGGAGTCATGTCCACTAC  TACGGTATGGACGTCTGGGGCCAGGGAACCCTGGTCACC  GTCTCCTCAGGTGGGGCGGTTGAGCGGAGGTGGCTCT  GGCGGTGGCGGATCGCAGTCTGCCCTGACTCAGCCTGCC  TCCGCGGCCGGTGTCTTGGACAGTCAGTCACCATCTCC  TGCACTGGAACCAGCAGTGATGTTGGTGGTTATAAATAT  GTCTCCTGGTACCAACAGCACCCAGGCAAAGCCCCAAA  CTCATGATTTATGACGTCAATAAGCGGCCCTCAGGGGT  CCTGATCGCTTCTTTGCCCTCAAGTCTGGCAACACGGCC  TCCCTGACCGTCTCTGGGCTCCAGGCTGACGATGAGGCT  GATTACTACTGCGCTTCATATGCAGGCACCTACAGTTAT  GTCTTCGGAAGTGGGACCCAGCTCACCGTTTTAGGTGCG  GCCGCA [Seq ID 24]</p> <p>EVQLLQSGAEVKKPGASVKVSKASGYTFTGYMHVVRQ  APGQGLEWMGWINPNSGGTNYAQKFGQGRVTMTRDTSIST  AYMELSRRLRSDDTAVYYCARDSPQNCTNGVCHRSHVHY  YGMVWVWGQTLVTVSSGGGGSGGGSGGGGSQSALTQPA</p>

TABLE 5-continued

Selected antibodies. MixTIL and MixLIB are mixture of libraries defined in table 2.			
Anti-body	Anti-gen	Library used for selection	Nucleotide/Amino acid sequence
			SAAGCGLQSVTISCTGTSSDVGKYKYSWYQHPGKAPK LMIYDVNKRPSGVPDRFPASKSGNTASLTVSGLQADDEA DYCYASYAGTYSYVFGTGTQLTLVLGAAA [Seq ID 25]
EDES	ED-B	scFvEC23	GAGGTGCAGCTGGTGGAGTCTGGGGCTGAGGTGAAGAAG CCTGGGGCCTCAGTGAAGGTCTCTGCAAGGCTTCTGGA TACACCTTACCGGCTACTATATGCACTGGGTGCGACAG GCCCCGACAAAGGCTTGGAGTGGATGGGATGGATCAAC CCTAACAGTGGTGGCACAACACTATGCACAGAAGTTTCAG GGCAGGGTCACCATGACCAGGGACACGTCCATCAGCACA GCCTACATGGAGCTGAGCAGGCTGAGATCTGACGACACG GCCGTGTATTACTGTGTGAGAGGTTGCCACAAAATTGT ACTAATGGTGTATGCCACCGGGGAGTCATGTCCACTAC TACGGTATGGACGTCTGGGGCCAAGGGACCAGGTCAAC GTCTCCTCAGGTGGGGGCGGTTCCAGGCGGAGGTGGCTCT GGCGGTGGCGGATCGCAGTCTGCCCTGACTCAGCCTGCC TCCGTGTCTGGGTCTCCTGGACAGTCGATCACCATCTCC TGCCTGGAACAGCAGTGTGTTGGGAGTTATAACCTT GTCTCCTGGTACCAACAGCAGCCAGGCAAGCCCCAAA CTCATGATTTATGAGGTGAGTAATCGGCCCTCAGGGGTT TGTAATCGCTTCTCTGGCTCCAAGTCTGGCAACACGGCC TCCCTGACCATCTCTGGGCTCCAGGCTGAGGACGAGGCT GATTATTACTGCAGCTCATATACAAGCAGCAGCACTCTC GAGGTGTTCCGGCGAGGGACCCAGCTCACCGTTTTAGGT GCGGCCGCA [Seq ID 26]
			EVQLVESGAEVKKPGASVKVSKASGYTFTGYMHWRQ APGQGLEWMGWINPNSGGTNYAQKFRVMTTRDTSIST AYMELSLRSDDTAVYYCVRGSPQNCNMGVCHRGSVHY YGMVWVGQTTTVTVSSGGGGSGGGSGGGGSQSALTQPA SVSGSPGQSITISCTGTSSDVGSYNLVSWYQHPGKAPK LMIYEVSNRPSGVCNRFSGSKSGNTASLTVSGLQAEDEA DYCYSSYTSSSTLEVFVGGGTQLTLVLGAAA [Seq ID 27]
EDEB	ED-B	mixTIL	CAGGAGGTGCAGCTGGTGGAGTCTGGGGGTGGCTTGGTC CAGCCTGGGGGGTCCCTGAGACTCTCCTGTGAGCCTCT GGATTCACCCCTCAGTAGCTATGCTATGCACTGGGTCCGC CAGGCTCCAGGGAAGGGGCTGGAGTGGTCTCAACTATT AGTGGTGGTGGTGGTAGCACATACTACGACAGCTCCGTG AAGGGCCGGTTCACCATCTCCAGAGACAATCCAAGAAC ACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGAC ACGGCCGTATATTAAGTGTGCGAGACGGGGGCGGGCTTTT GATATCTGGGGCCAAGGGACCAGGTCAACCTCTCCTTA GGTGGAGGCGGTTCCAGGCGGAGGTGGCTCTGGCGGTGGC GGATCGCAGTCTGTGTTGACGACAGCCGCCCTCAGTGTCT GGGGCCCCAGGGCAGAGGGTCAACATCTCCTGCACTGGG AGCAGCTCCAACATCGGGGCGGGTATGATGTACTACTGG TACCAGCAGCTTCCAGGAACAGCCCCAAACTCCTCATT TATGGTAACAGCAATCGGCCCTCAGGGTCCCTGACCGA TTCTCTGGCTCCAAGTCTGGCACCCTCAGCCTCCCTGGCC ATCACTGGGCTCCAGGCTGAGGATGAGGCTGATTATTAT TGCTCCAGTCTATGATCAGCAGCCTGAGTGGTCAATGTG GTATTCGGCGGAGGGACCAAGGTGACCGTCTTAGGTGCG GCCGCA [Seq ID 28]
			QEVQLVESGGGLVQPGGSLRLSCAASGFTLSSYAMHWVR QAPGKQLEWVSTISGGGGSTYYADSVKGRFTISRDNKSN TLYLQMNLSRAEDTAVYYCARRGRAFDIWGQTTTVTVSL GGGGSGGGSGGGGSQSVLTQPPSVSGAPQRVTISCTG SSSNIAGYDVHWYQQLPGLTAPKLLIYGNRPSGVPDR FSGSKSGLTASLAITGLQAEDEADYCYSSPMISLSSGHV VFGGGTKVTVLGLGAAA [Seq ID 29]
ME1	MUC1	scFvEC23	CAGGTGCAGCTGGTGCAGTCTGGGGCTGAGGTGAAGAAG CCTGGGGCCTCAGTGAAGGTCTCTGCAAGGCTTCTGGA TACACCTTACCGGCTACTATATGCACTGGGTGCGACAG GCCCCGACAAAGGCTTGGAGTGGATGGGATGGATCAAC CCTAACAGTGGTGGCACAACACTATGCACAGAAGTTCCAG GGCAGGGTCACCATGACCAGGGACACGTCCATTGGCACA GTCTACATGGAGTTGAGCAGCCTGACATCTGACGACACG GCCATGTATTATTGTGCGAGAAACAATGTTGCTATGGGT TATACTATGGACGTCTGGGGCCAAGGGACAATGGTCAAC GTCTCTCAGGTGGAGGCGGTTCCAGGCGGAGGTGGCTCT

TABLE 5-continued

Selected antibodies. MixTIL and MixLIB are mixture of libraries defined in table 2.			
Anti-body	Anti-gen	Library used for selection	Nucleotide/Amino acid sequence
			<p>GGCGGTGGCGGATCGCAGTCTGCCCTGACTCAGCCTGCC TCCGCGTCCGGTCTCCTGGACAGTCAGTCACCATCTCC TGACTGGAACCAGCAGTACGTTGGTGGTTATAACTAT GTCTCCTGGTACCAACAGCACCCAGGCAAAACCCCAA CTCTTGATTTATGAGGTGAGTAGTCGCCCTCAGGGGTT TCTAATCGCTTCTCTGGCTCCAAGCCTGGCAACACGGCC TCCCTGACCATCTCTGGTCTCCAGGCTGAGGACGAGGCT GATTATTACTGCATCTCATATACAAGCAGCAACTTGG GTGTTCCGGCGGAGGACCCAGCTCACCGTTTTAGGTGCG GCCGCA [Seq ID 30]</p> <p>QVQLVQSGAEVKKPGASVKVSKASGYFTGYMHVWRQ APGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRDTSIGT VYMELSSLTSDDTAMYYCARNNVAMGYTMDVWGQTMVT VSSGGGSGGGGSGGGGSSQALTQPASASGSPGQSVTIS CTGTSSDVGGYNYVSWYQQHPGKTPKLLIYEVSSRPSGV SNRFSGSKPGNTASLTISGLQAEDEADYYCISYTSNTW VFGGGTQLTLVLGAAA [Seq ID 31]</p>
ME2	MUC1	scFvEC23	<p>GAGGTGCAGCTGTTGCAGTCTGGGGCGGAGGTGAAGAAG CCTGGGGCCTCAGTGAAGGTCTCTGCAAGGCTTCTGGA TACACCTTACCAGCTACTATATGCACTGGGTGCGACAG GCCCCGACAAAGGCTTGGTGGATGGGATGGATCAAC CCTAACAGTGGTGGCACAACACTATGCACAGAAGTTTCAG GGCAGAGTCACCATGACCAGGAACACCTCCATAAGCACA GCCTACATGGAGCTGAGCAGCCTGAGATCTGAGGACACG GCCGTGTATTACTGTGCGGGTCAGGAGGCACATGGGGAC GGTATGGACGTCTGGGGCAAGGGACCACGTCACCGTC TCCTCGGTGGAGCGAGGTGGCTCTGGCGGTGGCGGATCG CAGTCTGCCCTGACTCAGCCTGCCCTCCGCGTCCGGGTCT CCTGGACAGTCGATCACCATCTCTGCACTGGAACCAGC GGTGACGTTGGTGGTTATAACTATGTCTCCTGGTACCAA CAGCACCCAGGCAAAGCCCCAAACTCATGATTTATGAA GTCAGTAATCGGCCCTCAGGGGTTTCTAATCGCTTCTCT GGCTCCAAGTCTGGCAGCACGGCTCCCTGACCATCTCT GGGCTCCAGGCTGAGGACGAGGCTGATTATTACTGCGTC TCATATACAAGCAGAAACACTTATGTCTTCGGATCCGGG ACCCAGCTCACCGTTTTAGGTGCGGCCGCGA [Seq ID 32]</p> <p>EVQLLQSGAEVKKPGASVKVSKASGYFTGYMHVWRQ APGQGLEWMGWINPNSGGTNYAQKFQGRVTMTRNTSIST AYMELSSLRSEDTAVYYCAGQEAHGDMDVWGQTTVTV SSVERGGSGGGGSSQALTQPASASGSPGQSI TISCTGTS GDVGGYNYVSWYQQHPGKAPKLM IYEVSNRPSGVSNRFS GSKSGSTASLTISGLQAEDEADYYCVSYTSRNTYVFGSG TQLTLVLGAAA [Seq ID 33]</p>
MB5	MUC1	mixTIL	<p>GAGGTGCAGCTGGTGGAGTCTGGAGCTGAGGTGAAGAAG CCCAGGGCCTCAGTGAAGGTCTCTGCAAGGCTTCTGGA TACACCTTACCAGCTCCTATATGCACTGGGTGCGACAG GCCCCGACAAAGGCTTGGTGGATGGGATGGTTCAAC CCTAATAGTGGTGGCACAACACTATGCACAGAAGTTTCAG GGCAGGGTCACCATGACCGGGACACGTCCACCAGCACA GGCTATATGGAGCTGAGCAGGCTGACATCTGACGACGCG NCCGTGTATTATTGTGCGAGAGATCGGGCCTCTGCTATG GGCGTCTGGGGCAAGGCACCCTGGTCACCGTCTCCTCA GGTGGAGGCGGTT CAGGCGGAGGTGGCTCTGGCGGNGGC CGATCGCAGTCTGCCCTGACTCAGCCTGCCCTCCGCGTCC GGGTCTCCTGGACAGTCAGTCACCATCTCTGCACTGGA ACCAGCAGTGACGTTGGTGGTTATAACTATGTCTCCTGG TACCAACAGCACCCAGGCAAAGCCCCAAACTCATGATT TATGACGTCAATAAGCGGCCCTCAGGGTCCCTGATCGC TTCTCTGGCTCCAAGTCTGGCAACACGGCTCCCTGACC GTCTCTGGGCTCCAGGCTGAGGATGAGGCTGATTATTAC TGCAGCTCATATGCAGGTAGTAACACTTTCTATTTCGGC GGAGGGACCCAGCTCACCGTTTTAGGTGCGGCCGCGA [Seq ID 2]</p> <p>EVQLVESGAEVKKPGASVKVSKASGYFTASYMHVWRQ APGQGLEWMGWFNPNSSGGTNYAQKFQGRVTMTGDTSTST GYMELSRLLTSDDATVYYCARDRASAMGVWGQTLVTVSS GGGSGGGGSGGGGSSQALTQPASASGSPGQSVTISCTG</p>

TABLE 5-continued

Selected antibodies. MixTIL and MixLIB are mixture of libraries defined in table 2.			
Anti-body	Anti-gen	Library used for selection	Nucleotide/Amino acid sequence
			TSSDVGGYNYVSWYQQHPGKAPKLMY YDVNKRPSGVPDR FSGSKSGNTASLTVSGLQAEDEADYYCSSYAGSNTFLFG GGTQLTVLGAA [Seq ID 3]
MB5/ C'1	MUC1	maturation library based on MB5 clone, as described in Example 3	ATGGAGGAGGTGCAGCTGCAGGAGTCTGGAGCTGAGGTG AAGAAGCCCGGGCCTCAGTGAAGGTCTCCTGCAAGGCT TCTGGATACACCTTCACCGCCTCCTATATGCACTGGGTG CGACAGGCCCTTGACAAGGGCTTGAGTGGATGGGATGG TTCAACCCTAATAGTGGTGGCACAACCTATGCACAGAAG TTTCAGGGCAGGGTCACCATGACCGGGGACACGTCCACC AGCACAGGCTATATGGAGCTGAGCAGGCTGACATCTGAC GACGCGCCGTGTATTATTGTGCGAGAGATCGGGCCTCT GCTATGGGCGTCTGGGGCCAAGGAACCTGGTCACCGTC TCCTCAGGTGGAGCGGTTTCAGGCGGAGGTGGCTCTGGC GGTGGCGGATCCAGTCTGCCCTGACTCAGCCTGCCTCC GTGTCTGGGTCTCCTGGACAGTCTGATCACCATCTCCTGC ACTGGAACCAGCAGTACGTTGGTGGTTATAACTATGTC TCCTGGTACCAACAGCACCCAGGCAAAGCCCCAAACTC ATGATTTATGATGTCAGTCAATCGGCCCTCAGGGATTTCT AATCGCTTCTCTGGCTCCAAGTCTGGCAACACGGCCTCC CTGACCATCTCTAGGCTCCAGGCTGAGGACGAGGCTGAT TATTACTGCAGCTCATATAAGCAGTAACACTTTCATC TTCGGAACCTGGGACCCAGCTCACCGTTTTAGGTGCGGCC GC [Seq ID 4]
			MEEVQLQESGAEVKKPGASVKVSKASGYTFTASYMHWV RQAPGQGLEWMGWFNPNSSGGTNYAQKFQGRVTMTGDTST STGYMELSRLLTSDDAVYYCARDRASAMGVWQGLVTV SSGGGSGGGGSGGGGSSALTQPASVSGSPGQSITISC TGTSSDVGGYNYVSWYQQHPGKAPKLMY YDVSHRPSGIS NRFSGSKSGNTASLTISRLQAEDEADYYCSYSSNTFI FGTGTQLTVLGAA [Seq ID 5]
MB5/ C'3	MUC1	maturation library based on MB5 clone, as described in Example 3	ATGGAGCAGGTGCAGCTGGTGCAGTCTGGAGCTGAGGTG AAGAAGCCCGGGCCTCAGTGAAGGTCTCCTGCAAGGCC TCTGGATACACCTTCACCGCCTCCTATATGCACTGGGTG CGACAGGCCCTTGACAAGGGCTTGAGTGGATGGGATGG TTCAACCCTAATAGTGGTGGCACAACCTATGCACAGAAG TTTCAGGGCAGGGTCACCATGACCGGGGACACGTCCACC AGCACAGGCTATATGGAGCTGAGCAGGCTGACATCTGAC GACGCGCCGTGTATTATTGTGCGAGAGATCGGGCCTCT GCTATGGGCGTCTGGGGCCAAGGCACCTGGTCACCGTC TCCTCAGGTGGAGCGGTTTCAGGCGGAGGCGGCTCTGGC CGTGGCGGATCGCAGTCTGCCCTGACTCAGCCTGCCTCC GTGTCTGGGTCTCCTGGACAGTCTGATCACCATCTCCTGC ACTGGAACCAGCAGTACGTTGGTGGTTATAACTATGTC TCCTGGTACCAACAGCACCCAGGCAAAGCCCCAAACTC ATGATTTATGATGTCATAATCGGCCCTCAGGGGTTTCT AGTCGCTTCTCTGGCTCCAAGTCTGGCAACACGGCCTCC CTGACCATCTCTGGACTCCAGACTGAGGACGAGGCTGAT TATTACTGCAACTCATTTACAAGCAGCAACACTTATGTC TTCGGAACCTGGGACCCAGCTCACCGTTTTAGGTGCGGCC GC [Seq ID 6]
			MEQVQLVQSGAEVKKPGASVKVSKASGYTFTASYMHWV RQAPGQGLEWMGWFNPNSSGGTNYAQKFQGRVTMTGDTST STGYMELSRLLTSDDAVYYCARDRASAMGVWQGLVTV SSGGGSGGGGSGGGGSSALTQPASVSGSPGQSITISC TGTSSDVGGYNYVSWYQQHPGKAPKLMY YDVNKRPSGVS SRFSGSKSGNTASLTISGLQTEDEADYYCNSFTSSNTYV FGTGTQLTVLGAA [Seq ID 7]
CB3	CEA	mixTIL	GAGGTGCAGCTGTTGCAGTCTGGGGCTGAGGTGAAGAAG CCTGGGGCCTCAGTGAAGGTCTCCTGCAAGGCTTCTGGA TACACCTTCACCGGCTCCTATATTCAGTGGGTGCGACAG GCCCCGCAAGGGCTTGAGTGGATGGGACGGATGAAC CCTAACAGTGGTGACACAACCTATGCACAGAAGTTTCAG GGCCGGGTACCATGACCAGGGACACGTCCATCAGCACA GCCTACATGGAGCTGAGCAGGCTGAGATCTGACGACACG GCCGTGTACTACTGTGCGACGGAGGGAGTGGCTTTACGT CCCGGTGCTTTTGTATTTCTGGGGCCAAGGGACCCAGCTC ACCGTTTTAGGTGCGGCCGCA [Seq ID 34]

TABLE 5-continued

Selected antibodies. MixTIL and MixLIB are mixture of libraries defined in table 2.			
Anti-body	Anti-gen	Library used for selection	Nucleotide/Amino acid sequence
			EVQLLQSGAEVKKPGASVKVSKASGYTFGTSYIHVWRQ APGQGLEWMGRMNPNSGDTNYAQKFQGRVTMTRDTSIST AYMELSRRLSDDTAVYYCATEGVALRPGAFDFWQGTQL TVLGAAA [Seq ID 35]
CB37	CEA	mixTIL	GAGGAGGTGCAGCTGGTGCAGTCTGGAGGAGGCTTGATC CAGCCGGGGGGTCCCTGAGACTCTCTTGTGTAGCCTCT GAGTTCAACGTGAGAAGCAACTACATGAGCTGGGTCCGC CAGGCTCCAGGAAGGGGCTGGAGTGGGTCTCAGTTATG TATGACGGCGGTAGTACATACTACGCAGACTCCGTGAAG GGCCGATTCACCATCTCCAGAGACAATTCAAGAACACG GTGTATCTTCAAATGAACAGCCTGAGAGCCGAGGACACG GCCGTCTATTACTGTGCGAGAGCGGATGGGGTTGCCT ACAATCGCGTCTGGGAGATCTGGGGCAAGGGACAATG GTCACCGTCTCTCAGGTGGAGGCGGTTCTGGCGGAGGT GGCTCTGGCGGTGGCGGATCGTCTATGTGCTGACTCAG CCACCCTCGGTGTGAGTGGCCCCAGGAAAGACGGCCACG ATTACCTGTGCGGAAACAATATAGGAAGTAACAGTGTA TACTGGTACCAGCAGAAACCAGGCCCTGGCCCCTGTACTG GTCGTCTATGATGATAGAGACCGGCCCTCAGGGATCCCT GAGCGATTCTCTGGCTCCAAATCCGGGAACACGGCCACC CTGACCATCAGCAGGGTCGAGGCCGGGGATCAGGCCGAC TATTCTTGTGAGTGTGGGATCCTAGTAGTGATCACCTC TATGTCTTCGGAAGTGGGACCCAGCTCACCGTTTTAGGT GCGGCCGCA [Seq ID 8]
			EEVQLVQSGGLIQPGGSLRLSCVAS EFNVRSNYMSWVR QAPGKLEWVSVMYDGGSTYYADSVKGRFTISRDNKNT VYLQMNSLRAEDTAVYYCARGGLPLTASWEIHWQGT VTVSSGGGSGGGSGGGSSYVLTQPPSVSVAPGKTAT ITCAGNIGSNSVYWYQKPLAPVLVYDDRDRPSGIP ERFSGSKSGNTATLTISRVEAGDEADYSCQVWDPSSDHL YVFGTGTQLTVLGAAA [Seq ID 9]
CB40	CEA	mixTIL	=CB37
CB41	CEA	mixTIL	GAGGAGGTGCAGCTGGTGGAGTCTGGGGGAGGCTTGATC CAGCCTGGGGGGTCCCTGAGACTCTCCTGTGAGCCTCT GGATTCACCGTCAGTAGCAACTACATGAGCTGGGTCCGC CAGGCTCCAGGAAGGGGCTGGAGTGGGTCTCAGTTGTT TATAGCGGTGGTAGCACATACTACGCAGACTCCGTGAAG GGCCGATTCACCATCTCCAGAGACAATTCAAGAACACG CTGTATCTTCAAATGAACAGCCTGAGAGCTGAGGACACG GCTGTGTATTACTGTGCGACAGACCTAGGGGGGACTACA GTTTGGCGCTACTACGGTATGGACGTCTGGGGCAAGGG ACCACGGTCACCGTCTCCTCAGGTGGAGGCGGTTGAGG GGAGGTGGCTCTGGCGGTGGCGGATCGTCTATGTGCTG ACTCAGCCACCCTCGGTGTGAGTGGCCCCAGGAAAGACG GCCACGATTACCTGTGCGGAAACAATATAGGAAGTAAC AGTGTATACTGGTACCAGCAGAAACCAGGCCCTGGCCCCT GACTGGTCTGATGATGATAGAGACCGGCCCTCAGGG ATCCCTGGGCGATTCTCTGGCTCCAAATCCGGGAACACG GCCACCCTGACCATCAGCAGGGTCGAGGCCGGGGATGAG GCCGACTATTCTTGTGAGTGTGGGATCCTAGTAGTGAT CACCTCTATGTCTTCGGAAGTGGGACCCAGCTCACCGTT TTAGGTGCGGCCGCA [Seq ID 36]
			EEVQLVESGGGLVQPGGSLRLSCAASGFTVSSNYMSWVR QAPGKLEWVSVVYSGGSTYYADSVKGRFTISRDNKNT LYLQMNSLRAEDTAVYYCARDLGGTTVWRYGMDVWQGT TTVTVSSGGGSGGGSGGGSSYVLTQPPSVSVAPGKT ATITCAGNIGSNSVYWYQKPLAPVLVYDDRDRPSG IPGRFSGSKSGNTATLTISRVEAGDEADYSCQVWDPSSD HLYVFGTGTQLTVLGAAA [Seq ID 37]
CB53	CEA	mixTIL	GAGGAGGTGCAGCTGGTGGAGTCTGGAGGAGACTTGATC CAGCCTGGGGGGTCCCTGAGACTCTCCTGTGAGCCTCT GGGTTTACCGTCGGTAGCAACTACATGAGCTGGGTCCGC CAGGCTCCAGGAAGGGGCTGGAATGGGTCTCAGTTATT TATAGCGGTGGTAGTACATACTACGCAGACTCCGTGAAG GGCCGATTCACCATCTCCAGAGACAATTCAAGAACACG CTGTATCTTCAAATGAACAGCCTGAGAGCCGAGGACACG GCCGTGTATTACTGTGTGAGAGATAGGGGTGATGCTTTT



TABLE 5-continued

Selected antibodies. MixTIL and MixLIB are mixture of libraries defined in table 2.			
Anti-body	Anti-gen	Library used for selection	Nucleotide/Amino acid sequence
			GATATCTGGGGCCAAGGGACAATGGTCACCGTCTCTTCA GGTGGAGGCGTCCAGGCGGAGGTGGCTCTGGCGGTGGC GGATCGTCCATGCGCTGACTCAGCCACCCTCGGTGTCA GTGGCCCCAGGAAAGACGGCCACGATTACCTGTGCGGGA AACAAATAGGAAGTAACAGTGTATACTGGTACCAGCAG AAACCAGGCTGGCCCTGTACTGGTGTCTATGATGAT AGCGACCGGCCCTCAGGGATGTCTGAGCGATTCTCTGGC TCCAAATCCGGGAACACGGCCACCCTGACCATCAGCAGG GTCGAGGCCGGGATGAGGCCGACTATTCTTGTGAGGTG TGGGATCCTAGTAGTGATCACCTCTATGTCTTCGGAAC GGGACCCAGCTCACCGTTTTAGGTGCGGCCGCA [Seq ID 38]
			EEVQLVESGGDLIQPGGSLRLSCAASGFTVGSNYMSWVR QAPGKLEWVSVIYSGGSTYYADSVKGRFTISRDNKNT LYLQMNSLRAEDTAVYYCVRDRGDAFDIWQGMVTVSS GGGVPGGGSSGGGSSYALTQPPSVSVAPGKTATITCAG NNIGSNSVYWYQPKPLAPVLVYDDSDRPSGMSERFSG SKSGNTATLTISRVEAGDEADYSCQVWDPSSDHLVYVFGT GTQLTVLGAAA [Seq ID 39]
CB60	CEA	mixTIL	=CB41
CB37/ 3B	CEA	maturation library based on CB37 clone, as described in Example 3.	ATGGAGGAGGTGCAGCTGGTGCAGTCTGGAGGAGGCTTG ATCCAGCCGGGGGGTCCCTGAGACTCTCTTGTGTAGCC TCTGAGTTCAACGTCAGAAGCAACTACATGAGCTGGGTG CGCCAGGCTCCAGGAAGGGGCTGGAGTGGGTCTCAGTT ATGTATGACGGCGGTAGTACATACTACGCAGACTCCGTG AAGGGCCGATTACCATCTCCAGAGACAATTCTAAGAAC ACGGTGTATCTTCAAATGAACAGCCTGAGAGCCGAGGAC ACGGCCGCTATTACTGTGCGAGAGGCGGATGGGGTTG CCTACAATCGCGCTTGGGAGATCTGGGGCCAAGGGACA ATGGTCACCGTCTCTCAGGTGGAGGCGGTTGAGGCGGA GGTGGCTCTGGCGGTGGCGGATCGTCTATGTGCTGACT CAGCCACCCTCGGTGTGAGTGGCCCCAGGAAAGACGGCC ACGATTACCTGTGCGGAAACAATATAGGAAGTAACAGT GTATACTGGTACCAACAAAACCAGGCTGGCCCTGTGTA CTGGTCGTCTATGATGATAGAGACCGGCCCTCAGGGATC CATGAGCGATTCTCTGGCTCAAATCCGGGAACACGGCC ACCCTGACCATCAGCAGGGTGGAGGCCGGGATGAGGCC GACTATTCTTGTGAGGTGTGGGATCCTAGTAGTGATCAC CTCTATGTCTTCGGAACGGGACCCAGCTCACCGTTTTA GGTGGCGCCG [Seq ID 10]
			MEEVQLVQSGGGLIQPGGSLRLSCVASEFNVRSNYMSWV RQAPGKLEWVSVMYDGGSTYYADSVKGRFTISRDNKNT TVYLQMNSLRAEDTAVYYCARGGLGLPTIAPWEIWQGT MVTVSSGGGSSGGGSSYVLTQPPSVSVAPGKTA TITCAGNNIGSNSVYWYQPKPLAPVLVYDDRDRPSGI HERFSGSKSGNTATLTISRVEAGDEADYSCQVWDPSSDH LYVFGTGTQLTVLGAA [Seq ID 11]
CB37/ 9C	CEA	maturation library based on CB37 clone, as described in Example 3.	ATGGAGGAGGTGCAGCTGGTGCAGTCTGGAGGAGGCTTG ATCCAGCCGGGGGGTCCCTGAGACTCTCTTGTGTAGCC TCTGAGTTCAACGTCAGAAGCAACTACATGAGCTGGGTG CGCCAGGCTCCAGGAAGGGGCTGGAGTGGGTCTCAGTT ATGTATGACGGCGGTAGTACATACTACGCAGACTCCGTG AAGGGCCGATTACCATCTCCAGAGACAATTCTAAGAAC ACGGTGTATCTTCAAATGAACAGCCTGAGAGCCGAGGAC ACGGCCGCTATTACTGTGCGAGAGGCGGATGGGGTTG CCTACAATCGCGCTTGGGAGATCTGGGGCCAAGGGACA ATGGTCACCGTCTCTCAGGTGGAGGCGGTTGAGGCGGA GGTGGCTCTGGCGGTGGCGGATCGTCTATGTGCTGACT CAGCCACCCTCGGTGTGAGTGGCCCCAGGAAAGACGGCC ACGATTACCTGTGCGGAAACAATATAGGAAGTAACAGT GTATACTGGTACCAGCAGAAAACCAGGCTGGCCCTGTGTA CTGGTCGTCTATGATGATAGAGACCGGCCCTCAGGGCTC CCCGGGCGATTCTCTGGCTCAAATCCGGGAACACGGCC ACCCTGACCATCAGCAGGGTGGAGGCCGGGATGAGGCC GACTATTCTTGTGAGGTGTGGGATCCTAGTAGTGATCAC CTCTATGTCTTCGGAACGGGACCCAGCTCACCGTTTTA GGTGGCGCCG [Seq ID 12]

TABLE 5-continued

Selected antibodies. MixTIL and MixLIB are mixture of libraries defined in table 2.			
Anti-body	Anti-gen	Library used for selection	Nucleotide/Amino acid sequence
			MEEVQLVQSGGGLIQPGGSLRLSCVASEFNVRSNYMSWV RQAPGKGLEWVSVMYDGGSTYYADSVKGRFTISRDNSEN TVYLQMNLSRAEDTAVYYCARGGLGLPTIASWEIWGQGT MVTVSSGGGSGGGGSGGGGSSYVLTQPPSVSVAPGKTA TITCAGNNIGSNVYWYQOKPGLAPLVVYDDRDRPSGL PGRFSGSKSGNTATLTISRVEAGDEADYSCQVWDPSSDH LYVFGTGTQLTVLGAA [Seq ID 13]
anti-SP2	SP2	scFvEC23	ATGGAGGAGGTGCAGCTGGTGGAGTCTGGGGGAGCCTTG GTACAGCCTGGGGGTCCCTGAGAATCTTGTGTAGGC TCTGGATTCACCTCCGACAGCATGACATGAGCTGGGTC CGCCAGGCTCCTGGGAAGGGCTGGAGTGGGTCGCAACT ATAAGTGGAAAGTGCTGATAACACATTTTACGCAGACTCC GTGAAGGGCCGGTTCACCATCTCCAGAGACAATTCCAAG AACACGC'TGTATCTGCAGATGAACACCTGAAAGCCGAC GACACGGCCGTATATTACTGTGCGAAGAAATATATAGAA CCAGGTGCTACCCGATTTGACTACTGGGGCCAGAGAACC CTGGTCACCGTCTCCTCAGGTGGAGCGGTT'CAGGCGGA GGTGGCTCTGGCGGTGGCGGATCGGATGTTGTGATGACT CAGTCTCCACTCTCTGTCCGTCACCCCTGGACAGCCG GCCTCCATCTCCTGCAAGTCTAGTCAGAGCCTCCTGCAT AGTGATGGAAAGACCTATTTGTATTGGTACCTGCAGAAG CCAGGCCAGTCTCCACAGCTCCTGATCTATGAAGTTTCC AACCGTTCCTCGAGTGCCAGATAGGTCAGTGGCAGC GGGTCAGGGACAGATTTCACTGAAAATCAGCCGGGTG GAGGCTGAGGATGTTGGGGTTTATTACTGCATGCAAAGT ATACAGCTCCCGATCACCTTCGGCCAAGGGACACGACTG GAGATTAACGTGCGGCCGC [Seq ID 40]
			MEEVQLVESGGALVQPGGSLRISCVGSGFTFRQHDMSWV RQAPGKGLEWVATISGSADNTFYADSVKGRFTISRDNSEN NTLYLQMNLTAKADDTAVYYCAKKYIEPGATRFDYWGQRT LVTVSSGGGSGGGGSGGGGSDVVMQSPLSLSVTPGQP ASISCKSSQSLHSDGKTYLYWYLQKPGQSPQLLIYEVS NRFSGVPDRFSGSGSDFTLTKISRVEAEDVGVYYCMQS IQLPITFGQGRLEIKRAA [Seq ID 41]
mix7	MCF7 cells	mixLIB	GAGCAGGTGCAGCTGGTGCAGTCTGGGGCGGAGGTGAAG AAGCCTGGGGCCTCAGTGAGAGTTTCTGCCAGGCATCT GGATACACATTCAGCAGGTACCATATGCACTGGGTGCGA CAGGCCCTGGACAAGGGCTTGAGTGGATGGGAGTGATC GACCCCAATAGTGGTAGAGTAAGTTACTCACAGAAGTTC CAGGACAGAGTTACCATGACCAGGGACACGTCACAGAGC ACAGTATACATGGAGCTGAACAGCCCGAGATCTGAGGAC ACGGCCGTTTATTATTGTGCGAGAGATCGAGGATATTGT AATGGTGGCAGGTGCTTTATGGATGCATTTGACTACTGG GGCCAGGGGACAATGGTCACCGTCTCTTCAGGTGGAGGC GGTTTAGGGCGAGGTGGCTCTGGCGGTGGCGGATCGTCC TATGTGCTGACTCACCCACCTCATTGTCTGGGGCCCCA GGGCAGAGCATCACCATCTCCTGCCTGGGAGCAGTTCC AACATCGGGCAGGTTTTATATACACTGGTACCAGCAG TTTCCAAAACAGCCCCAACTCCTTATCTATGGTAGT AGTAATCGACCCCTCAGGGTCCCTGACCGCTCTCTGGC TCCAGGTCTGGCTCCTCAGGCTCCCTGGCCATCACTGGG CTCCAGGCAGACGATGAGGCTGATTATTACTGTGTGGGA TGGGATGGCAGCCTGAGTGGTTATGTCTTCGGAAGTGGG ACCCAGCTCACCGTTTTAGGTGCGGCCGCA [Seq ID 16]
			EQVQLVQSGAEVKKPGASVRVSCQASGYTFSRYHMHVVR QAPGQGLEWGMVIDPNSGRVSYSQKFQDRVMTMRDTS TVYMEINSPREDAVYYCARDRGYCNGGRCFMDAFDYW GQGTMTVSSGGGLGGGSGGGGSSYVLTHTPPSLSGAP GQSITTSCTGSSNI GAGFHIHWYQFPKTA PKLLIYGS SNRPSGVPDRFSGSRSGSLAITGLQADDEADYICVGV WDGSLSGYVFGTGTQLTVLGAA [Seq ID 17]
mix8	MCF7 cells	mixLIB	GAGCAGGTGCAGCTGGTGCAGTCTGGGGGAGCGTGGTC CAGCCTGGGAGTCCCTGAGACTCTCCTGTCAGCCTCT GGATTGAGCTTCACTAATATGTTATGCACTGGGTCCGC CAGGCTCCAGGCAAGGGGCTGGAGTGGGTGGCAGTTATA TCACATGATGGAAGCAATAAATACTACGCAGACTCCGTG AAGGGCCGATTCACCATCTCCAGAGACAATCCAAGAAC ACGCTATATCTGCAAATGAAAAGCCTGAGACCTGAGGAC

TABLE 5-continued

Selected antibodies. MixTIL and MixLIB are mixture of libraries defined in table 2.			
Anti-body	Anti-gen	Library used for selection	Nucleotide/Amino acid sequence
			<p>ACGGCTGTGTATTACTGTGCGAGAAGTAGTGGCTGGTAC  CTTCTCTTTGATGCTTTTGATATCTGGGGCCAAGGGACA  ATGGTCACCGTCTCTTCAGGTGGAGGCGGTTTCAGGCGGA  GGTGGCTCTGGCGGTGGCGGATCGGACATCCAGATGACC  CAGTCTCCAGACTCCCTGCCTGTGTCTCTGGGCGAGAGG  GCCACCATCAACTGCAGGTCCAGCCAGAGTGTTTTATAC  AGCTCCAACAATAAGAACTACTTAGCTTGGTACCAGCAG  AAACCAGGACAGCCTCCTAAGCTGCTCATTTACTGGGCA  TCTACCCGGGAATCCGGTGTCCCTGACCGATTCAGTGGC  AGCGGGTCTGGGACAGATTTCACTCTCACCATCAGCAGC  CTGCAGGCTGAAGATGTGGCAGTTTATTACTGTGAGCAA  TATTATAGGATTCCGTGGACGTTCCGGCCAAGGGACGAAG  GTGGAAATCAAACGTGCGGCCGCA [Seq ID 42]</p> <p>EQVQLVQSGGGVVPGRSLRLSCAASGF SFSNYVMHWVR  QAPGKLEWVAVI SHDGSNKYYADSVKGRFTISRDNSEN  TLYLQMKSLRPEDTAVYYCARSSGWYLLFDADFIDWQGT  MVTVSSGGGSGGGGSGGGSDIQMTQSPDSLPLVSLGER  ATINCRSSQSVLYSSNNKNYLAWYQQKPGQPPKLLIYWA  STRESGVPDRFSGSGSGTDFTLTISLQAEDVAVYYCQQ  YYRIPWTFGQGTKVEIKRAAA [Seq ID 43]</p>
mix11	MCF7 cells	mixLIB	<p>GAGGAGGTGCAGCTGTTGCAGTCTGGGGGAGGTGTGGTA  CGGCCTGGGGGTCCTGAGACTCTCCTGTGCAGCCTCT  GGATTCACCTTTGATGATTATGGCATGACCTGGGTCCGC  CAGGCTCCAGGGAAGGGGCTGGAGTGGGTCTCAGCTATT  AGTGGTAGTGGTGGTAGCACATACTACGCAGACTCCGTG  AAGGGCCGGTTCGCCATCTCCAGAGACAATCCAAGAAC  ACGCTGTATCTGCAAATGAACAGCCTGAGAGCCGAGGAC  ACGGCCGTATATTACTGTGCGAAATCTCGCTACTATGAT  AGTAGTGGTTATTACTACACCGTGCAGCTGATGCTTTT  GATATCTGGGGCAAGGGGCAATGGTCACCGTCTCTTCA  GGTGGAGGCGGTGGAGGTGGCTCTGGCGGTGGCGGATCG  TCTTCTGAGCTGACTCAACCACCTCAGTGTCCGTGTCC  CCAGGACAGACAGCCATCATCACCTGCCTGGAGATAAA  TTGGGGGATAAATATGCTTCTGGTATCAGCACAGGCCA  GGCCAGTCGCCGTCTTGGTCACTATCAGGATTCCAGG  CGGCCCTCAGACATCCCTGAGCGATTCTCTGGCTCCAAC  TCTGGGAACACAGCCACTCTGACCATCACCGAGGCCAG  GCTTTGGATGAGGCTGACTATTATTGTGAGGCTGGGCC  GGCAGATCTGTGGTCTTCGGCGGGGGACCCAGCTCACC  GTTTTAGGTGCGGCCGCA [Seq ID 44]</p> <p>EEVQLLQSGGGVVRPGGSLRLSCAASGFTFDDYGMTWVR  QAPGKLEWVSAISGSGGSTYYADSVKGRFAISRDNSEN  TLYLQMNSLRAEDTAVYYCAKSRYYDSSGYYYTVRPDAF  DIWQGGAMVTVSSGGGGGGGGGGSSSELTQPPSVSVS  PGQTAIITCSGDKLGDKYASWYQHRPGQSPVLVIYQDSR  RPSDIPERFSGSNSGNTATLTITEAQLDEADYYCQAWA  GRSVVFGGGTQLTVLGAAG [Seq ID 45]</p>
mix12	MCF7 cells	mixLIB	<p>GAGGAGGTGCAGCTGTTGCAGTCTGGGGCGGAGGTGAAG  AAGCCTGGGGCCTCAGTGAGAGTTTCTGCCAGGCATCT  GGATACACATTACAGAGGTACCATATGCACTGGGTGCGA  CAGGCCCTGGACAAGGCCTTGAGTGGATGGGAGTGATC  GACCCCAATAGTGGTAGAGTAAGTTACTCACAGAAGTTC  CAGGACAGAGTCACCATGACCAGGGACACGTTTACGAGC  ACAGTATACATGGAGCTGAACAGCCTGAGATCTGAGGAC  ACGGCCGTTTATTATTGTGCGAGAGATCGAGGATATTGT  AATGGTGGCAGGTGCTTTATGGATGCATTTGACTACTGG  GGCCAGGGGACCACGGTCACCGTCTCCTCAGGTGGAGGC  GGTTCAGGCGGAGGTGGCCCTGGCGGTGGCGGATCGTCC  TATGTGCTGACTCAGCCACCCTCAGCGTCTGGGGCCCCC  GGACAGAGGGTACCATCTCTTGTCTGGAAGCAACTCC  AACATCGGACGTAATTGGGTATACTGGTACCAGCAACTC  CCAGGAACGGCCCCAAACTCCTCATGTTTAGGAATAAT  GAACGGTCTCAGGGGTCCCTGACCGATTCTCTGGCTCC  AAGACTGGCACCTCAGCCTCCCTGGCCATCAGTGGGCTC  CGGTCTGAGGATGAGGGTGATTACTACTGTGCATCATGG  GATGACAGTCTGCATGCTTGGGTGTTCCGGCGGGGGACC  CAGCTCACCGTTTTAGGTGCGGCCGCA [Seq ID 46]</p>

TABLE 5-continued

Selected antibodies. MixTIL and MixLIB are mixture of libraries defined in table 2.			
Anti-body	Anti-gen	Library used for selection	Nucleotide/Amino acid sequence
			EEVQLLQSGAEVKKPGASVRVSCQASGYTFSSRYHMHWVR QAPGQGLEWVMDPNSGRVSYSQKFQDRVTMTRDTFTS TVYMEINSLRSEDVAVYYCARDRGYCNNGRRCFMDAFDYW GQGTTVTVSSGGGSGGGGPGGGSSYVLTQPPSASGAP GQRVTISCSGSNSNIGRNWVYQQLPGTAPKLLMFRNN ERSSGVPDRFSGSKTGTASLAISGLRSEDEGDYICASW DDSLHAWVFGGTQLTVLGAAA [Seq ID 47]
mix17	MCF7 cells	mixLIB	GAGCAGGTGCAGCTGGTGCAGTCTGGGGGAGGCTTGGTA CAGCCTGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCT GGATTCACCTTTAGCAGCTATGCCATGAGCTGGGTCCGC CAGGCTCCAGGAAGGGGCTGGAGTGGGTCTCAGCTATT AGTGGTAGTGGTGGTAGCACATACTACGCAGACTCCGTG AAGGGCCGGTTCACCATCTCCAGAGAGAATCCAAGAAC ACGCTATATCTGCAAATGAATAGCCTGAGAGCCGAGGAC ACGGCTGTGTATTACTGTGCGAGACAAACAAGAGTCCGT GCTTTTGATATCTGGGGCCAAGGACAATGGTCACCGTC TCTTCAGGTGGAGGCGGTTTCAGGCGGAGGTGGCTCTGGC GGTGGCGGATCGGACATCCAGATGACCCAGTCTCCTTCC GCCCTGTCTGCATCTGTAGGAGGCAGAGTCACCATCACT TGCCGGGCAAGTCAGAGCACTAGTAGCGATTTAAATTGG TATCAGCAAAGACCAGGAAAGCCCTAAACTCCTGATC TCTGTTGCATCCACTTTACAAAGTGACGTCCCATCAAGG TTCAGTGGCAGTGGTCTGGGACAGATTCAGTCTCACC ATCAGCAGTCTGCAACCTGAAGACTTTGCAACTTACTTC TGTC AACAGAGTTACAGCACCCCGTACACTTTTGGCCAG GGGACCAAAGTGGATATCAAACGTGCGGCCGCA [Seq ID 18]
			EQVQLVQSGGLVQPGGSLRLSCAASGFTFSSYAMSWVR QAPGKLEWVSAISGSGGSTYYADSVKGRFTISRENSN TLYLQMNSLRAEDVAVYYCARQTRVRAFDIWGQTMVTV SSGGGSGGGGSGGGSDIQMTQSPSALSASVGGRTIT CRASQSTSSDLNHYQQRPGKAPKLLISVASTLQSDVPSR FSGSGSTDFSLTISLQPEDFATYFCQQSYSTPYTFGQ GTKVDIKRAAA [Seq ID 19]
mix23	MCF7 cells	mixLIB	GAGGAGGTGCAGCTGGTGGAGTCTGGGGGAAACTTGGTT CAGCCTGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCT GGATTCACCTTTAGCAGTTATGCCATGAGCTGGGTCCGC CAGGCTCCAGGAAGGGGCTGGAATGGGTCTCAGCTATT AGTGTAGTGGTGGCACCACATACTACGCAGATTCCGTG AAGGGCCGGTTCACCATCTCCAGAGACAATCCAAGAAC ACGCTGTATCTTCAAATGAACAGCCTGAGAACTGAGGAC ACGGCTGTGTATTACTGTGCGAGAGACAGCCGTGCATAC AGCTATGGTTACCTCTACGTCTTTGACTACTGGGGCCAG GGCACCTGGTACCGTCTCCTCAGGTGGAGGCGGTTCA GGCGGAGGTGGCTCTGGCGGTGGCGGATCGCAGTCTGCC CTGACTCAGCCTGCCTCCGTGTCTGGGTCTCCTGGACAG TCGATCACCATCTCCTGCACTGGAACCAGCAATGATGTT GGGAGTTATAACCTTGCTCCTGGTACCAACAACACCCA GGCAAAGCCCCAAACTCCTGATTTATGAGGGCAGTAAG CGGCCCTCAGGATTTCTAATCGCTTCTCTGGCTCCAAG TCTGGCAACACGGCCTCCCTGACCATCTCTGGGCTCCAG GCTGAGGACGAGGCTGATTATTACTGCATGTCATATACG AGCAGTGGCACTCCTTATGTCTTCGGAACCTGGGACCCAG CTCACCGTTTTAGGTGCGGCCGCA [Seq ID 48]
			EEVQLVESGGNVLVQPGGSLRLSCAASGFTFSSYAMSWVR QAPGKLEWVSAISASGGTTYADSVKGRFTISRDNSEN TLYLQMNSLRTEDEVAVYYCARDSTRAYSIGYLVFDYWGQ GTLVTVSSGGGSGGGGSGGGSSQSALTQPASVSGSPGQ SITISCTGTSNDVGSYNLVSQYQHPGKAPKLLIYEGSK RPSGISNRFSGSKSGNTASLTIISGLQAEDEADYICMSYT SSGTPYVFGTGTQLTVLGAAA [Seq ID 49]
mix25	MCF7 cells	mixLIB	GAGGAGGTGCAGCTGGTGGAGTCTGGGGCTGAGGTGAAG AAGCCTGGGGCTCAGTGAGAGTTTCTGCCAGGCATCT GGATACACATTACAGGTACCATATACACTGGGTGCGA CAGGCCCTGGACAAGGGCTTGAGTGGATGGGAGTGATC GACCCCAATAGTGGTAGAATAAGTTACTCACAGAAGTTC CAGGACAGAGTACCATGACCAGGGACACGTCCACGAGC

TABLE 5-continued

Selected antibodies. MixTIL and MixLIB are mixture of libraries defined in table 2.			
Anti-body	Anti-gen	Library used for selection	Nucleotide/Amino acid sequence
			<p>ACAGTCTACATGGAGCTGAACAGCCTGAGATCTGAGGAC  ACAGCCATTTAATTACTGTGCGAGAGATCGAGGATATTGT  AATGGTGGCAGGTGCTTTATGGATGCATTTGACTACTGG  GGCCAGGGGACCACGGTCACCGTCTCCTCAGGTGGAGGC  GGTTCAGGCGGAGGTGGCTCTGGCGGTGGCGGATCGCAG  TCTGTGTTGACGACCCGCCCTCAGCGTCTGGGACCCCC  GGGCAGAGGGTACCATCGCTTGTCTGGAAGCAGCTCC  AACATCGGAATTAATACTGTAACTGGTACCAGCAGATC  CCAGGAACGGCCCCAAACTCCTCATCTATAATAATGAT  CAGCGGCCCTCAGGGTCCCTGACCGATTCTCTGGCTCC  AAGTCTGCCACCTCAGCCTCCCTGGCCATCACTGGGCTC  CAGGTTGACGATGAGGCTGATTACTGCCAGTCCTAT  GACAGCAGCCTGGGTGGTTATGTCTTCGGAAGTGGGACC  CAGCTCACCGTTTTAGGTGCGCCCGCA [Seq ID 50]</p> <p>EEVQLVESGAEVKKPGASVRVSCQASGYTFTRYHIHWVR  QAPGQGLEWMGVIDPNSGRISYSQKFDQDRVTMRDSTST  TVYMELNSLRSEDTAIYYCARDRGYCNGGRFCFMDAFDYW  GQGTTVTVVSSGGGSGGGGSGGGGSSVLTQPPSASGTP  GQRVTIACSGSSNIGINTVNWYQQIPGTAPKLLIYNND  QRPSGVPDRFSGSKSATSASLAITGLQVDDEADYQCQSY  DSSLGGYVFGTGTQLTVLGAAA [Seq ID 51]</p>
mix39	MCF7 cells	mixLIB	<p>GAGGAGGTGCAGCTGTTGCAGTCTGGGGGAGGCGTGGTC  CAGCCTGGGAGGTCCCTGAGACTCTCCTGTGCAGCCTCT  GGATTCAGCTTCAGTAATATGTTATGCACTGGGTCCGC  CAGGCTCCAGCAAGGGGCTGGAGTGGGTGGCAGTTATA  TCATATGATGGAAGCAATAAATACTACGCAGACTCCGTG  AAGGGCCGATTACCATCTCCAGAGACAATTCCAAGAAC  ACGCTATATCTGCAAATGAAAGGCCTGAGACTGAGGAC  ACGGCTGTGTATTACTGTGCGAGAAGTAGTGGCTGGTAC  CTTCTCTTTGATGCTTTTGATATCTGGGGCCAAGGGACA  ATGGTCACCGTCTCTTCAGGTGGAGGCGGTTTCAGGCGGA  GGTGGCTCTGGCGGTGGCGGATCGGATGTTGTGATGACA  CAGTCTCCAGACTCCCTGGCTGTGTGCTGGGCGAGAGG  GCCACCATCAACTGCGAGTCCAGCCAGAGTGTTTTATTC  AGCTCCAACAATAAGAATACTTAGCTTGGTACCAGCAG  AAACCAGGACAGCCTCCTAAGCTGCTCATTTACTGGGCA  TCTACCCGGGAATCCGGGTCCTGACCGATTTCAGTGGC  AGCGGGTCTGAGACAGATTTCACTCTCACCATCAGCAGC  CTGCAGGCTGAAGATGTGGCAGTTTATTACTGTGAGCAA  TATTATAGGATTCCTGGACGTTTCGGCCAGGGACAAA  GTGGATATCAAACGTGCGGCCGCA [Seq ID 20]</p> <p>EEVQLLQSGGGVVQPGRSLRLSCAASGF SFSNYVMHWVR  QAPGKGLEWVAVISYDGSNKYYADSVKGRFTISRDNSEN  TLYLQMKGLRPEDTAVYYCARSSGWYLLFDADFIDWQGT  MVTVSSGGGSGGGGSGGGGSDVMTQSPDSLAVSLGER  ATINCESSQSVLFSNNKNYLAWYQQKPGQPPKLLIYWA  STRESGVPDRFSGSGSETDFTLTISSLQAEDVAVYYCQQ  YYRIPWTFGQTKVDIKRAA [Seq ID 21]</p>
B96/4F	MCF7 cells	scFvB96	<p>ATGGAGCAGGTGCAGCTGCAGGAGTCTGGGGGAGGCTTG  GTACAGCCTGGGGGTCCCTGAGACTCTCCTGTGCAGCC  TCTGGATTACCTTTAGTACTTATGCCATGAGCTGGGTG  CGCCAGGCTCCAGGAAGGGGCTGGAGTGGGTCTCAGTT  ATTAGTGGTAGTGGTCATAACAACAACTACGCCGACTCC  GTGAAGGGCCGCTCACCATATCCAGAGACAATTCCAAG  AACACACTATATCTGCAAATCAACAGCCTGAGAGCCGAC  GACACGGCCGTGATTACTGTGCGAGAGATGTGTTAGTC  CTACAGAATGCTTTTGATATCTGGGGCCAAGGGACACG  GTCACCGTCTCCTCAGGTGGAGGTGGTTCAGGCGGAGGT  GGCTCTGGCGGTGGCGGATCGGATGTTGTGATGACCCAG  TCTCCATCCTCACTGTCTGCATCTGTAGGAGACAGAGTC  ACCATCACTTGTCCGGCGAGTCAGGGTATTAGCAGGTGG  TTAGCCTGGTATCAACAGAAACCAGGGAAAGCCCTAAG  CTCCTGATCTACGCTGCATCCAGTTTGCAAAGTGGGGTC  CCATCAAGGTTAGTGGCAGTGGATCTGGGACAGATTTTC  ACTCTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCA  ACTTACATCTGTCAACAGAGTTACAGTAGGCCGCTCACT  TTCGGCGGAGGGACCAAGGTGGAATCAAACGTGCGGCC  GCA [Seq ID 52]</p>

TABLE 5-continued

Selected antibodies. MixTIL and MixLIB are mixture of libraries defined in table 2.

Anti-body	Anti-gen	Library used for selection	Nucleotide/Amino acid sequence
			MEQVQLQESGGGLVQPGGSLRLSCAASGFTFSTYAMSWV RQAPGKGLEWVSVISGSGHTTNYADSVKGRVTISRDNK NTLYLQINSLRADDTAVYYCARDVLLQNAFDIWGGTT VTVSSGGGGSGGGSGGGSDVVMQSPSSLSASVGDV TITCRASQGISRWLAWYQQKPKAPKLLIYAASSLQSGV PSRFSGSGSGTDFTLTISSLQPEDFATYICQQSYSRPLT FGGGTKVEIKRAA [Seq ID 53]
B96/11L	MCF7 cells	scFvB96	GAGCAGGTGCAGCTGCAGGAGTCTGGGGGAGGCTTGGTA CAGCCTGGGGGGTCCCTGAGACTCTCCTGTGCAGCCTCT GGATTCACCTTAGTACTTATGCCATGAGCTGGGTCCGC CAGGCTCCAGGGAAGGGCTGGAGTGGGTCTCAGTTATT AGTGGTAGTGGTCATAACAACAACTACGCCGACTCCGTG AAGGGCCCGTCAACATATCCAGAGACAATCCAAGAAC ACACTATATCTGCAAATCAACAGCCTGAGAGCCGACGAC ACGGCCGTGTATTACTGTGCGAGAGATGTGTTAGTCCTA CAGAATGCTTTTGATATCTGGGGCCAAGGGACCACGGTC ACCGTCTCCTCAGGTGGAGGTGGTTCAGGCGGAGGTGGC TCTGGCGGTGGCGGATCGGATGTTGTGATGACCCAGTCT CCATCCTCACTGTCTGCATCTGTAGGAGACAGAGTCACC ATCACTTGTGGGCGAGTCAGGATATTAGCAGGTGGTTA GCCTGGTATCAACAGAAACCAGGAAAGCCCTAAGCTC CTGATCTACGCTGCATCCAGTTTGCAAAGTGGGGTCCCA TCAAGGTTTCAGTGGCAGTGGATCTGGGACAGATTTCACT CTCACCATCAGCAGTCTGCAACCTGAAGATTTTGCAACT TACATCTGTCAACAGAGTTACAGTAGGCCGCTCACTTTC GGCGGAGGGACCAAGGTGGAATCAACCTGCGGCCGCA [Seq ID 14]
			EQVQLQESGGGLVQPGGSLRLSCAASGFTFSTYAMSWVR QAPGKGLEWVSVISGSGHTTNYADSVKGRVTISRDNSEN TLYLQINSLRADDTAVYYCARDVLLQNAFDIWGGTTV TVSSGGGGSGGGSGGGSDVVMQSPSSLSASVGDV ITCRASQGISRWLAWYQQKPKAPKLLIYAASSLQSGVP SRFSGSGSGTDFTLTISSLQPEDFATYICQQSYSRPLTF GGGTKVEIKRAA [Seq ID 15]

TABLE 6

40

## SEQUENCE LISTING

Kinetic values of parental and affinity matured single-chain antibodies. Parental anti-CEA antibody CB37 is not stable in soluble form. Matured single-chain antibodies have nanomolar affinity.  $K_a$  = association constant,  $K_d$  = dissociation constant,  $KD = K_d/K_a$ .  $K_a$ , SE = standard error. Data are expressed in Molar.

scFV	$k_a$ (+/-SE)	$k_d$ (+/-SE)	$K_D$
MB5	2.13E+04 (2.45E+02)	8.55E-03 (6.25E-05)	4.01E-07
MB5/C'1	1.53E+05 (4.15E+02)	1.45E-03 (1.29E-05)	9.46E-09
MB5/C'3	7.11E+04 (4.33E+02)	1.64E-03 (2.46E-05)	2.31E-08
CB37	—	—	—
CB37/3B	1.27E+05 (9.79E+02)	1.42E-04 (3.23E-05)	3.66E-09
CB37/9C	1.00E+05 (5.75E+02)	4.65E-04 (2.54E-05)	1.42E-09

This study with Biacore provided quantitative measures of scFv-antigen binding and dissociation kinetics. Table 6 reports the kinetic values of the parental and affinity-matured scFvs. The matured antiMUC1 antibodies MB5/C'1 and MB5/C'3 have over 42 times and 17 times higher affinity to the antigen, compared to MB5, respectively. The matured anti-CEA antibodies CB37/3B and CB37/9C have nanomolar affinity. Moreover, the matured antibodies are more stable than original CB37, which was not reactive in soluble form. These results indicate that pKM19 vector is a suitable tool for maturation of scFv antibodies.

45

50

55

60

65

&lt;160&gt; NUMBER OF SEQ ID NOS: 102

&lt;210&gt; SEQ ID NO 1

&lt;211&gt; LENGTH: 3770

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: Escherichia coli

&lt;400&gt; SEQUENCE: 1

gccaatac gcaaacgcct ctccccgc gttggccgat tcattaatgc

agctggcagc 60

acaggttcc cgactggaaa gcgggcagtg agcgcaacgc aattaatgtg agt-

tagctca 120

ctcattaggc acccaggct ttacttta tgctccggc tcgtatgtg tgtg-

gaattg 180

55 tgagcggata acaattcac acaagatcta gctattctag agattacgcc aagc-

cccgtta 240

ttttaccgt ttaatggaag cttataaagg aggaaatcct catgaaatag agcac-

catcg 300

60 cactggcact gttaccgta ctgtcacc cggttacc aaagcagc agcacgtacc atg-

gtttccc 360

ttgcggccgc aggagactac aaagcagc acgacaaaga attcctgct

caactcctg 420

tcaatgctgg cggcgctct ggtggtggt ctggtggcg cctgagggt

65 ggcgctctg 480

&lt;400&gt; SEQUENCE: 102

gctgaggaga cggtagcc

## SEQUENCE LISTING

<160> NUMBER OF SEQ ID NOS: 102

<210> SEQ ID NO 1

<211> LENGTH: 3770

<212> TYPE: DNA

<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 1

```

gcccaatacg caaacgcct ctccccgcgc gttggccgat tcattaatgc agctggcacg      60
acaggtttcc cgactggaaa gcgggcagtg agcgcaacgc aattaatgtg agttagctca     120
ctcattaggg accccaggct ttacacttta tgcttccggc tcgtatgttg tgtggaattg     180
tgagcggata acaatttcac acaagatcta gctattctag agattacgcc aagccccgta     240
ttttaccogt ttaatggaag cttataaagg aggaaatcct catgaaatag agcaccatcg     300
cactggcact gttaccgta ctgttcaccc cggttaccaa agcacgtacc atggtttccc     360
ttgcggccgc aggagactac aaagacgacg acgacaaaga attcctgcct caacctcctg     420
tcaatgctgg cggcggctct ggtggtggtt ctggtggcgg ctctgagggt ggcggctctg     480
agggtggcgg ttctgagggt ggcggctctg agggtgccgg ttccgggtggc ggctccggtt     540
ccggtgattt tgattatgaa aaaatggcaa acgtaataa gggggctatg accgaaaatg     600
ccgatgaaaa cgcgctacag tctgacgcta aaggcaaact tgattctgtc gctactgatt     660
acggtgctgc tctgatggt ttcattggtg acgtttccgg ccttgctaat ggtaatggtg     720
ctactggtga ttttgctggc tctaattccc aaatggctca agtcggtgac ggtgataatt     780
cacctttaat gaataatttc cgtcaatatt taccttcttt gcctcagtcg gttgaatgtc     840
gcccttatgt ctttggcgtt ggtaaaccat atgaattttc tattgattgt gacaaaataa     900
acttattccg tgggtgtctt gcgtttcttt tataatggtg cacctttatg tatgtatttt     960
cgacgtttgc taacatactg cgtaataagg agtcttaagg atcctaatat tgttctggat    1020
attaccagca aggccgatag tttgagttct tctactcagg caagtgatgt tattactaat    1080
caaagaagta ttgcgacaac ggttaatttg cgtgatggac agactctttt actcgggtggc    1140
ctcactgatt ataaaaacac ttctcaggat tctggcgtac cgttctgtc taaaatccct    1200
ttaatcggcc tcctgtttag ctcccgtctt gattctaacg aggaaagcac gttatacgtg    1260
ctcgtcaaag caaccatagt acgcgccttg tagcggcgca ttaagcgcgg cgggtgtggt    1320
ggttacgcgc agcgtgaccg ctacacttgc cagcgccta gcgcccgtc ctttcgcttt    1380
cttcccttcc tttctcgcca cgttcgcccg ctttcccogt caagctctaa atcgggggct    1440
ccctttaggg ttccgattta gtgctttacg gcacctgac cccaaaaaac ttgattaggg    1500
tgatggttca cgtagtggc catcgccctg atagacggtt tttcgccctt tgacgttggg    1560
gtccacgttc ttaatagtg gactcttgtt ccaaactgga acaaacactca accctatctc    1620
ggtctattct tttgatttat aagggtttt gccgatttcg gcctattggt taaaaaatga    1680
gctgatttaa caaaaattta acgcgaattt taacaaaata ttaacgttta caatttaaat    1740
atttgcttat acaatcttcc tgtttttggg gcttttctga ttatcaaccg gggtacatat    1800
gattgacatg ctagttttac gattaccgtt catcgcagggt ggcacttttc ggggaaatgt    1860
gcgcggaacc cctatttgtt tatttttcta aatacattca aatatgtatc cgctcatgag    1920
acaataaacc tgataaatgc ttcaataata ttgaaaagg aagagtatga gtattcaaca    1980
tttccgtgtc gcccttattc ccttttttgc ggcattttgc cttcctgttt ttgctcacc     2040
agaaacgctg gtgaaagtaa aagatgctga agatcagttg ggtgcacgag tgggttacat     2100

```

-continued

```

cgaactggat ctcaacagcg gtaagatcct tgagagtttt cgccccgaag aacgttttcc 2160
aatgatgagc acttttaaag ttctgctatg tggcgcggtta ttatcccgta ttgacgccgg 2220
gcaagagcaa ctcggtcgcc gcatacacta ttctcagaat gacttggttg agtactcacc 2280
agtcacagaa aagcatctta cggatggcat gacagtaaga gaattatgca gtgctgccat 2340
aaccatgagt gataaactg cgcccaactt acttctgaca acgatcggag gaccgaagga 2400
gctaaccgct tttttgcaca acatggggga tcatgtaact cgccttgatc gttgggaacc 2460
ggagctgaat gaagccatac caaacgacga gcgtgacacc acgatgcctg tagcaatggc 2520
aacaacgttg cgcaactat taactggcga actacttact ctagcttccc ggcaacaatt 2580
aatagactgg atggaggcgg ataaagttgc aggaccactt ctgcgctcgg cccttccggc 2640
tggtcgtttt attgctgata aatctggagc cggtgagcgt gggctcgcg gtatcattgc 2700
agcactgggg ccagatggta agccctcccg tatcgtagtt atctacacga cggggagtca 2760
ggcaactatg gatgaacgaa atagacagat cgctgagata ggtgcctcac tgattaagca 2820
ttggtaactg tcagaccaag tttactcata tatactttag attgatttaa aacttcattt 2880
ttaatttaaa aggatctagg tgaagatcct ttttgataat ctcatgacca aaatccctta 2940
acgtgagttt tegtccact gagcgtcaga ccccgtagaa aagatcaaag gatcttcttg 3000
agatcctttt tttctgcgcg taatctgctg cttgcaaaaa aaaaaaccac cgctaccagc 3060
ggtggtttgt ttgccgcatc aagagctacc aactcctttt ccgaaggtaa ctggcttcag 3120
cagagcgcag ataccaata ctgtccttct agtgtagccg tagttaggcc accacttcaa 3180
gaactctgta gcaccgcta catacctcgc tctgctaata ctggtaccag tggctgctgc 3240
cagtggcgat aagtcgtgtc ttaccggggt ggactcaaga cgatagttac cggataaggg 3300
gcagcggtcg ggctgaacgg ggggttcgtg cacacagccc agcttgagc gaacgaccta 3360
caccgaactg agatacctac agcgtgagct atgagaaagc gccacgcttc ccgaaggag 3420
aaaggcggac aggtatccgg taagcggcag ggtcggaaaca ggagagcgca cgagggagct 3480
tccaggggga aacgctggt atctttatag tctgtcggg tttcgcacc tctgacttga 3540
cgctcgattt ttgtgatgct cgtcaggggg gcggagccta tggaaaaacg ccagcaacgc 3600
ggccttttta cggttcctgg ccttttctg gccttttget cacatgttct ttctgcggt 3660
atcccctgat tctgtggata accgtattac cgcctttgag tgagctgata ccgctcggc 3720
cagccgaacg accgagcgca gcgagtcagt gagcgaggaa gcggaagagc 3770

```

```

<210> SEQ ID NO 2
<211> LENGTH: 738
<212> TYPE: DNA
<213> ORGANISM: Escherichia coli
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(738)
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (274)..(274)
<223> OTHER INFORMATION: n is a, c, g, or t
<220> FEATURE:
<221> NAME/KEY: misc_feature
<222> LOCATION: (387)..(387)
<223> OTHER INFORMATION: n is a, c, g, or t

<400> SEQUENCE: 2

```

```

gag gtg cag ctg gtg gag tct gga gct gag gtg aag aag ccc ggg gcc 48
Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1 5 10 15

```



-continued

```

tca gtg aag gtc tcc tgc aag gct tct gga tac acc ttc acc gcc tcc      96
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ala Ser
          20                      25                      30

tat atg cac tgg gtg cga cag gcc cct gga caa ggg ctt gag tgg atg      144
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met
          35                      40                      45

gga tgg ttc aac cct aat agt ggt ggc aca aac tat gca cag aag ttt      192
Gly Trp Phe Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe
          50                      55                      60

cag ggc agg gtc acc atg acc ggg gac acg tcc acc agc aca ggc tat      240
Gln Gly Arg Val Thr Met Thr Gly Asp Thr Ser Thr Ser Thr Gly Tyr
          65                      70                      75                      80

atg gag ctg agc agg ctg aca tct gac gac gcg ncc gtg tat tat tgt      288
Met Glu Leu Ser Arg Leu Thr Ser Asp Asp Ala Xaa Val Tyr Tyr Cys
          85                      90                      95

gcg aga gat cgg gcc tct gct atg ggc gtc tgg ggc caa ggc acc ctg      336
Ala Arg Asp Arg Ala Ser Ala Met Gly Val Trp Gly Gln Gly Thr Leu
          100                     105                     110

gtc acc gtc tcc tca ggt gga ggc ggt tca ggc gga ggt ggc tct ggc      384
Val Thr Val Ser Ser Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly
          115                     120                     125

ggn ggc gga tgg cag tct gcc ctg act cag cct gcc tcc gcg tcc ggg      432
Gly Gly Gly Ser Gln Ser Ala Leu Thr Gln Pro Ala Ser Ala Ser Gly
          130                     135                     140

tct cct gga cag tca gtc acc atc tcc tgc act gga acc agc agt gac      480
Ser Pro Gly Gln Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp
          145                     150                     155                     160

gtt ggt ggt tat aac tat gtc tcc tgg tac caa cag cac cca ggc aaa      528
Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys
          165                     170                     175

gcc ccc aaa ctc atg att tat gac gtc aat aag cgg ccc tca ggg gtc      576
Ala Pro Lys Leu Met Ile Tyr Asp Val Asn Lys Arg Pro Ser Gly Val
          180                     185                     190

cct gat cgc ttc tct ggc tcc aag tct ggc aac acg gcc tcc ctg acc      624
Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr
          195                     200                     205

gtc tct ggg ctc cag gct gag gat gag gct gat tat tac tgc agc tca      672
Val Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser
          210                     215                     220

tat gca ggt agt aac act ttc cta ttc ggc gga ggg acc cag ctc acc      720
Tyr Ala Gly Ser Asn Thr Phe Leu Phe Gly Gly Gly Thr Gln Leu Thr
          225                     230                     235                     240

gtt tta ggt gcg gcc gca
Val Leu Gly Ala Ala Ala
          245

```

&lt;210&gt; SEQ ID NO 3

&lt;211&gt; LENGTH: 246

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Escherichia coli

&lt;220&gt; FEATURE:

&lt;221&gt; NAME/KEY: misc\_feature

&lt;222&gt; LOCATION: (92)..(92)

<223> OTHER INFORMATION: The 'Xaa' at location 92 stands for Thr, Ala,  
Pro, or Ser.

&lt;400&gt; SEQUENCE: 3

```

Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ala
1          5          10          15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Ala Ser
          20          25          30

```



-continued

Tyr	Cys	Ala	Arg	Asp	Arg	Ala	Ser	Ala	Met	Gly	Val	Trp	Gly	Gln	Gly		
			100					105					110				
acc	ctg	gtc	acc	gtc	tcc	tca	ggt	gga	ggc	ggt	tca	ggc	gga	ggt	ggc		384
Thr	Leu	Val	Thr	Val	Ser	Ser	Gly	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly		
		115					120					125					
tct	ggc	ggt	ggc	gga	tcc	cag	tct	gcc	ctg	act	cag	cct	gcc	tcc	gtg		432
Ser	Gly	Gly	Gly	Gly	Ser	Gln	Ser	Ala	Leu	Thr	Gln	Pro	Ala	Ser	Val		
	130					135					140						
tct	ggg	tct	cct	gga	cag	tcg	atc	acc	atc	tcc	tgc	act	gga	acc	agc		480
Ser	Gly	Ser	Pro	Gly	Gln	Ser	Ile	Thr	Ile	Ser	Cys	Thr	Gly	Thr	Ser		
	145				150					155					160		
agt	gac	ggt	ggt	ggt	tat	aac	tat	gtc	tcc	tgg	tac	caa	cag	cac	cca		528
Ser	Asp	Val	Gly	Gly	Tyr	Asn	Tyr	Val	Ser	Trp	Tyr	Gln	Gln	His	Pro		
			165					170						175			
ggc	aaa	gcc	ccc	aaa	ctc	atg	att	tat	gat	gtc	agt	cat	cgg	ccc	tca		576
Gly	Lys	Ala	Pro	Lys	Leu	Met	Ile	Tyr	Asp	Val	Ser	His	Arg	Pro	Ser		
			180					185					190				
ggg	att	tct	aat	cgc	ttc	tct	ggc	tcc	aag	tct	ggc	aac	acg	gcc	tcc		624
Gly	Ile	Ser	Asn	Arg	Phe	Ser	Gly	Ser	Lys	Ser	Gly	Asn	Thr	Ala	Ser		
		195					200					205					
ctg	acc	atc	tct	agg	ctc	cag	gct	gag	gac	gag	gct	gat	tat	tac	tgc		672
Leu	Thr	Ile	Ser	Arg	Leu	Gln	Ala	Glu	Asp	Glu	Ala	Asp	Tyr	Tyr	Cys		
		210				215					220						
agc	tca	tat	aca	agc	agt	aac	act	ttc	atc	ttc	gga	act	ggg	acc	cag		720
Ser	Ser	Tyr	Thr	Ser	Ser	Asn	Thr	Phe	Ile	Phe	Gly	Thr	Gly	Thr	Gln		
						230				235					240		
ctc	acc	ggt	tta	ggt	gcg	gcc	gc										743
Leu	Thr	Val	Leu	Gly	Ala	Ala											
				245													

<210> SEQ ID NO 5  
 <211> LENGTH: 247  
 <212> TYPE: PRT  
 <213> ORGANISM: Escherichia coli

<400> SEQUENCE: 5

Met	Glu	Glu	Val	Gln	Leu	Gln	Glu	Ser	Gly	Ala	Glu	Val	Lys	Lys	Pro		
1				5					10					15			
Gly	Ala	Ser	Val	Lys	Val	Ser	Cys	Lys	Ala	Ser	Gly	Tyr	Thr	Phe	Thr		
			20					25					30				
Ala	Ser	Tyr	Met	His	Trp	Val	Arg	Gln	Ala	Pro	Gly	Gln	Gly	Leu	Glu		
			35				40					45					
Trp	Met	Gly	Trp	Phe	Asn	Pro	Asn	Ser	Gly	Gly	Thr	Asn	Tyr	Ala	Gln		
			50			55					60						
Lys	Phe	Gln	Gly	Arg	Val	Thr	Met	Thr	Gly	Asp	Thr	Ser	Thr	Ser	Thr		
			65			70				75					80		
Gly	Tyr	Met	Glu	Leu	Ser	Arg	Leu	Thr	Ser	Asp	Asp	Ala	Ala	Val	Tyr		
				85					90					95			
Tyr	Cys	Ala	Arg	Asp	Arg	Ala	Ser	Ala	Met	Gly	Val	Trp	Gly	Gln	Gly		
			100					105						110			
Thr	Leu	Val	Thr	Val	Ser	Ser	Gly	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly		
		115					120					125					
Ser	Gly	Gly	Gly	Gly	Ser	Gln	Ser	Ala	Leu	Thr	Gln	Pro	Ala	Ser	Val		
						135					140						
Ser	Gly	Ser	Pro	Gly	Gln	Ser	Ile	Thr	Ile	Ser	Cys	Thr	Gly	Thr	Ser		
						150				155					160		
Ser	Asp	Val	Gly	Gly	Tyr	Asn	Tyr	Val	Ser	Trp	Tyr	Gln	Gln	His	Pro		
						165				170				175			

-continued

Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Ser His Arg Pro Ser  
 180 185 190

Gly Ile Ser Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser  
 195 200 205

Leu Thr Ile Ser Arg Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys  
 210 215 220

Ser Ser Tyr Thr Ser Ser Asn Thr Phe Ile Phe Gly Thr Gly Thr Gln  
 225 230 235 240

Leu Thr Val Leu Gly Ala Ala  
 245

<210> SEQ ID NO 6  
 <211> LENGTH: 743  
 <212> TYPE: DNA  
 <213> ORGANISM: Escherichia coli  
 <220> FEATURE:  
 <221> NAME/KEY: CDS  
 <222> LOCATION: (1)..(741)

<400> SEQUENCE: 6

atg gag cag gtg cag ctg gtg cag tct gga gct gag gtg aag aag ccc 48  
 Met Glu Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro  
 1 5 10 15

ggg gcc tca gtg aag gtc tcc tgc aag gcc tct gga tac acc ttc acc 96  
 Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr  
 20 25 30

gcc tcc tat atg cac tgg gtg cga cag gcc cct gga caa ggg ctt gag 144  
 Ala Ser Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu  
 35 40 45

tgg atg gga tgg ttc aac cct aat agt ggt ggc aca aac tat gca cag 192  
 Trp Met Gly Trp Phe Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln  
 50 55 60

aag ttt cag ggc agg gtc acc atg acc ggg gac acg tcc acc agc aca 240  
 Lys Phe Gln Gly Arg Val Thr Met Thr Gly Asp Thr Ser Thr Ser Thr  
 65 70 75 80

ggc tat atg gag ctg agc agg ctg aca tct gac gac gcg gcc gtg tat 288  
 Gly Tyr Met Glu Leu Ser Arg Leu Thr Ser Asp Asp Ala Ala Val Tyr  
 85 90 95

tat tgt gcg aga gat cgg gcc tct gct atg ggc gtc tgg gcc caa ggc 336  
 Tyr Cys Ala Arg Asp Arg Ala Ser Ala Met Gly Val Trp Gly Gln Gly  
 100 105 110

acc ctg gtc acc gtc tcc tca ggt gga ggc ggt tca ggc gga ggc ggc 384  
 Thr Leu Val Thr Val Ser Ser Gly Gly Gly Ser Gly Gly Gly Gly  
 115 120 125

tct ggc ggt ggc gga tcg cag tct gcc ctg act cag cct gcc tcc gtg 432  
 Ser Gly Gly Gly Gly Ser Gln Ser Ala Leu Thr Gln Pro Ala Ser Val  
 130 135 140

tct ggg tct cct gga cag tcg atc acc atc tcc tgc act gga acc agc 480  
 Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser  
 145 150 155 160

agt gac gtt ggt ggt tat aac tat gtc tcc tgg tac caa cag cac cca 528  
 Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro  
 165 170 175

ggc aaa gcc ccc aaa ctc atg att tat gat gtc act aat cgg cct tca 576  
 Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Thr Asn Arg Pro Ser  
 180 185 190

ggg gtt tct agt cgc ttc tct ggc tcc aag tct ggc aac acg gcc tcc 624  
 Gly Val Ser Ser Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser  
 195 200 205

-continued

---

```

ctg acc atc tct gga ctc cag act gag gac gag gct gat tat tac tgc      672
Leu Thr Ile Ser Gly Leu Gln Thr Glu Asp Glu Ala Asp Tyr Tyr Cys
   210                               215                               220

aac tca ttt aca agc agc aac act tat gtc ttc gga act ggg acc cag      720
Asn Ser Phe Thr Ser Ser Asn Thr Tyr Val Phe Gly Thr Gly Thr Gln
  225                               230                               235                               240

ctc acc gtt tta ggt gcg gcc gc      743
Leu Thr Val Leu Gly Ala Ala
                               245

```

```

<210> SEQ ID NO 7
<211> LENGTH: 247
<212> TYPE: PRT
<213> ORGANISM: Escherichia coli

```

```

<400> SEQUENCE: 7

```

```

Met Glu Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro
 1                               5                               10                               15

Gly Ala Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr
 20                               25                               30

Ala Ser Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu
 35                               40                               45

Trp Met Gly Trp Phe Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln
 50                               55                               60

Lys Phe Gln Gly Arg Val Thr Met Thr Gly Asp Thr Ser Thr Ser Thr
 65                               70                               75                               80

Gly Tyr Met Glu Leu Ser Arg Leu Thr Ser Asp Asp Ala Ala Val Tyr
 85                               90                               95

Tyr Cys Ala Arg Asp Arg Ala Ser Ala Met Gly Val Trp Gly Gln Gly
 100                              105                              110

Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
 115                              120                              125

Ser Gly Gly Gly Gly Ser Gln Ser Ala Leu Thr Gln Pro Ala Ser Val
 130                              135                              140

Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser
 145                              150                              155                              160

Ser Asp Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro
 165                              170                              175

Gly Lys Ala Pro Lys Leu Met Ile Tyr Asp Val Thr Asn Arg Pro Ser
 180                              185                              190

Gly Val Ser Ser Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser
 195                              200                              205

Leu Thr Ile Ser Gly Leu Gln Thr Glu Asp Glu Ala Asp Tyr Tyr Cys
 210                              215                              220

Asn Ser Phe Thr Ser Ser Asn Thr Tyr Val Phe Gly Thr Gly Thr Gln
 225                              230                              235                              240

Leu Thr Val Leu Gly Ala Ala
 245

```

```

<210> SEQ ID NO 8
<211> LENGTH: 750
<212> TYPE: DNA
<213> ORGANISM: Escherichia coli
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(750)

```

```

<400> SEQUENCE: 8

```

-continued

gag gag gtg cag ctg gtg cag tct gga gga ggc ttg atc cag ccg ggg	48
Glu Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Ile Gln Pro Gly	
1 5 10 15	
ggg tcc ctg aga ctc tct tgt gta gcc tct gag ttc aac gtc aga agc	96
Gly Ser Leu Arg Leu Ser Cys Val Ala Ser Glu Phe Asn Val Arg Ser	
20 25 30	
aac tac atg agc tgg gtc cgc cag gct cca ggg aag ggg ctg gag tgg	144
Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp	
35 40 45	
gtc tca gtt atg tat gac ggc ggt agt aca tac tac gca gac tcc gtg	192
Val Ser Val Met Tyr Asp Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val	
50 55 60	
aag ggc cga ttc acc atc tcc aga gac aat tct aag aac acg gtg tat	240
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr	
65 70 75 80	
ctt caa atg aac agc ctg aga gcc gag gac acg gcc gtc tat tac tgt	288
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys	
85 90 95	
gcg aga ggc gga ttg ggg ttg cct aca atc gcg tct tgg gag atc tgg	336
Ala Arg Gly Gly Leu Gly Leu Pro Thr Ile Ala Ser Trp Glu Ile Trp	
100 105 110	
ggc caa ggg aca atg gtc acc gtc tct tca ggt gga ggc ggt tct ggc	384
Gly Gln Gly Thr Met Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly	
115 120 125	
gga ggt ggc tct ggc ggt ggc gga tgc tcc tat gtg ctg act cag cca	432
Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser Tyr Val Leu Thr Gln Pro	
130 135 140	
ccc tgc gtg tca gtg gcc cca gga aag acg gcc acg att acc tgt gcg	480
Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Thr Ile Thr Cys Ala	
145 150 155 160	
gga aac aat ata gga agt aac agt gta tac tgg tac cag cag aaa cca	528
Gly Asn Asn Ile Gly Ser Asn Ser Val Tyr Trp Tyr Gln Gln Lys Pro	
165 170 175	
ggc ctg gcc cct gta ctg gtc gtc tat gat gat aga gac cgg ccc tca	576
Gly Leu Ala Pro Val Leu Val Val Tyr Asp Asp Arg Asp Arg Pro Ser	
180 185 190	
ggg atc cct gag cga ttc tct ggc tcc aaa tcc ggg aac acg gcc acc	624
Gly Ile Pro Glu Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Thr	
195 200 205	
ctg acc atc agc agg gtc gag gcc ggg gat gag gcc gac tat tct tgt	672
Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Ser Cys	
210 215 220	
cag gtg tgg gat cct agt agt gat cac ctc tat gtc ttc gga act ggg	720
Gln Val Trp Asp Pro Ser Ser Asp His Leu Tyr Val Phe Gly Thr Gly	
225 230 235 240	
acc cag ctc acc gtt tta ggt gcg gcc gca	750
Thr Gln Leu Thr Val Leu Gly Ala Ala Ala	
245 250	

<210> SEQ ID NO 9  
 <211> LENGTH: 250  
 <212> TYPE: PRT  
 <213> ORGANISM: Escherichia coli

<400> SEQUENCE: 9

Glu Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Ile Gln Pro Gly	
1 5 10 15	
Gly Ser Leu Arg Leu Ser Cys Val Ala Ser Glu Phe Asn Val Arg Ser	
20 25 30	
Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp	

-continued

35	40	45
Val Ser Val Met Tyr Asp Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60		
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val Tyr 65 70 75 80		
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95		
Ala Arg Gly Gly Leu Gly Leu Pro Thr Ile Ala Ser Trp Glu Ile Trp 100 105 110		
Gly Gln Gly Thr Met Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly 115 120 125		
Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser Tyr Val Leu Thr Gln Pro 130 135 140		
Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Thr Ile Thr Cys Ala 145 150 155 160		
Gly Asn Asn Ile Gly Ser Asn Ser Val Tyr Trp Tyr Gln Gln Lys Pro 165 170 175		
Gly Leu Ala Pro Val Leu Val Val Tyr Asp Asp Arg Asp Arg Pro Ser 180 185 190		
Gly Ile Pro Glu Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Thr 195 200 205		
Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Ser Cys 210 215 220		
Gln Val Trp Asp Pro Ser Ser Asp His Leu Tyr Val Phe Gly Thr Gly 225 230 235 240		
Thr Gln Leu Thr Val Leu Gly Ala Ala Ala 245 250		

&lt;210&gt; SEQ ID NO 10

&lt;211&gt; LENGTH: 752

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: Escherichia coli

&lt;220&gt; FEATURE:

&lt;221&gt; NAME/KEY: CDS

&lt;222&gt; LOCATION: (1)..(750)

&lt;400&gt; SEQUENCE: 10

atg gag gag gtg cag ctg gtg cag tct gga gga ggc ttg atc cag ccg Met Glu Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Ile Gln Pro 1 5 10 15	48
ggg ggg tcc ctg aga ctc tct tgt gta gcc tct gag ttc aac gtc aga Gly Gly Ser Leu Arg Leu Ser Cys Val Ala Ser Glu Phe Asn Val Arg 20 25 30	96
agc aac tac atg agc tgg gtc cgc cag gct cca ggg aag ggg ctg gag Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu 35 40 45	144
tgg gtc tca gtt atg tat gac ggc ggt agt aca tac tac gca gac tcc Trp Val Ser Val Met Tyr Asp Gly Gly Ser Thr Tyr Tyr Ala Asp Ser 50 55 60	192
gtg aag ggc cga ttc acc atc tcc aga gac aat tct aag aac acg gtg Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val 65 70 75 80	240
tat ctt caa atg aac agc ctg aga gcc gag gac acg gcc gtc tat tac Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr 85 90 95	288
tgt gcg aga ggc gga ttg ggg ttg cct aca atc gcg cct tgg gag atc Cys Ala Arg Gly Gly Leu Gly Leu Pro Thr Ile Ala Pro Trp Glu Ile 100 105 110	336

-continued

tgg ggc caa ggg aca atg gtc acc gtc tct tca ggt gga ggc ggt tca	384
Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Gly Gly Gly Gly Ser	
115 120 125	
ggc gga ggt ggc tct ggc ggt ggc gga tct tcc tat gtg ctg act cag	432
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser Tyr Val Leu Thr Gln	
130 135 140	
cca ccc tct ggt tca gtc gcc cca gga aag acg gcc acg att acc tgt	480
Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Thr Ile Thr Cys	
145 150 155 160	
gcg gga aac aat ata gga agt aac agt gta tac tgg tac caa caa aaa	528
Ala Gly Asn Asn Ile Gly Ser Asn Ser Val Tyr Trp Tyr Gln Gln Lys	
165 170 175	
cca ggc ctg gcc cct gta ctg gtc gtc tat gat gat aga gac cgg ccc	576
Pro Gly Leu Ala Pro Val Leu Val Val Tyr Asp Asp Arg Asp Arg Pro	
180 185 190	
tca ggg atc cat gag cga ttc tct ggc tcc aaa tcc ggg aac acg gcc	624
Ser Gly Ile His Glu Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala	
195 200 205	
acc ctg acc atc agc agg gtc gag gcc ggg gat gag gcc gac tat tct	672
Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Ser	
210 215 220	
tgt cag gtc tgg gat cct agt agt gat cac ctc tat gtc ttc gga act	720
Cys Gln Val Trp Asp Pro Ser Ser Asp His Leu Tyr Val Phe Gly Thr	
225 230 235 240	
ggg acc cag ctc acc gtt tta ggt ggc gcc gc	752
Gly Thr Gln Leu Thr Val Leu Gly Ala Ala	
245 250	

<210> SEQ ID NO 11  
 <211> LENGTH: 250  
 <212> TYPE: PRT  
 <213> ORGANISM: Escherichia coli

<400> SEQUENCE: 11

Met Glu Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Ile Gln Pro	1 5 10 15
Gly Gly Ser Leu Arg Leu Ser Cys Val Ala Ser Glu Phe Asn Val Arg	20 25 30
Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu	35 40 45
Trp Val Ser Val Met Tyr Asp Gly Gly Ser Thr Tyr Tyr Ala Asp Ser	50 55 60
Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val	65 70 75 80
Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr	85 90 95
Cys Ala Arg Gly Gly Leu Gly Leu Pro Thr Ile Ala Pro Trp Glu Ile	100 105 110
Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Gly Gly Gly Gly Ser	115 120 125
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser Tyr Val Leu Thr Gln	130 135 140
Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Thr Ile Thr Cys	145 150 155 160
Ala Gly Asn Asn Ile Gly Ser Asn Ser Val Tyr Trp Tyr Gln Gln Lys	165 170 175
Pro Gly Leu Ala Pro Val Leu Val Val Tyr Asp Asp Arg Asp Arg Pro	



-continued

180	185	190	
Ser Gly Ile His Glu Arg Phe	Ser Gly Ser Lys Ser Gly Asn Thr Ala		
195	200	205	
Thr Leu Thr Ile Ser Arg Val	Glu Ala Gly Asp Glu Ala Asp Tyr Ser		
210	215	220	
Cys Gln Val Trp Asp Pro Ser Ser Asp His Leu Tyr Val Phe Gly Thr			
225	230	235	240
Gly Thr Gln Leu Thr Val Leu Gly Ala Ala			
	245	250	
<p>&lt;210&gt; SEQ ID NO 12                  &lt;211&gt; LENGTH: 752                  &lt;212&gt; TYPE: DNA                  &lt;213&gt; ORGANISM: Escherichia coli                  &lt;220&gt; FEATURE:                  &lt;221&gt; NAME/KEY: CDS                  &lt;222&gt; LOCATION: (1)..(750)</p>			
<p>&lt;400&gt; SEQUENCE: 12</p>			
atg gag gag gtg cag ctg gtg cag tct gga gga ggc ttg atc cag ccg			48
Met Glu Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Ile Gln Pro			
1	5	10	15
ggg ggg tcc ctg aga ctc tct tgt gta gcc tct gag ttc aac gtc aga			96
Gly Gly Ser Leu Arg Leu Ser Cys Val Ala Ser Glu Phe Asn Val Arg			
	20	25	30
agc aac tac atg agc tgg gtc cgc cag gct cca ggg aag ggg ctg gag			144
Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu			
	35	40	45
tgg gtc tca gtt atg tat gac ggc ggt agt aca tac tac gca gac tcc			192
Trp Val Ser Val Met Tyr Asp Gly Gly Ser Thr Tyr Tyr Ala Asp Ser			
	50	55	60
gtg aag ggc cga ttc acc atc tcc aga gac aat tct aag aac acg gtg			240
Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val			
65	70	75	80
tat ctt caa atg aac agc ctg aga gcc gag gac acg gcc gtc tat tac			288
Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr			
	85	90	95
tgt gcg aga ggc gga ttg ggg ttg cct aca atc gcg tct tgg gag atc			336
Cys Ala Arg Gly Gly Leu Gly Leu Pro Thr Ile Ala Ser Trp Glu Ile			
	100	105	110
tgg ggc caa ggg aca atg gtc acc gtc tct tca ggt gga ggc ggt tca			384
Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Gly Gly Gly Ser			
	115	120	125
ggc gga ggt ggc tct ggc ggt ggc gga tcg tcc tat gtg ctg act cag			432
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser Tyr Val Leu Thr Gln			
	130	135	140
cca ccc tcg gtg tca gtg gcc cca gga aag acg gcc acg att acc tgt			480
Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Thr Ile Thr Cys			
145	150	155	160
gcg gga aac aat ata gga agt aac agt gta tac tgg tac cag cag aaa			528
Ala Gly Asn Asn Ile Gly Ser Asn Ser Val Tyr Trp Tyr Gln Gln Lys			
	165	170	175
cca ggc ctg gcc cct gta ctg gtc gtc tat gat gat aga gac cgg ccc			576
Pro Gly Leu Ala Pro Val Leu Val Val Tyr Asp Asp Arg Asp Arg Pro			
	180	185	190
tca ggg ctc ccc ggg cga ttc tct ggc tcc aaa tcc ggg aac acg gcc			624
Ser Gly Leu Pro Gly Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala			
	195	200	205
acc ctg acc atc agc agg gtc gag gcc ggg gat gag gcc gac tat tct			672
Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Ser			

-continued

210	215	220	
tgt cag gtg tgg gat cct agt agt gat cac ctc tat gtc ttc gga act			720
Cys Gln Val Trp Asp Pro Ser Ser Asp His Leu Tyr Val Phe Gly Thr			
225	230	235	240
ggg acc cag ctc acc gtt tta ggt gcg gcc gc			752
Gly Thr Gln Leu Thr Val Leu Gly Ala Ala			
	245	250	

<210> SEQ ID NO 13  
 <211> LENGTH: 250  
 <212> TYPE: PRT  
 <213> ORGANISM: Escherichia coli

<400> SEQUENCE: 13

Met Glu Glu Val Gln Leu Val Gln Ser Gly Gly Gly Leu Ile Gln Pro			
1	5	10	15
Gly Gly Ser Leu Arg Leu Ser Cys Val Ala Ser Glu Phe Asn Val Arg			
	20	25	30
Ser Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu			
	35	40	45
Trp Val Ser Val Met Tyr Asp Gly Gly Ser Thr Tyr Tyr Ala Asp Ser			
	50	55	60
Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Val			
65	70	75	80
Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr			
	85	90	95
Cys Ala Arg Gly Gly Leu Gly Leu Pro Thr Ile Ala Ser Trp Glu Ile			
	100	105	110
Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Gly Gly Gly Gly Ser			
	115	120	125
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser Tyr Val Leu Thr Gln			
	130	135	140
Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Thr Ile Thr Cys			
145	150	155	160
Ala Gly Asn Asn Ile Gly Ser Asn Ser Val Tyr Trp Tyr Gln Gln Lys			
	165	170	175
Pro Gly Leu Ala Pro Val Leu Val Val Tyr Asp Asp Arg Asp Arg Pro			
	180	185	190
Ser Gly Leu Pro Gly Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala			
	195	200	205
Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr Ser			
	210	215	220
Cys Gln Val Trp Asp Pro Ser Ser Asp His Leu Tyr Val Phe Gly Thr			
225	230	235	240
Gly Thr Gln Leu Thr Val Leu Gly Ala Ala			
	245	250	

<210> SEQ ID NO 14  
 <211> LENGTH: 741  
 <212> TYPE: DNA  
 <213> ORGANISM: Escherichia coli  
 <220> FEATURE:  
 <221> NAME/KEY: CDS  
 <222> LOCATION: (1)..(741)

<400> SEQUENCE: 14

gag cag gtg cag ctg cag gag tct ggg gga ggc ttg gta cag cct ggg				48
Glu Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Pro Gly				

-continued

1	5	10	15	
ggg tcc ctg aga ctc tcc tgt gca gcc tct gga ttc acc ttt agt act				96
Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr	20	25	30	
tat gcc atg agc tgg gtc cgc cag gct cca ggg aag ggg ctg gag tgg				144
Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp	35	40	45	
gtc tca gtt att agt ggt agt ggt cat aca aca aac tac gcc gac tcc				192
Val Ser Val Ile Ser Gly Ser Gly His Thr Thr Asn Tyr Ala Asp Ser	50	55	60	
gtg aag ggc cgc gtc acc ata tcc aga gac aat tcc aag aac aca cta				240
Val Lys Gly Arg Val Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu	65	70	75	80
tat ctg caa atc aac agc ctg aga gcc gac gac acg gcc gtg tat tac				288
Tyr Leu Gln Ile Asn Ser Leu Arg Ala Asp Asp Thr Ala Val Tyr Tyr	85	90	95	
tgt gcg aga gat gtg tta gtc cta cag aat gct ttt gat atc tgg ggc				336
Cys Ala Arg Asp Val Leu Val Leu Gln Asn Ala Phe Asp Ile Trp Gly	100	105	110	
caa ggg acc acg gtc acc gtc tcc tca ggt gga ggt ggt tca ggc gga				384
Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Ser Gly Gly	115	120	125	
ggt ggc tct ggc ggt ggc gga tgc gat gtt gtg atg acc cag tct cca				432
Gly Gly Ser Gly Gly Gly Ser Asp Val Val Met Thr Gln Ser Pro	130	135	140	
tcc tca ctg tct gca tct gta gga gac aga gtc acc atc act tgt cgg				480
Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys Arg	145	150	155	160
gcg agt cag ggt att agc agg tgg tta gcc tgg tat caa cag aaa cca				528
Ala Ser Gln Gly Ile Ser Arg Trp Leu Ala Trp Tyr Gln Gln Lys Pro	165	170	175	
ggg aaa gcc cct aag ctc ctg atc tac gct gca tcc agt ttg caa agt				576
Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln Ser	180	185	190	
ggg gtc cca tca agg ttc agt ggc agt gga tct ggg aca gat ttc act				624
Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr	195	200	205	
ctc acc atc agc agt ctg caa cct gaa gat ttt gca act tac atc tgt				672
Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Ile Cys	210	215	220	
caa cag agt tac agt agg ccg ctc act ttc ggc gga ggg acc aag gtg				720
Gln Gln Ser Tyr Ser Arg Pro Leu Thr Phe Gly Gly Gly Thr Lys Val	225	230	235	240
gaa atc aaa cgt gcg gcc gca				741
Glu Ile Lys Arg Ala Ala Ala	245			

&lt;210&gt; SEQ ID NO 15

&lt;211&gt; LENGTH: 247

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Escherichia coli

&lt;400&gt; SEQUENCE: 15

Glu Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Pro Gly				
1	5	10	15	
Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Thr	20	25	30	
Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp	35	40	45	

-continued

Val	Ser	Val	Ile	Ser	Gly	Ser	Gly	His	Thr	Thr	Asn	Tyr	Ala	Asp	Ser
	50					55					60				
Val	Lys	Gly	Arg	Val	Thr	Ile	Ser	Arg	Asp	Asn	Ser	Lys	Asn	Thr	Leu
65					70					75					80
Tyr	Leu	Gln	Ile	Asn	Ser	Leu	Arg	Ala	Asp	Asp	Thr	Ala	Val	Tyr	Tyr
				85					90					95	
Cys	Ala	Arg	Asp	Val	Leu	Val	Leu	Gln	Asn	Ala	Phe	Asp	Ile	Trp	Gly
			100					105					110		
Gln	Gly	Thr	Thr	Val	Thr	Val	Ser	Ser	Gly	Gly	Gly	Gly	Ser	Gly	Gly
		115					120					125			
Gly	Gly	Ser	Gly	Gly	Gly	Gly	Ser	Asp	Val	Val	Met	Thr	Gln	Ser	Pro
	130						135				140				
Ser	Ser	Leu	Ser	Ala	Ser	Val	Gly	Asp	Arg	Val	Thr	Ile	Thr	Cys	Arg
145					150					155					160
Ala	Ser	Gln	Gly	Ile	Ser	Arg	Trp	Leu	Ala	Trp	Tyr	Gln	Gln	Lys	Pro
				165					170					175	
Gly	Lys	Ala	Pro	Lys	Leu	Leu	Ile	Tyr	Ala	Ala	Ser	Ser	Leu	Gln	Ser
			180					185					190		
Gly	Val	Pro	Ser	Arg	Phe	Ser	Gly	Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr
		195					200					205			
Leu	Thr	Ile	Ser	Ser	Leu	Gln	Pro	Glu	Asp	Phe	Ala	Thr	Tyr	Ile	Cys
	210					215					220				
Gln	Gln	Ser	Tyr	Ser	Arg	Pro	Leu	Thr	Phe	Gly	Gly	Gly	Thr	Lys	Val
225					230					235					240
Glu	Ile	Lys	Arg	Ala	Ala	Ala									
				245											

<210> SEQ ID NO 16  
 <211> LENGTH: 771  
 <212> TYPE: DNA  
 <213> ORGANISM: Escherichia coli  
 <220> FEATURE:  
 <221> NAME/KEY: CDS  
 <222> LOCATION: (1)..(771)

<400> SEQUENCE: 16

gag	cag	gtg	cag	ctg	gtg	cag	tct	ggg	gcg	gag	gtg	aag	aag	cct	ggg	48
Glu	Gln	Val	Gln	Leu	Val	Gln	Ser	Gly	Ala	Glu	Val	Lys	Lys	Pro	Gly	
1				5					10					15		
gcc	tca	gtg	aga	ggt	tcc	tgc	cag	gca	tct	gga	tac	aca	ttc	agc	agg	96
Ala	Ser	Val	Arg	Val	Ser	Cys	Gln	Ala	Ser	Gly	Tyr	Thr	Phe	Ser	Arg	
			20					25					30			
tac	cat	atg	cac	tgg	gtg	cga	cag	gcc	cct	gga	caa	ggg	ctt	gag	tgg	144
Tyr	His	Met	His	Trp	Val	Arg	Gln	Ala	Pro	Gly	Gln	Gly	Leu	Glu	Trp	
		35					40					45				
atg	gga	gtg	atc	gac	ccc	aat	agt	ggt	aga	gta	agt	tac	tca	cag	aag	192
Met	Gly	Val	Ile	Asp	Pro	Asn	Ser	Gly	Arg	Val	Ser	Tyr	Ser	Gln	Lys	
	50					55					60					
ttc	cag	gac	aga	ggt	acc	atg	acc	agg	gac	acg	tcc	acg	agc	aca	gta	240
Phe	Gln	Asp	Arg	Val	Thr	Met	Thr	Arg	Asp	Thr	Ser	Thr	Ser	Thr	Val	
65					70					75					80	
tac	atg	gag	ctg	aac	agc	ccg	aga	tct	gag	gac	acg	gcc	ggt	tat	tat	288
Tyr	Met	Glu	Leu	Asn	Ser	Pro	Arg	Ser	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	
				85					90					95		
tgt	gcg	aga	gat	cga	gga	tat	tgt	aat	ggt	ggc	agg	tgc	ttt	atg	gat	336
Cys	Ala	Arg	Asp	Arg	Gly	Tyr	Cys	Asn	Gly	Gly	Arg	Cys	Phe	Met	Asp	
			100					105					110			
gca	ttt	gac	tac	tgg	ggc	cag	ggg	aca	atg	gtc	acc	gtc	tct	tca	ggt	384

-continued

Ala	Phe	Asp	Tyr	Trp	Gly	Gln	Gly	Thr	Met	Val	Thr	Val	Ser	Ser	Gly		
		115					120					125					
gga	ggc	ggt	tta	ggc	gga	ggt	ggc	tct	ggc	ggt	ggc	gga	tcg	tcc	tat		432
Gly	Gly	Gly	Leu	Gly	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Ser	Ser	Tyr		
	130					135					140						
gtg	ctg	act	cac	cca	ccc	tca	ttg	tct	ggg	gcc	cca	ggg	cag	agc	atc		480
Val	Leu	Thr	His	Pro	Pro	Ser	Leu	Ser	Gly	Ala	Pro	Gly	Gln	Ser	Ile		
145					150					155					160		
acc	atc	tcc	tgc	act	ggg	agc	agt	tcc	aac	atc	ggg	gca	ggt	ttt	cat		528
Thr	Ile	Ser	Cys	Thr	Gly	Ser	Ser	Ser	Asn	Ile	Gly	Ala	Gly	Phe	His		
				165					170					175			
ata	cac	tgg	tac	cag	cag	ttt	cca	aaa	aca	gcc	ccc	aaa	ctc	ctt	atc		576
Ile	His	Trp	Tyr	Gln	Gln	Phe	Pro	Lys	Thr	Ala	Pro	Lys	Leu	Leu	Ile		
			180					185					190				
tat	ggt	agt	agt	aat	cga	ccc	tca	ggg	gtc	cct	gac	cgc	ttc	tct	ggc		624
Tyr	Gly	Ser	Ser	Asn	Arg	Pro	Ser	Gly	Val	Pro	Asp	Arg	Phe	Ser	Gly		
		195					200					205					
tcc	agg	tct	ggc	tcc	tca	ggc	tcc	ctg	gcc	atc	act	ggg	ctc	cag	gca		672
Ser	Arg	Ser	Gly	Ser	Ser	Gly	Ser	Leu	Ala	Ile	Thr	Gly	Leu	Gln	Ala		
	210					215					220						
gac	gat	gag	gct	gat	tat	tac	tgt	gtg	gga	tgg	gat	ggc	agc	ctg	agt		720
Asp	Asp	Glu	Ala	Asp	Tyr	Tyr	Cys	Val	Gly	Trp	Asp	Gly	Ser	Leu	Ser		
225					230					235					240		
ggt	tat	gtc	ttc	gga	act	ggg	acc	cag	ctc	acc	ggt	tta	ggt	gcg	gcc		768
Gly	Tyr	Val	Phe	Gly	Thr	Gly	Thr	Gln	Leu	Thr	Val	Leu	Gly	Ala	Ala		
				245					250					255			
gca																	771
Ala																	

<210> SEQ ID NO 17  
 <211> LENGTH: 257  
 <212> TYPE: PRT  
 <213> ORGANISM: Escherichia coli

<400> SEQUENCE: 17

Glu	Gln	Val	Gln	Leu	Val	Gln	Ser	Gly	Ala	Glu	Val	Lys	Lys	Pro	Gly		
1				5					10					15			
Ala	Ser	Val	Arg	Val	Ser	Cys	Gln	Ala	Ser	Gly	Tyr	Thr	Phe	Ser	Arg		
			20					25					30				
Tyr	His	Met	His	Trp	Val	Arg	Gln	Ala	Pro	Gly	Gln	Gly	Leu	Glu	Trp		
		35					40					45					
Met	Gly	Val	Ile	Asp	Pro	Asn	Ser	Gly	Arg	Val	Ser	Tyr	Ser	Gln	Lys		
	50					55					60						
Phe	Gln	Asp	Arg	Val	Thr	Met	Thr	Arg	Asp	Thr	Ser	Thr	Ser	Thr	Val		
65					70				75						80		
Tyr	Met	Glu	Leu	Asn	Ser	Pro	Arg	Ser	Glu	Asp	Thr	Ala	Val	Tyr	Tyr		
				85					90					95			
Cys	Ala	Arg	Asp	Arg	Gly	Tyr	Cys	Asn	Gly	Gly	Arg	Cys	Phe	Met	Asp		
			100					105					110				
Ala	Phe	Asp	Tyr	Trp	Gly	Gln	Gly	Thr	Met	Val	Thr	Val	Ser	Ser	Gly		
		115					120					125					
Gly	Gly	Gly	Leu	Gly	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Ser	Ser	Tyr		
	130					135						140					
Val	Leu	Thr	His	Pro	Pro	Ser	Leu	Ser	Gly	Ala	Pro	Gly	Gln	Ser	Ile		
145					150					155					160		
Thr	Ile	Ser	Cys	Thr	Gly	Ser	Ser	Ser	Asn	Ile	Gly	Ala	Gly	Phe	His		
				165					170					175			

-continued

---

```

Ile His Trp Tyr Gln Gln Phe Pro Lys Thr Ala Pro Lys Leu Leu Ile
      180                      185                      190

Tyr Gly Ser Ser Asn Arg Pro Ser Gly Val Pro Asp Arg Phe Ser Gly
      195                      200                      205

Ser Arg Ser Gly Ser Ser Gly Ser Leu Ala Ile Thr Gly Leu Gln Ala
      210                      215                      220

Asp Asp Glu Ala Asp Tyr Tyr Cys Val Gly Trp Asp Gly Ser Leu Ser
      225                      230                      235                      240

Gly Tyr Val Phe Gly Thr Gly Thr Gln Leu Thr Val Leu Gly Ala Ala
      245                      250                      255

```

Ala

```

<210> SEQ ID NO 18
<211> LENGTH: 735
<212> TYPE: DNA
<213> ORGANISM: Escherichia coli
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(735)

```

&lt;400&gt; SEQUENCE: 18

```

gag cag gtg cag ctg gtg cag tct ggg gga ggc ttg gta cag cct ggg      48
Glu Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly
1                      5                      10                      15

ggg tcc ctg aga ctc tcc tgt gca gcc tct gga ttc acc ttt agc agc      96
Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser
      20                      25                      30

tat gcc atg agc tgg gtc cgc cag gct cca ggg aag ggg ctg gag tgg      144
Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
      35                      40                      45

gtc tca gct att agt ggt agt ggt ggt agc aca tac tac gca gac tcc      192
Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser
      50                      55                      60

gtg aag ggc cgg ttc acc atc tcc aga gag aat tcc aag aac acg cta      240
Val Lys Gly Arg Phe Thr Ile Ser Arg Glu Asn Ser Lys Asn Thr Leu
65                      70                      75                      80

tat ctg caa atg aat agc ctg aga gcc gag gac acg gct gtg tat tac      288
Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr
      85                      90                      95

tgt gcg aga caa aca aga gtc cgt gct ttt gat atc tgg ggc caa ggg      336
Cys Ala Arg Gln Thr Arg Val Arg Ala Phe Asp Ile Trp Gly Gln Gly
      100                      105                      110

aca atg gtc acc gtc tct tca ggt gga ggc ggt tca ggc gga ggt ggc      384
Thr Met Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly
      115                      120                      125

tct ggc ggt ggc gga tcg gac atc cag atg acc cag tct cct tcc gcc      432
Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Ala
      130                      135                      140

ctg tct gca tct gta gga ggc aga gtc acc atc act tgc cgg gca agt      480
Leu Ser Ala Ser Val Gly Gly Arg Val Thr Ile Thr Cys Arg Ala Ser
145                      150                      155                      160

cag agc act agt agc gat tta aat tgg tat cag caa aga cca ggg aaa      528
Gln Ser Thr Ser Ser Asp Leu Asn Trp Tyr Gln Gln Arg Pro Gly Lys
      165                      170                      175

gcc cct aaa ctc ctg atc tct gtt gca tcc act tta caa agt gac gtc      576
Ala Pro Lys Leu Leu Ile Ser Val Ala Ser Thr Leu Gln Ser Asp Val
      180                      185                      190

cca tca agg ttc agt ggc agt ggt tct ggg aca gat ttc agt ctc acc      624
Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Ser Leu Thr
      195                      200                      205

```

-continued

atc agc agt ctg caa cct gaa gac ttt gca act tac ttc tgt caa cag 672  
 Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln  
           210                          215                          220

agt tac agc acc ccg tac act ttt ggc cag ggg acc aaa gtg gat atc 720  
 Ser Tyr Ser Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Asp Ile  
 225                          230                          235                          240

aaa cgt gcg gcc gca 735  
 Lys Arg Ala Ala Ala  
                           245

<210> SEQ ID NO 19  
 <211> LENGTH: 245  
 <212> TYPE: PRT  
 <213> ORGANISM: Escherichia coli

<400> SEQUENCE: 19

Glu Gln Val Gln Leu Val Gln Ser Gly Gly Gly Leu Val Gln Pro Gly  
 1                          5                          10                          15

Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser  
                           20                          25                          30

Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp  
                           35                          40                          45

Val Ser Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser  
                           50                          55                          60

Val Lys Gly Arg Phe Thr Ile Ser Arg Glu Asn Ser Lys Asn Thr Leu  
 65                          70                          75                          80

Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr  
                           85                          90                          95

Cys Ala Arg Gln Thr Arg Val Arg Ala Phe Asp Ile Trp Gly Gln Gly  
                           100                          105                          110

Thr Met Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly  
                           115                          120                          125

Ser Gly Gly Gly Gly Ser Asp Ile Gln Met Thr Gln Ser Pro Ser Ala  
 130                          135                          140

Leu Ser Ala Ser Val Gly Gly Arg Val Thr Ile Thr Cys Arg Ala Ser  
 145                          150                          155                          160

Gln Ser Thr Ser Ser Asp Leu Asn Trp Tyr Gln Gln Arg Pro Gly Lys  
                           165                          170                          175

Ala Pro Lys Leu Leu Ile Ser Val Ala Ser Thr Leu Gln Ser Asp Val  
                           180                          185                          190

Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Ser Leu Thr  
                           195                          200                          205

Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln  
 210                          215                          220

Ser Tyr Ser Thr Pro Tyr Thr Phe Gly Gln Gly Thr Lys Val Asp Ile  
 225                          230                          235                          240

Lys Arg Ala Ala Ala  
                           245

<210> SEQ ID NO 20  
 <211> LENGTH: 765  
 <212> TYPE: DNA  
 <213> ORGANISM: Escherichia coli  
 <220> FEATURE:  
 <221> NAME/KEY: CDS  
 <222> LOCATION: (1)..(765)

<400> SEQUENCE: 20

-continued

```

gag gag gtg cag ctg ttg cag tct ggg gga ggc gtg gtc cag cct ggg      48
Glu Glu Val Gln Leu Leu Gln Ser Gly Gly Gly Val Val Gln Pro Gly
1          5          10          15

agg tcc ctg aga ctc tcc tgt gca gcc tct gga ttc agc ttc agt aac      96
Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Asn
          20          25          30

tat gtt atg cac tgg gtc cgc cag gct cca ggc aag ggg ctg gag tgg      144
Tyr Val Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
          35          40          45

gtg gca gtt ata tca tat gat gga agc aat aaa tac tac gca gac tcc      192
Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser
          50          55          60

gtg aag ggc cga ttc acc atc tcc aga gac aat tcc aag aac acg cta      240
Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu
65          70          75          80

tat ctg caa atg aaa ggc ctg aga cct gag gac acg gct gtg tat tac      288
Tyr Leu Gln Met Lys Gly Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr
          85          90          95

tgt gcg aga agt agt ggc tgg tac ctt ctc ttt gat gct ttt gat atc      336
Cys Ala Arg Ser Ser Gly Trp Tyr Leu Leu Phe Asp Ala Phe Asp Ile
          100          105          110

tgg ggc caa ggg aca atg gtc acc gtc tct tca ggt gga ggc ggt tca      384
Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Gly Gly Gly Gly Ser
          115          120          125

ggc gga ggt ggc tct ggc ggt ggc gga tcg gat gtt gtg atg aca cag      432
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln
          130          135          140

tct cca gac tcc ctg gct gtg tcg ctg ggc gag agg gcc acc atc aac      480
Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn
145          150          155          160

tgc gag tcc agc cag agt gtt tta ttc agc tcc aac aat aag aac tac      528
Cys Glu Ser Ser Gln Ser Val Leu Phe Ser Ser Asn Asn Lys Asn Tyr
          165          170          175

tta gct tgg tac cag cag aaa cca gga cag cct cct aag ctg ctc att      576
Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile
          180          185          190

tac tgg gca tct acc cgg gaa tcc ggg gtc cct gac cga ttc agt ggc      624
Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly
          195          200          205

agc ggg tct gag aca gat ttc act ctc acc atc agc agc ctg cag gct      672
Ser Gly Ser Glu Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala
          210          215          220

gaa gat gtg gca gtt tat tac tgt cag caa tat tat agg att ccg tgg      720
Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Arg Ile Pro Trp
225          230          235          240

acg ttc ggc caa ggg acc aaa gtg gat atc aaa cgt gcg gcc gca      765
Thr Phe Gly Gln Thr Lys Val Asp Ile Lys Arg Ala Ala Ala
          245          250          255

```

```

<210> SEQ ID NO 21
<211> LENGTH: 255
<212> TYPE: PRT
<213> ORGANISM: Escherichia coli

```

```

<400> SEQUENCE: 21

```

```

Glu Glu Val Gln Leu Leu Gln Ser Gly Gly Gly Val Val Gln Pro Gly
1          5          10          15

Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Asn
          20          25          30

```



-continued

---

Tyr Val Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp  
 35 40 45

Val Ala Val Ile Ser Tyr Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser  
 50 55 60

Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu  
 65 70 75 80

Tyr Leu Gln Met Lys Gly Leu Arg Pro Glu Asp Thr Ala Val Tyr Tyr  
 85 90 95

Cys Ala Arg Ser Ser Gly Trp Tyr Leu Leu Phe Asp Ala Phe Asp Ile  
 100 105 110

Trp Gly Gln Gly Thr Met Val Thr Val Ser Ser Gly Gly Gly Gly Ser  
 115 120 125

Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln  
 130 135 140

Ser Pro Asp Ser Leu Ala Val Ser Leu Gly Glu Arg Ala Thr Ile Asn  
 145 150 155 160

Cys Glu Ser Ser Gln Ser Val Leu Phe Ser Ser Asn Asn Lys Asn Tyr  
 165 170 175

Leu Ala Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro Lys Leu Leu Ile  
 180 185 190

Tyr Trp Ala Ser Thr Arg Glu Ser Gly Val Pro Asp Arg Phe Ser Gly  
 195 200 205

Ser Gly Ser Glu Thr Asp Phe Thr Leu Thr Ile Ser Ser Leu Gln Ala  
 210 215 220

Glu Asp Val Ala Val Tyr Tyr Cys Gln Gln Tyr Tyr Arg Ile Pro Trp  
 225 230 235 240

Thr Phe Gly Gln Gly Thr Lys Val Asp Ile Lys Arg Ala Ala Ala  
 245 250 255

<210> SEQ ID NO 22  
 <211> LENGTH: 791  
 <212> TYPE: DNA  
 <213> ORGANISM: Escherichia coli  
 <220> FEATURE:  
 <221> NAME/KEY: CDS  
 <222> LOCATION: (1)..(786)

<400> SEQUENCE: 22

cag gtg cag ctg cag gag tct ggg gct gag gtg aag aag cct ggg gcc 48  
 Gln Val Gln Leu Gln Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ala  
 1 5 10 15

tca gtg aag gtc tcc tgc aag gct tct gga tac acc ttc acc ggc tac 96  
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr  
 20 25 30

tat atg cac tgg gtg cga cag gcc cct gga caa ggg ctt gag tgg atg 144  
 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met  
 35 40 45

gga tgg atc aac cct aac agt ggt ggc aca aac tat gca cag aag ttt 192  
 Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe  
 50 55 60

cag ggc agg gtc acc atg acc agg gac acg tcc atc agc aca gcc tac 240  
 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr  
 65 70 75 80

atg gag ctg agc agg ctg aga tct gac gac acg gcc gtg tat tac tgt 288  
 Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95

gcg aga gat tcg cca caa aat tgt act aat ggt gta tgc cac cgg ggg 336  
 Ala Arg Asp Ser Pro Gln Asn Cys Thr Asn Gly Val Cys His Arg Gly



-continued

Ser Pro Gly Gln Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp  
 165 170 175

Val Gly Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys  
 180 185 190

Ala Pro Lys Leu Met Ile Tyr Asp Val Asn Lys Arg Pro Ser Gly Val  
 195 200 205

Pro Asp Arg Phe Ser Ala Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr  
 210 215 220

Val Ser Gly Leu Gln Ala Asp Asp Glu Ala Asp Tyr Tyr Cys Ala Ser  
 225 230 235 240

Tyr Ala Gly Thr Tyr Ser Tyr Val Phe Gly Thr Gly Thr Gln Leu Thr  
 245 250 255

Val Leu Gly Ala Ala Ala  
 260

<210> SEQ ID NO 24  
 <211> LENGTH: 786  
 <212> TYPE: DNA  
 <213> ORGANISM: Escherichia coli  
 <220> FEATURE:  
 <221> NAME/KEY: CDS  
 <222> LOCATION: (1)..(786)

<400> SEQUENCE: 24

gag gtg cag ctg ttg cag tct ggg gcc gag gtg aag aag cct ggg gcc 48  
 Glu Val Gln Leu Leu Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala  
 1 5 10 15

tca gtg aag gtc tcc tgc aag gct tct gga tac acc ttc acc ggc tac 96  
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr  
 20 25 30

tat atg cac tgg gtg cga cag gcc cct gga caa ggg ctt gag tgg atg 144  
 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met  
 35 40 45

gga tgg atc aac cct aac agt ggt ggc aca aac tat gca cag aag ttt 192  
 Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe  
 50 55 60

cag ggc agg gtc acc atg acc agg gac acg tcc atc agc aca gcc tac 240  
 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr  
 65 70 75 80

atg gag ctg agc agg ctg aga tct gac gac acg gcc gtg tat tac tgt 288  
 Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95

gcg aga gat tcg cca caa aat tgt act aat ggt gta tgc cac cgg ggg 336  
 Ala Arg Asp Ser Pro Gln Asn Cys Thr Asn Gly Val Cys His Arg Gly  
 100 105 110

agt cat gtc cac tac tac ggt atg gac gtc tgg ggc cag gga acc ctg 384  
 Ser His Val His Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Leu  
 115 120 125

gtc acc gtc tcc tca ggt ggg ggc ggt tca ggc gga ggt ggc tct ggc 432  
 Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly  
 130 135 140

ggt ggc gga tcg cag tct gcc ctg act cag cct gcc tcc gcg gcc ggg 480  
 Gly Gly Gly Ser Gln Ser Ala Leu Thr Gln Pro Ala Ser Ala Ala Gly  
 145 150 155 160

tgt ctt gga cag tca gtc acc atc tcc tgc act gga acc agc agt gat 528  
 Cys Leu Gly Gln Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp  
 165 170 175

gtt ggt ggt tat aaa tat gtc tcc tgg tac caa cag cac cca ggc aaa 576  
 Val Gly Gly Tyr Lys Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys

-continued

180	185	190	
gcc ccc aaa ctc atg att tat	gac gtc aat aag cgg ccc tca ggg gtc		624
Ala Pro Lys Leu Met Ile Tyr	Asp Val Asn Lys Arg Pro Ser Gly Val		
195	200	205	
cct gat cgc ttc ttt gcc tcc aag tct ggc aac acg gcc tcc ctg acc			672
Pro Asp Arg Phe Phe Ala Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr			
210	215	220	
gtc tct ggg ctc cag gct gac gat gag gct gat tac tac tgc gct tca			720
Val Ser Gly Leu Gln Ala Asp Asp Glu Ala Asp Tyr Tyr Cys Ala Ser			
225	230	235	240
tat gca ggc acc tac agt tat gtc ttc gga act ggg acc cag ctc acc			768
Tyr Ala Gly Thr Tyr Ser Tyr Val Phe Gly Thr Gly Thr Gln Leu Thr			
245	250	255	
gtt tta ggt gcg gcc gca			786
Val Leu Gly Ala Ala Ala			
260			
<210> SEQ ID NO 25			
<211> LENGTH: 262			
<212> TYPE: PRT			
<213> ORGANISM: Escherichia coli			
<400> SEQUENCE: 25			
Glu Val Gln Leu Leu Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala			
1	5	10	15
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr			
20	25	30	
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met			
35	40	45	
Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe			
50	55	60	
Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr			
65	70	75	80
Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys			
85	90	95	
Ala Arg Asp Ser Pro Gln Asn Cys Thr Asn Gly Val Cys His Arg Gly			
100	105	110	
Ser His Val His Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Leu			
115	120	125	
Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly			
130	135	140	
Gly Gly Gly Ser Gln Ser Ala Leu Thr Gln Pro Ala Ser Ala Ala Gly			
145	150	155	160
Cys Leu Gly Gln Ser Val Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp			
165	170	175	
Val Gly Gly Tyr Lys Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys			
180	185	190	
Ala Pro Lys Leu Met Ile Tyr Asp Val Asn Lys Arg Pro Ser Gly Val			
195	200	205	
Pro Asp Arg Phe Phe Ala Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr			
210	215	220	
Val Ser Gly Leu Gln Ala Asp Asp Glu Ala Asp Tyr Tyr Cys Ala Ser			
225	230	235	240
Tyr Ala Gly Thr Tyr Ser Tyr Val Phe Gly Thr Gly Thr Gln Leu Thr			
245	250	255	
Val Leu Gly Ala Ala Ala			



-continued

260

<210> SEQ ID NO 27  
 <211> LENGTH: 263  
 <212> TYPE: PRT  
 <213> ORGANISM: Escherichia coli  
  
 <400> SEQUENCE: 27  
  
 Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly Ala  
 1 5 10 15  
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr  
 20 25 30  
 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met  
 35 40 45  
 Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe  
 50 55 60  
 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr  
 65 70 75 80  
 Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95  
 Val Arg Gly Ser Pro Gln Asn Cys Thr Asn Gly Val Cys His Arg Gly  
 100 105 110  
 Ser His Val His Tyr Tyr Gly Met Asp Val Trp Gly Gln Gly Thr Thr  
 115 120 125  
 Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly  
 130 135 140  
 Gly Gly Gly Ser Gln Ser Ala Leu Thr Gln Pro Ala Ser Val Ser Gly  
 145 150 155 160  
 Ser Pro Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Ser Asp  
 165 170 175  
 Val Gly Ser Tyr Asn Leu Val Ser Trp Tyr Gln Gln His Pro Gly Lys  
 180 185 190  
 Ala Pro Lys Leu Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val  
 195 200 205  
 Cys Asn Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Ser Leu Thr  
 210 215 220  
 Ile Ser Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser  
 225 230 235 240  
 Tyr Thr Ser Ser Ser Thr Leu Glu Val Phe Gly Gly Gly Thr Gln Leu  
 245 250 255  
 Thr Val Leu Gly Ala Ala Ala  
 260

<210> SEQ ID NO 28  
 <211> LENGTH: 747  
 <212> TYPE: DNA  
 <213> ORGANISM: Escherichia coli  
 <220> FEATURE:  
 <221> NAME/KEY: CDS  
 <222> LOCATION: (1)..(747)

&lt;400&gt; SEQUENCE: 28

cag gag gtg cag ctg gtg gag tct ggg ggt ggc ttg gtc cag cct ggg 48  
 Gln Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly  
 1 5 10 15  
 ggg tcc ctg aga ctc tcc tgt gca gcc tct gga ttc acc ctc agt agc 96  
 Gly Ser Leu Arg Leu Ser Cys Ala Ser Gly Phe Thr Leu Ser Ser  
 20 25 30

-continued

tat gct atg cac tgg gtc cgc cag gct cca ggg aag ggg ctg gag tgg	144
Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp	
35 40 45	
gtc tca act att agt ggt ggt ggt ggt agc aca tac tac gca gac tcc	192
Val Ser Thr Ile Ser Gly Gly Gly Gly Ser Thr Tyr Tyr Ala Asp Ser	
50 55 60	
gtg aag ggc cgg ttc acc atc tcc aga gac aat tcc aag aac acg ctg	240
Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu	
65 70 75 80	
tat ctg caa atg aac agc ctg aga gcc gag gac acg gcc gta tat tac	288
Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr	
85 90 95	
tgt gcg aga cgg ggg cgg gct ttt gat atc tgg ggc caa ggg acc acg	336
Cys Ala Arg Arg Gly Arg Ala Phe Asp Ile Trp Gly Gln Gly Thr Thr	
100 105 110	
gtc acc gtc tcc tta ggt gga ggc ggt tca ggc gga ggt ggc tct ggc	384
Val Thr Val Ser Leu Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly	
115 120 125	
ggt ggc gga tcg cag tct gtg ttg acg cag ccg ccc tca gtg tct ggg	432
Gly Gly Gly Ser Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly	
130 135 140	
gcc cca ggg cag agg gtc acc atc tcc tgc act ggg agc agc tcc aac	480
Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn	
145 150 155 160	
atc ggg gcg ggg tat gat gta cac tgg tac cag cag ctt cca gga aca	528
Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr	
165 170 175	
gcc ccc aaa ctc ctc att tat ggt aac agc aat cgg ccc tca ggg gtc	576
Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val	
180 185 190	
cct gac cga ttc tct ggc tcc aag tct ggc acc tca gcc tcc ctg gcc	624
Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala	
195 200 205	
atc act ggg ctc cag gct gag gat gag gct gat tat tat tgc tcc agt	672
Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser	
210 215 220	
cct atg atc agc agc ctg agt ggt cat gtg gta ttc ggc gga ggg acc	720
Pro Met Ile Ser Ser Leu Ser Gly His Val Val Phe Gly Gly Gly Thr	
225 230 235 240	
aag gtg acc gtc cta ggt gcg gcc gca	747
Lys Val Thr Val Leu Gly Ala Ala Ala	
245	

&lt;210&gt; SEQ ID NO 29

&lt;211&gt; LENGTH: 249

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Escherichia coli

&lt;400&gt; SEQUENCE: 29

Gln Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly	
1 5 10 15	
Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Leu Ser Ser	
20 25 30	
Tyr Ala Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp	
35 40 45	
Val Ser Thr Ile Ser Gly Gly Gly Gly Ser Thr Tyr Tyr Ala Asp Ser	
50 55 60	
Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu	
65 70 75 80	

-continued

Tyr Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr  
 85 90 95  
 Cys Ala Arg Arg Gly Arg Ala Phe Asp Ile Trp Gly Gln Gly Thr Thr  
 100 105 110  
 Val Thr Val Ser Leu Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly  
 115 120 125  
 Gly Gly Gly Ser Gln Ser Val Leu Thr Gln Pro Pro Ser Val Ser Gly  
 130 135 140  
 Ala Pro Gly Gln Arg Val Thr Ile Ser Cys Thr Gly Ser Ser Ser Asn  
 145 150 155 160  
 Ile Gly Ala Gly Tyr Asp Val His Trp Tyr Gln Gln Leu Pro Gly Thr  
 165 170 175  
 Ala Pro Lys Leu Leu Ile Tyr Gly Asn Ser Asn Arg Pro Ser Gly Val  
 180 185 190  
 Pro Asp Arg Phe Ser Gly Ser Lys Ser Gly Thr Ser Ala Ser Leu Ala  
 195 200 205  
 Ile Thr Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Ser Ser  
 210 215 220  
 Pro Met Ile Ser Ser Leu Ser Gly His Val Val Phe Gly Gly Gly Thr  
 225 230 235 240  
 Lys Val Thr Val Leu Gly Ala Ala Ala  
 245

<210> SEQ ID NO 30  
 <211> LENGTH: 747  
 <212> TYPE: DNA  
 <213> ORGANISM: Escherichia coli  
 <220> FEATURE:  
 <221> NAME/KEY: CDS  
 <222> LOCATION: (1)..(747)

<400> SEQUENCE: 30

cag gtg cag ctg gtg cag tct ggg gct gag gtg aag aag cct ggg gcc 48  
 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala  
 1 5 10 15  
 tca gtg aag gtc tcc tgc aag gct tct gga tac acc ttc acc ggc tac 96  
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr  
 20 25 30  
 tat atg cac tgg gtg cga cag gcc cct gga caa ggg ctt gag tgg atg 144  
 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met  
 35 40 45  
 gga tgg atc aac cct aac agt ggt ggc aca aac tat gca cag aag ttc 192  
 Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe  
 50 55 60  
 cag ggc agg gtc acc atg acc agg gac acg tcc att ggc aca gtc tac 240  
 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Gly Thr Val Tyr  
 65 70 75 80  
 atg gag ttg agc agc ctg aca tct gac gac acg gcc atg tat tat tgt 288  
 Met Glu Leu Ser Ser Leu Thr Ser Asp Asp Thr Ala Met Tyr Tyr Cys  
 85 90 95  
 gcg aga aac aat gtt gct atg ggt tat act atg gac gtc tgg ggc caa 336  
 Ala Arg Asn Asn Val Ala Met Gly Tyr Thr Met Asp Val Trp Gly Gln  
 100 105 110  
 ggg aca atg gtc acc gtc tct tca ggt gga ggc ggt tca ggc gga ggt 384  
 Gly Thr Met Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly Gly Gly  
 115 120 125  
 ggc tct ggc ggt ggc gga tcg cag tct gcc ctg act cag cct gcc tcc 432  
 Gly Ser Gly Gly Gly Gly Ser Gln Ser Ala Leu Thr Gln Pro Ala Ser





-continued

Cys Ile Ser Tyr Thr Ser Ser Asn Thr Trp Val Phe Gly Gly Gly Thr  
225 230 235 240

Gln Leu Thr Val Leu Gly Ala Ala Ala  
245

<210> SEQ ID NO 32

<211> LENGTH: 733

<212> TYPE: DNA

<213> ORGANISM: Escherichia coli

<220> FEATURE:

<221> NAME/KEY: CDS

<222> LOCATION: (1)..(732)

<400> SEQUENCE: 32

gag gtg cag ctg ttg cag tct ggg gcg gag gtg aag aag cct ggg gcc 48  
Glu Val Gln Leu Leu Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala  
1 5 10 15

tca gtg aag gtc tcc tgc aag gct tct gga tac acc ttc acc ggc tac 96  
Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr  
20 25 30

tat atg cac tgg gtg cga cag gcc cct gga caa ggg ctt gag tgg atg 144  
Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met  
35 40 45

gga tgg atc aac cct aac agt ggt ggc aca aac tat gca cag aag ttt 192  
Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe  
50 55 60

cag ggc aga gtc acc atg acc agg aac acc tcc ata agc aca gcc tac 240  
Gln Gly Arg Val Thr Met Thr Arg Asn Thr Ser Ile Ser Thr Ala Tyr  
65 70 75 80

atg gag ctg agc agc ctg aga tct gag gac acg gcc gtg tat tac tgt 288  
Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys  
85 90 95

gcg ggt cag gag gca cat ggg gac ggt atg gac gtc tgg ggc caa ggg 336  
Ala Gly Gln Glu Ala His Gly Asp Gly Met Asp Val Trp Gly Gln Gly  
100 105 110

acc acg gtc acc gtc tcc tcg gtg gag cga ggt ggc tct ggc ggt ggc 384  
Thr Thr Val Thr Val Ser Ser Val Glu Arg Gly Gly Ser Gly Gly Gly  
115 120 125

gga tcg cag tct gcc ctg act cag cct gcc tcc gcg tcc ggg tct cct 432  
Gly Ser Gln Ser Ala Leu Thr Gln Pro Ala Ser Ala Ser Gly Ser Pro  
130 135 140

gga cag tcg atc acc atc tcc tgc act gga acc agc ggt gac gtt ggt 480  
Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Gly Asp Val Gly  
145 150 155 160

ggt tat aac tat gtc tcc tgg tac caa cag cac cca ggc aaa gcc ccc 528  
Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro  
165 170 175

aaa ctc atg att tat gaa gtc agt aat cgg ccc tca ggg gtt tct aat 576  
Lys Leu Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn  
180 185 190

cgc ttc tct ggc tcc aag tct ggc agc acg gcc tcc ctg acc atc tct 624  
Arg Phe Ser Gly Ser Lys Ser Gly Ser Thr Ala Ser Leu Thr Ile Ser  
195 200 205

ggg ctc cag gct gag gac gag gct gat tat tac tgc gtc tca tat aca 672  
Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Val Ser Tyr Thr  
210 215 220

agc aga aac act tat gtc ttc gga tcc ggg acc cag ctc acc gtt tta 720  
Ser Arg Asn Thr Tyr Val Phe Gly Ser Gly Thr Gln Leu Thr Val Leu  
225 230 235 240

ggt gcg gcc gcg a 733

-continued

Gly Ala Ala Ala

<210> SEQ ID NO 33  
 <211> LENGTH: 244  
 <212> TYPE: PRT  
 <213> ORGANISM: Escherichia coli

&lt;400&gt; SEQUENCE: 33

Glu Val Gln Leu Leu Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala  
 1 5 10 15  
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Tyr  
 20 25 30  
 Tyr Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met  
 35 40 45  
 Gly Trp Ile Asn Pro Asn Ser Gly Gly Thr Asn Tyr Ala Gln Lys Phe  
 50 55 60  
 Gln Gly Arg Val Thr Met Thr Arg Asn Thr Ser Ile Ser Thr Ala Tyr  
 65 70 75 80  
 Met Glu Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys  
 85 90 95  
 Ala Gly Gln Glu Ala His Gly Asp Gly Met Asp Val Trp Gly Gln Gly  
 100 105 110  
 Thr Thr Val Thr Val Ser Ser Val Glu Arg Gly Gly Ser Gly Gly Gly  
 115 120 125  
 Gly Ser Gln Ser Ala Leu Thr Gln Pro Ala Ser Ala Ser Gly Ser Pro  
 130 135 140  
 Gly Gln Ser Ile Thr Ile Ser Cys Thr Gly Thr Ser Gly Asp Val Gly  
 145 150 155 160  
 Gly Tyr Asn Tyr Val Ser Trp Tyr Gln Gln His Pro Gly Lys Ala Pro  
 165 170 175  
 Lys Leu Met Ile Tyr Glu Val Ser Asn Arg Pro Ser Gly Val Ser Asn  
 180 185 190  
 Arg Phe Ser Gly Ser Lys Ser Gly Ser Thr Ala Ser Leu Thr Ile Ser  
 195 200 205  
 Gly Leu Gln Ala Glu Asp Glu Ala Asp Tyr Tyr Cys Val Ser Tyr Thr  
 210 215 220  
 Ser Arg Asn Thr Tyr Val Phe Gly Ser Gly Thr Gln Leu Thr Val Leu  
 225 230 235 240

Gly Ala Ala Ala

<210> SEQ ID NO 34  
 <211> LENGTH: 372  
 <212> TYPE: DNA  
 <213> ORGANISM: Escherichia coli  
 <220> FEATURE:  
 <221> NAME/KEY: CDS  
 <222> LOCATION: (1)..(372)

&lt;400&gt; SEQUENCE: 34

gag gtg cag ctg ttg cag tct ggg gct gag gtg aag aag cct ggg gcc 48  
 Glu Val Gln Leu Leu Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala  
 1 5 10 15  
 tca gtg aag gtc tcc tgc aag gct tct gga tac acc ttc acc ggc tcc 96  
 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Ser  
 20 25 30  
 tat att cac tgg gtg cga cag gcc cct gga caa ggg ctt gag tgg atg 144  
 Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met  
 35 40 45

-continued

---

gga cgg atg aac cct aac agt ggt gac aca aac tat gca cag aag ttt 192  
 Gly Arg Met Asn Pro Asn Ser Gly Asp Thr Asn Tyr Ala Gln Lys Phe  
     50                    55                    60

cag ggc cgg gtc acc atg acc agg gac acg tcc atc agc aca gcc tac 240  
 Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr  
     65                    70                    75                    80

atg gag ctg agc agg ctg aga tct gac gac acg gcc gtg tac tac tgt 288  
 Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys  
                     85                    90                    95

gcg acg gag gga gtg gct tta cgt ccc ggt gct ttt gat ttc tgg ggc 336  
 Ala Thr Glu Gly Val Ala Leu Arg Pro Gly Ala Phe Asp Phe Trp Gly  
                     100                    105                    110

caa ggg acc cag ctc acc gtt tta ggt gcg gcc gca 372  
 Gln Gly Thr Gln Leu Thr Val Leu Gly Ala Ala Ala  
                     115                    120

<210> SEQ ID NO 35  
 <211> LENGTH: 124  
 <212> TYPE: PRT  
 <213> ORGANISM: Escherichia coli

<400> SEQUENCE: 35

Glu Val Gln Leu Leu Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Ala  
 1                    5                    10                    15

Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Gly Ser  
                     20                    25                    30

Tyr Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met  
                     35                    40                    45

Gly Arg Met Asn Pro Asn Ser Gly Asp Thr Asn Tyr Ala Gln Lys Phe  
     50                    55                    60

Gln Gly Arg Val Thr Met Thr Arg Asp Thr Ser Ile Ser Thr Ala Tyr  
     65                    70                    75                    80

Met Glu Leu Ser Arg Leu Arg Ser Asp Asp Thr Ala Val Tyr Tyr Cys  
                     85                    90                    95

Ala Thr Glu Gly Val Ala Leu Arg Pro Gly Ala Phe Asp Phe Trp Gly  
                     100                    105                    110

Gln Gly Thr Gln Leu Thr Val Leu Gly Ala Ala Ala  
                     115                    120

<210> SEQ ID NO 36  
 <211> LENGTH: 756  
 <212> TYPE: DNA  
 <213> ORGANISM: Escherichia coli  
 <220> FEATURE:  
 <221> NAME/KEY: CDS  
 <222> LOCATION: (1)..(756)

<400> SEQUENCE: 36

gag gag gtg cag ctg gtg gag tct ggg gga ggc ttg gtc cag cct ggg 48  
 Glu Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly  
     1                    5                    10                    15

ggg tcc ctg aga ctc tcc tgt gca gcc tct gga ttc acc gtc agt agc 96  
 Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser  
                     20                    25                    30

aac tac atg agc tgg gtc cgc cag gct cca ggg aag ggg ctg gag tgg 144  
 Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp  
                     35                    40                    45

gtc tca gtt gtt tat agc ggt ggt agc aca tac tac gca gac tcc gtg 192  
 Val Ser Val Val Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val  
     50                    55                    60

-continued

```

aag ggc cga ttc acc atc tcc aga gac aat tcc aag aac acg ctg tat      240
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                               70                               75                               80

ctt caa atg aac agc ctg aga gct gag gac acg gct gtg tat tac tgt      288
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85                               90                               95

gcg aga gac cta ggg ggg act aca gtt tgg cgc tac tac ggt atg gac      336
Ala Arg Asp Leu Gly Gly Thr Thr Val Trp Arg Tyr Tyr Gly Met Asp
100                              105                              110

gtc tgg ggc caa ggg acc acg gtc acc gtc tcc tca ggt gga ggc ggt      384
Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly
115                              120                              125

tca ggc gga ggt ggc tct ggc ggt ggc gga tcg tcc tat gtg ctg act      432
Ser Gly Gly Gly Ser Ser Gly Gly Gly Ser Ser Tyr Val Leu Thr
130                              135                              140

cag cca ccc tcg gtg tca gtg gcc cca gga aag acg gcc acg att acc      480
Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Thr Ile Thr
145                              150                              155                              160

tgt gcg gga aac aat ata gga agt aac agt gta tac tgg tac cag cag      528
Cys Ala Gly Asn Asn Ile Gly Ser Asn Ser Val Tyr Trp Tyr Gln Gln
165                              170                              175

aaa cca ggc ctg gcc cct gta ctg gtc gtc tat gat gat aga gac cgg      576
Lys Pro Gly Leu Ala Pro Val Leu Val Val Tyr Asp Asp Arg Asp Arg
180                              185                              190

ccc tca ggg atc cct ggg cga ttc tct ggc tcc aaa tcc ggg aac acg      624
Pro Ser Gly Ile Pro Gly Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr
195                              200                              205

gcc acc ctg acc atc agc agg gtc gag gcc ggg gat gag gcc gac tat      672
Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr
210                              215                              220

tct tgt cag gtg tgg gat cct agt agt gat cac ctc tat gtc ttc gga      720
Ser Cys Gln Val Trp Asp Pro Ser Ser Asp His Leu Tyr Val Phe Gly
225                              230                              235                              240

act ggg acc cag ctc acc gtt tta ggt gcg gcc gca                        756
Thr Gly Thr Gln Leu Thr Val Leu Gly Ala Ala Ala
245                              250

```

&lt;210&gt; SEQ ID NO 37

&lt;211&gt; LENGTH: 252

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Escherichia coli

&lt;400&gt; SEQUENCE: 37

```

Glu Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly
1                               5                               10                               15

Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Ser Ser
20                              25                              30

Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
35                              40                              45

Val Ser Val Val Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val
50                              55                              60

Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr
65                               70                               75                               80

Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys
85                               90                               95

Ala Arg Asp Leu Gly Gly Thr Thr Val Trp Arg Tyr Tyr Gly Met Asp
100                              105                              110

Val Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly

```

-continued

115	120	125
Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Ser Tyr Val Leu Thr 130 135 140		
Gln Pro Pro Ser Val Ser Val Ala Pro Gly Lys Thr Ala Thr Ile Thr 145 150 155 160		
Cys Ala Gly Asn Asn Ile Gly Ser Asn Ser Val Tyr Trp Tyr Gln Gln 165 170 175		
Lys Pro Gly Leu Ala Pro Val Leu Val Val Tyr Asp Asp Arg Asp Arg 180 185 190		
Pro Ser Gly Ile Pro Gly Arg Phe Ser Gly Ser Lys Ser Gly Asn Thr 195 200 205		
Ala Thr Leu Thr Ile Ser Arg Val Glu Ala Gly Asp Glu Ala Asp Tyr 210 215 220		
Ser Cys Gln Val Trp Asp Pro Ser Ser Asp His Leu Tyr Val Phe Gly 225 230 235 240		
Thr Gly Thr Gln Leu Thr Val Leu Gly Ala Ala Ala 245 250		

<210> SEQ ID NO 38  
 <211> LENGTH: 735  
 <212> TYPE: DNA  
 <213> ORGANISM: Escherichia coli  
 <220> FEATURE:  
 <221> NAME/KEY: CDS  
 <222> LOCATION: (1)..(735)

<400> SEQUENCE: 38

gag gag gtg cag ctg gtg gag tct gga gga gac ttg atc cag cct ggg Glu Glu Val Gln Leu Val Glu Ser Gly Gly Asp Leu Ile Gln Pro Gly 1 5 10 15	48
ggg tcc ctg aga ctc tcc tgt gca gcc tct ggg ttt acc gtc ggt agc Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Gly Ser 20 25 30	96
aac tac atg agc tgg gtc cgc cag gct cca ggg aag ggg ctg gaa tgg Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp 35 40 45	144
gtc tca gtt att tat agc ggt ggt agt aca tac tac gca gac tcc gtg Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val 50 55 60	192
aag ggc cga ttc acc atc tcc aga gac aat tcc aag aac acg ctg tat Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80	240
ctt caa atg aac agc ctg aga gcc gag gac acg gcc gtg tat tac tgt Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95	288
gtg aga gat agg ggt gat gct ttt gat atc tgg ggc caa ggg aca atg Val Arg Asp Arg Gly Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met 100 105 110	336
gtc acc gtc tct tca ggt gga ggc gtt cca ggc gga ggt ggc tct ggc Val Thr Val Ser Ser Gly Gly Gly Val Pro Gly Gly Gly Gly Ser Gly 115 120 125	384
ggt ggc gga tcg tcc tat gcg ctg act cag cca ccc tcg gtg tca gtg Gly Gly Gly Ser Ser Tyr Ala Leu Thr Gln Pro Pro Ser Val Ser Val 130 135 140	432
gcc cca gga aag acg gcc acg att acc tgt gcg gga aac aat ata gga Ala Pro Gly Lys Thr Ala Thr Ile Thr Cys Ala Gly Asn Asn Ile Gly 145 150 155 160	480
agt aac agt gta tac tgg tac cag cag aaa cca ggc ctg gcc cct gta Ser Asn Ser Val Tyr Trp Tyr Gln Gln Lys Pro Gly Leu Ala Pro Val	528

-continued

165	170	175	
ctg gtc gtc tat gat gat agc gac	egg ccc tca ggg atg tct gag cga		576
Leu Val Val Tyr Asp Asp Ser Asp	Arg Pro Ser Gly Met Ser Glu Arg		
180	185	190	
ttc tct ggc tcc aaa tcc ggg aac	acg gcc acc ctg acc atc agc agg		624
Phe Ser Gly Ser Lys Ser Gly Asn	Thr Ala Thr Leu Thr Ile Ser Arg		
195	200	205	
gtc gag gcc ggg gat gag gcc gac	tat tct tgt cag gtg tgg gat cct		672
Val Glu Ala Gly Asp Glu Ala Asp	Tyr Ser Cys Gln Val Trp Asp Pro		
210	215	220	
agt agt gat cac ctc tat gtc ttc	gga act ggg acc cag ctc acc gtt		720
Ser Ser Asp His Leu Tyr Val Phe	Gly Thr Gly Thr Gln Leu Thr Val		
225	230	235	240
tta ggt gcg gcc gca			735
Leu Gly Ala Ala Ala			245

&lt;210&gt; SEQ ID NO 39

&lt;211&gt; LENGTH: 245

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Escherichia coli

&lt;400&gt; SEQUENCE: 39

Glu Glu Val Gln Leu Val Glu Ser Gly Gly Asp Leu Ile Gln Pro Gly	
1 5 10 15	
Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Val Gly Ser	
20 25 30	
Asn Tyr Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp	
35 40 45	
Val Ser Val Ile Tyr Ser Gly Gly Ser Thr Tyr Tyr Ala Asp Ser Val	
50 55 60	
Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr	
65 70 75 80	
Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys	
85 90 95	
Val Arg Asp Arg Gly Asp Ala Phe Asp Ile Trp Gly Gln Gly Thr Met	
100 105 110	
Val Thr Val Ser Ser Gly Gly Gly Val Pro Gly Gly Gly Gly Ser Gly	
115 120 125	
Gly Gly Gly Ser Ser Tyr Ala Leu Thr Gln Pro Pro Ser Val Ser Val	
130 135 140	
Ala Pro Gly Lys Thr Ala Thr Ile Thr Cys Ala Gly Asn Asn Ile Gly	
145 150 155 160	
Ser Asn Ser Val Tyr Trp Tyr Gln Gln Lys Pro Gly Leu Ala Pro Val	
165 170 175	
Leu Val Val Tyr Asp Asp Ser Asp Arg Pro Ser Gly Met Ser Glu Arg	
180 185 190	
Phe Ser Gly Ser Lys Ser Gly Asn Thr Ala Thr Leu Thr Ile Ser Arg	
195 200 205	
Val Glu Ala Gly Asp Glu Ala Asp Tyr Ser Cys Gln Val Trp Asp Pro	
210 215 220	
Ser Ser Asp His Leu Tyr Val Phe Gly Thr Gly Thr Gln Leu Thr Val	
225 230 235 240	
Leu Gly Ala Ala Ala	
245	

-continued

```

<210> SEQ ID NO 40
<211> LENGTH: 761
<212> TYPE: DNA
<213> ORGANISM: Escherichia coli
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(759)

<400> SEQUENCE: 40

atg gag gag gtg cag ctg gtg gag tct ggg gga gcc ttg gta cag cct      48
Met Glu Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Gln Pro
1                               5                               10                               15

ggg ggg tcc ctg aga atc tct tgt gta ggc tct gga ttc acc ttc cga      96
Gly Gly Ser Leu Arg Ile Ser Cys Val Gly Ser Gly Phe Thr Phe Arg
20                               25                               30

cag cat gac atg agc tgg gtc cgc cag gct cct ggg aag ggg ctg gag      144
Gln His Asp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu
35                               40                               45

tgg gtc gca act ata agt gga agt gct gat aac aca ttt tac gca gac      192
Trp Val Ala Thr Ile Ser Gly Ser Ala Asp Asn Thr Phe Tyr Ala Asp
50                               55                               60

tcc gtg aag ggc cgg ttc acc atc tcc aga gac aat tcc aag aac acg      240
Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr
65                               70                               75                               80

ctg tat ctg cag atg aac acc ctg aaa gcc gac gac acg gcc gta tat      288
Leu Tyr Leu Gln Met Asn Thr Leu Lys Ala Asp Asp Thr Ala Val Tyr
85                               90                               95

tac tgt gcg aag aaa tat ata gaa cca ggt gct acc cga ttt gac tac      336
Tyr Cys Ala Lys Lys Tyr Ile Glu Pro Gly Ala Thr Arg Phe Asp Tyr
100                              105                              110

tgg ggc cag aga acc ctg gtc acc gtc tcc tca ggt gga ggc ggt tca      384
Trp Gly Gln Arg Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser
115                              120                              125

ggc gga ggt ggc tct ggc ggt ggc gga tcc gat gtt gtg atg act cag      432
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln
130                              135                              140

tct cca ctc tct ctg tcc gtc acc cct gga cag ccg gcc tcc atc tcc      480
Ser Pro Leu Ser Leu Ser Val Thr Pro Gly Gln Pro Ala Ser Ile Ser
145                              150                              155                              160

tgc aag tct agt cag agc ctc ctg cat agt gat gga aag acc tat ttg      528
Cys Lys Ser Ser Gln Ser Leu Leu His Ser Asp Gly Lys Thr Tyr Leu
165                              170                              175

tat tgg tac ctg cag aag cca ggc cag tct cca cag ctc ctg atc tat      576
Tyr Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr
180                              185                              190

gaa gtt tcc aac cgg ttc tct gga gtg cca gat agg ttc agt ggc agc      624
Glu Val Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser
195                              200                              205

ggg tca ggg aca gat ttc aca ctg aaa atc agc cgg gtg gag gct gag      672
Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu
210                              215                              220

gat gtt ggg gtt tat tac tgc atg caa agt ata cag ctc ccg atc acc      720
Asp Val Gly Val Tyr Tyr Cys Met Gln Ser Ile Gln Leu Pro Ile Thr
225                              230                              235                              240

ttc ggc caa ggg aca cga ctg gag att aaa cgt gcg gcc gc              761
Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys Arg Ala Ala
245                              250

```

```

<210> SEQ ID NO 41
<211> LENGTH: 253
<212> TYPE: PRT
<213> ORGANISM: Escherichia coli

```



-continued

&lt;400&gt; SEQUENCE: 41

```

Met Glu Glu Val Gln Leu Val Glu Ser Gly Gly Ala Leu Val Gln Pro
1           5           10           15
Gly Gly Ser Leu Arg Ile Ser Cys Val Gly Ser Gly Phe Thr Phe Arg
20           25           30
Gln His Asp Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu
35           40           45
Trp Val Ala Thr Ile Ser Gly Ser Ala Asp Asn Thr Phe Tyr Ala Asp
50           55           60
Ser Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr
65           70           75           80
Leu Tyr Leu Gln Met Asn Thr Leu Lys Ala Asp Asp Thr Ala Val Tyr
85           90           95
Tyr Cys Ala Lys Lys Tyr Ile Glu Pro Gly Ala Thr Arg Phe Asp Tyr
100          105          110
Trp Gly Gln Arg Thr Leu Val Thr Val Ser Ser Gly Gly Gly Gly Ser
115          120          125
Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln
130          135          140
Ser Pro Leu Ser Leu Ser Val Thr Pro Gly Gln Pro Ala Ser Ile Ser
145          150          155          160
Cys Lys Ser Ser Gln Ser Leu Leu His Ser Asp Gly Lys Thr Tyr Leu
165          170          175
Tyr Trp Tyr Leu Gln Lys Pro Gly Gln Ser Pro Gln Leu Leu Ile Tyr
180          185          190
Glu Val Ser Asn Arg Phe Ser Gly Val Pro Asp Arg Phe Ser Gly Ser
195          200          205
Gly Ser Gly Thr Asp Phe Thr Leu Lys Ile Ser Arg Val Glu Ala Glu
210          215          220
Asp Val Gly Val Tyr Tyr Cys Met Gln Ser Ile Gln Leu Pro Ile Thr
225          230          235          240
Phe Gly Gln Gly Thr Arg Leu Glu Ile Lys Arg Ala Ala
245          250

```

&lt;210&gt; SEQ ID NO 42

&lt;211&gt; LENGTH: 765

&lt;212&gt; TYPE: DNA

&lt;213&gt; ORGANISM: Escherichia coli

&lt;220&gt; FEATURE:

&lt;221&gt; NAME/KEY: CDS

&lt;222&gt; LOCATION: (1)..(765)

&lt;400&gt; SEQUENCE: 42

```

gag cag gtg cag ctg gtg cag tct ggg gga ggc gtg gtc cag cct ggg      48
Glu Gln Val Gln Leu Val Gln Ser Gly Gly Gly Val Val Gln Pro Gly
1           5           10           15
agg tcc ctg aga ctc tcc tgt gca gcc tct gga ttc agc ttc agt aac      96
Arg Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Ser Phe Ser Asn
20           25           30
tat gtt atg cac tgg gtc cgc cag gct cca ggc aag ggg ctg gag tgg      144
Tyr Val Met His Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp
35           40           45
gtg gca gtt ata tca cat gat gga agc aat aaa tac tac gca gac tcc      192
Val Ala Val Ile Ser His Asp Gly Ser Asn Lys Tyr Tyr Ala Asp Ser
50           55           60
gtg aag ggc cga ttc acc atc tcc aga gac aat tcc aag aac acg cta      240

```

-continued

Val 65	Lys	Gly	Arg	Phe	Thr 70	Ile	Ser	Arg	Asp	Asn 75	Ser	Lys	Asn	Thr	Leu 80	
tat	ctg	caa	atg	aaa	agc	ctg	aga	cct	gag	gac	acg	gct	gtg	tat	tac	288
Tyr	Leu	Gln	Met	Lys 85	Ser	Leu	Arg	Pro	Glu	Asp 90	Thr	Ala	Val	Tyr	Tyr 95	
tgt	gcg	aga	agt	agt	ggc	tgg	tac	ctt	ctc	ttt	gat	gct	ttt	gat	atc	336
Cys	Ala	Arg	Ser	Ser 100	Gly	Trp	Tyr	Leu	Leu	Phe	Asp	Ala	Phe	Asp	Ile 110	
tgg	ggc	caa	ggg	aca	atg	gtc	acc	gtc	tct	tca	ggg	gga	ggc	ggg	tca	384
Trp	Gly	Gln	Gly	Thr 115	Met	Val	Thr	Val	Ser	Ser	Gly	Gly	Gly	Gly	Ser 125	
ggc	gga	ggg	ggc	tct	ggc	ggg	ggc	gga	tcg	gac	atc	cag	atg	acc	cag	432
Gly	Gly	Gly	Gly	Ser 130	Gly	Gly	Gly	Gly	Ser	Asp	Ile	Gln	Met	Thr	Gln 140	
tct	cca	gac	tcc	ctg	cct	gtg	tct	ctg	ggc	gag	agg	gcc	acc	atc	aac	480
Ser	Pro	Asp	Ser	Leu 145	Pro	Val	Ser	Leu	Gly	Glu	Arg	Ala	Thr	Ile	Asn 160	
tgc	agg	tcc	agc	cag	agt	ggt	tta	tac	agc	tcc	aac	aat	aag	aac	tac	528
Cys	Arg	Ser	Ser	Gln 165	Ser	Val	Leu	Tyr	Ser	Ser	Asn	Asn	Lys	Asn	Tyr 175	
tta	gct	tgg	tac	cag	cag	aaa	cca	gga	cag	cct	cct	aag	ctg	ctc	att	576
Leu	Ala	Trp	Tyr	Gln 180	Gln	Lys	Pro	Gly	Gln	Pro	Pro	Lys	Leu	Leu	Ile 190	
tac	tgg	gca	tct	acc	cgg	gaa	tcc	ggt	gtc	cct	gac	cga	ttc	agt	ggc	624
Tyr	Trp	Ala	Ser	Thr 195	Arg	Glu	Ser	Gly	Val	Pro	Asp	Arg	Phe	Ser	Gly 205	
agc	ggg	tct	ggg	aca	gat	ttc	act	ctc	acc	atc	agc	agc	ctg	cag	gct	672
Ser	Gly	Ser	Gly	Thr 210	Asp	Phe	Thr	Leu	Thr	Ile	Ser	Ser	Leu	Gln	Ala 220	
gaa	gat	gtg	gca	ggt	tat	tac	tgt	cag	caa	tat	tat	agg	att	ccg	tgg	720
Glu	Asp	Val	Ala	Val 225	Tyr	Tyr	Cys	Gln	Gln	Tyr	Tyr	Arg	Ile	Pro	Trp 240	
acg	ttc	ggc	caa	ggg	acg	aag	gtg	gaa	atc	aaa	cgt	gcg	gcc	gca		765
Thr	Phe	Gly	Gln	Thr 245	Thr	Lys	Val	Glu	Ile	Lys	Arg	Ala	Ala	Ala 255		

&lt;210&gt; SEQ ID NO 43

&lt;211&gt; LENGTH: 255

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Escherichia coli

&lt;400&gt; SEQUENCE: 43

Glu	Gln	Val	Gln	Leu	Val	Gln	Ser	Gly	Gly	Gly	Val	Val	Gln	Pro	Gly
1				5				10						15	
Arg	Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Ser	Phe	Ser	Asn
		20						25					30		
Tyr	Val	Met	His	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp
		35					40					45			
Val	Ala	Val	Ile	Ser	His	Asp	Gly	Ser	Asn	Lys	Tyr	Tyr	Ala	Asp	Ser
		50				55					60				
Val	Lys	Gly	Arg	Phe	Thr	Ile	Ser	Arg	Asp	Asn	Ser	Lys	Asn	Thr	Leu
65					70					75					80
Tyr	Leu	Gln	Met	Lys	Ser	Leu	Arg	Pro	Glu	Asp	Thr	Ala	Val	Tyr	Tyr
			85						90					95	
Cys	Ala	Arg	Ser	Ser	Gly	Trp	Tyr	Leu	Leu	Phe	Asp	Ala	Phe	Asp	Ile
			100					105					110		
Trp	Gly	Gln	Gly	Thr	Met	Val	Thr	Val	Ser	Ser	Gly	Gly	Gly	Gly	Ser
		115					120					125			

-continued

Gly	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Ser	Asp	Ile	Gln	Met	Thr	Gln
130						135					140				
Ser	Pro	Asp	Ser	Leu	Pro	Val	Ser	Leu	Gly	Glu	Arg	Ala	Thr	Ile	Asn
145				150						155					160
Cys	Arg	Ser	Ser	Gln	Ser	Val	Leu	Tyr	Ser	Ser	Asn	Asn	Lys	Asn	Tyr
				165					170					175	
Leu	Ala	Trp	Tyr	Gln	Gln	Lys	Pro	Gly	Gln	Pro	Pro	Lys	Leu	Leu	Ile
			180					185					190		
Tyr	Trp	Ala	Ser	Thr	Arg	Glu	Ser	Gly	Val	Pro	Asp	Arg	Phe	Ser	Gly
		195					200					205			
Ser	Gly	Ser	Gly	Thr	Asp	Phe	Thr	Leu	Thr	Ile	Ser	Ser	Leu	Gln	Ala
	210					215					220				
Glu	Asp	Val	Ala	Val	Tyr	Tyr	Cys	Gln	Gln	Tyr	Tyr	Arg	Ile	Pro	Trp
225					230					235					240
Thr	Phe	Gly	Gln	Gly	Thr	Lys	Val	Glu	Ile	Lys	Arg	Ala	Ala	Ala	
				245					250					255	

<210> SEQ ID NO 44  
 <211> LENGTH: 759  
 <212> TYPE: DNA  
 <213> ORGANISM: Escherichia coli  
 <220> FEATURE:  
 <221> NAME/KEY: CDS  
 <222> LOCATION: (1)..(759)

<400> SEQUENCE: 44

gag	gag	gtg	cag	ctg	ttg	cag	tct	ggg	gga	ggt	gtg	gta	cgg	cct	ggg	48
Glu	Glu	Val	Gln	Leu	Leu	Gln	Ser	Gly	Gly	Gly	Val	Val	Arg	Pro	Gly	
1				5				10					15			
ggg	tcc	ctg	aga	ctc	tcc	tgt	gca	gcc	tct	gga	ttc	acc	ttt	gat	gat	96
Gly	Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Asp	Asp	
			20				25						30			
tat	ggc	atg	acc	tgg	gtc	cgc	cag	gct	cca	ggg	aag	ggg	ctg	gag	tgg	144
Tyr	Gly	Met	Thr	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	
			35				40					45				
gtc	tca	gct	att	agt	ggt	agt	ggt	ggt	agc	aca	tac	tac	gca	gac	tcc	192
Val	Ser	Ala	Ile	Ser	Gly	Ser	Gly	Gly	Ser	Thr	Tyr	Tyr	Ala	Asp	Ser	
			50			55					60					
gtg	aag	ggc	cgg	ttc	gcc	atc	tcc	aga	gac	aat	tcc	aag	aac	acg	ctg	240
Val	Lys	Gly	Arg	Phe	Ala	Ile	Ser	Arg	Asp	Asn	Ser	Lys	Asn	Thr	Leu	
65					70				75					80		
tat	ctg	caa	atg	aac	agc	ctg	aga	gcc	gag	gac	acg	gcc	gta	tat	tac	288
Tyr	Leu	Gln	Met	Asn	Ser	Leu	Arg	Ala	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	
				85					90					95		
tgt	gcg	aaa	tct	cgc	tac	tat	gat	agt	agt	ggt	tat	tac	tac	acc	gtg	336
Cys	Ala	Lys	Ser	Arg	Tyr	Tyr	Asp	Ser	Ser	Gly	Tyr	Tyr	Tyr	Thr	Val	
			100					105					110			
cga	cct	gat	gct	ttt	gat	atc	tgg	ggc	caa	ggg	gca	atg	gtc	acc	gtc	384
Arg	Pro	Asp	Ala	Phe	Asp	Ile	Trp	Gly	Gln	Gly	Ala	Met	Val	Thr	Val	
			115				120					125				
tct	tca	ggt	gga	ggc	ggt	gga	ggt	ggc	tct	ggc	ggt	ggc	gga	tcg	tct	432
Ser	Ser	Gly	Gly	Gly	Gly	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Ser	Ser	
			130			135						140				
tct	gag	ctg	act	caa	cca	ccc	tca	gtg	tcc	gtg	tcc	cca	gga	cag	aca	480
Ser	Glu	Leu	Thr	Gln	Pro	Pro	Ser	Val	Ser	Val	Ser	Pro	Gly	Gln	Thr	
145					150					155					160	
gcc	atc	atc	acc	tgc	tct	gga	gat	aaa	ttg	ggg	gat	aaa	tat	gct	tcc	528
Ala	Ile	Ile	Thr	Cys	Ser	Gly	Asp	Lys	Leu	Gly	Asp	Lys	Tyr	Ala	Ser	
				165					170					175		

-continued

tgg	tat	cag	cac	agg	cca	ggc	cag	tcg	cct	gtc	ttg	gtc	atc	tat	cag	576
Trp	Tyr	Gln	His	Arg	Pro	Gly	Gln	Ser	Pro	Val	Leu	Val	Ile	Tyr	Gln	
		180						185					190			
gat	tcc	agg	cgg	ccc	tca	gac	atc	cct	gag	cga	ttc	tct	ggc	tcc	aac	624
Asp	Ser	Arg	Arg	Pro	Ser	Asp	Ile	Pro	Glu	Arg	Phe	Ser	Gly	Ser	Asn	
		195					200					205				
tct	ggg	aac	aca	gcc	act	ctg	acc	atc	acc	gag	gcc	cag	gct	ttg	gat	672
Ser	Gly	Asn	Thr	Ala	Thr	Leu	Thr	Ile	Thr	Glu	Ala	Gln	Ala	Leu	Asp	
	210					215				220						
gag	gct	gac	tat	tat	tgt	cag	gcc	tgg	gcc	ggc	aga	tct	gtg	gtc	ttc	720
Glu	Ala	Asp	Tyr	Tyr	Cys	Gln	Ala	Trp	Ala	Gly	Arg	Ser	Val	Val	Phe	
	225				230				235						240	
ggc	ggg	ggg	acc	cag	ctc	acc	ggt	tta	ggt	gcg	gcc	gca				759
Gly	Gly	Gly	Thr	Gln	Leu	Thr	Val	Leu	Gly	Ala	Ala	Ala				
			245					250								

<210> SEQ ID NO 45  
 <211> LENGTH: 253  
 <212> TYPE: PRT  
 <213> ORGANISM: Escherichia coli

<400> SEQUENCE: 45

Glu	Glu	Val	Gln	Leu	Leu	Gln	Ser	Gly	Gly	Gly	Val	Val	Arg	Pro	Gly	
1				5					10					15		
Gly	Ser	Leu	Arg	Leu	Ser	Cys	Ala	Ala	Ser	Gly	Phe	Thr	Phe	Asp	Asp	
			20					25					30			
Tyr	Gly	Met	Thr	Trp	Val	Arg	Gln	Ala	Pro	Gly	Lys	Gly	Leu	Glu	Trp	
		35					40					45				
Val	Ser	Ala	Ile	Ser	Gly	Ser	Gly	Gly	Ser	Thr	Tyr	Tyr	Ala	Asp	Ser	
	50					55					60					
Val	Lys	Gly	Arg	Phe	Ala	Ile	Ser	Arg	Asp	Asn	Ser	Lys	Asn	Thr	Leu	
	65				70					75					80	
Tyr	Leu	Gln	Met	Asn	Ser	Leu	Arg	Ala	Glu	Asp	Thr	Ala	Val	Tyr	Tyr	
				85					90					95		
Cys	Ala	Lys	Ser	Arg	Tyr	Tyr	Asp	Ser	Ser	Gly	Tyr	Tyr	Tyr	Thr	Val	
			100					105						110		
Arg	Pro	Asp	Ala	Phe	Asp	Ile	Trp	Gly	Gln	Gly	Ala	Met	Val	Thr	Val	
		115					120					125				
Ser	Ser	Gly	Gly	Gly	Gly	Gly	Gly	Gly	Ser	Gly	Gly	Gly	Gly	Ser	Ser	
	130					135						140				
Ser	Glu	Leu	Thr	Gln	Pro	Pro	Ser	Val	Ser	Val	Ser	Pro	Gly	Gln	Thr	
	145				150					155				160		
Ala	Ile	Ile	Thr	Cys	Ser	Gly	Asp	Lys	Leu	Gly	Asp	Lys	Tyr	Ala	Ser	
				165					170					175		
Trp	Tyr	Gln	His	Arg	Pro	Gly	Gln	Ser	Pro	Val	Leu	Val	Ile	Tyr	Gln	
			180					185					190			
Asp	Ser	Arg	Arg	Pro	Ser	Asp	Ile	Pro	Glu	Arg	Phe	Ser	Gly	Ser	Asn	
		195					200					205				
Ser	Gly	Asn	Thr	Ala	Thr	Leu	Thr	Ile	Thr	Glu	Ala	Gln	Ala	Leu	Asp	
	210					215					220					
Glu	Ala	Asp	Tyr	Tyr	Cys	Gln	Ala	Trp	Ala	Gly	Arg	Ser	Val	Val	Phe	
	225				230					235					240	
Gly	Gly	Gly	Thr	Gln	Leu	Thr	Val	Leu	Gly	Ala	Ala	Ala				
				245					250							

<210> SEQ ID NO 46  
 <211> LENGTH: 768

-continued

```

<212> TYPE: DNA
<213> ORGANISM: Escherichia coli
<220> FEATURE:
<221> NAME/KEY: CDS
<222> LOCATION: (1)..(768)

<400> SEQUENCE: 46

gag gag gtg cag ctg ttg cag tct ggg gcg gag gtg aag aag cct ggg      48
Glu Glu Val Gln Leu Leu Gln Ser Gly Ala Glu Val Lys Lys Pro Gly
1          5          10          15

gcc tca gtg aga gtt tcc tgc cag gca tct gga tac aca ttc agc agg      96
Ala Ser Val Arg Val Ser Cys Gln Ala Ser Gly Tyr Thr Phe Ser Arg
          20          25          30

tac cat atg cac tgg gtg cga cag gcc cct gga caa ggg ctt gag tgg      144
Tyr His Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp
          35          40          45

atg gga gtg atc gac ccc aat agt ggt aga gta agt tac tca cag aag      192
Met Gly Val Ile Asp Pro Asn Ser Gly Arg Val Ser Tyr Ser Gln Lys
          50          55          60

ttc cag gac aga gtc acc atg acc agg gac acg ttc acg agc aca gta      240
Phe Gln Asp Arg Val Thr Met Thr Arg Asp Thr Phe Thr Ser Thr Val
65          70          75          80

tac atg gag ctg aac agc ctg aga tct gag gac acg gcc gtt tat tat      288
Tyr Met Glu Leu Asn Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr
          85          90          95

tgt gcg aga gat cga gga tat tgt aat ggt ggc agg tgc ttt atg gat      336
Cys Ala Arg Asp Arg Gly Tyr Cys Asn Gly Gly Arg Cys Phe Met Asp
          100          105          110

gca ttt gac tac tgg ggc cag ggg acc acg gtc acc gtc tcc tca ggt      384
Ala Phe Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly
          115          120          125

gga ggc ggt tca ggc gga ggt ggc cct ggc ggt ggc gga tcg tcc tat      432
Gly Gly Gly Ser Gly Gly Gly Gly Pro Gly Gly Gly Gly Ser Ser Tyr
          130          135          140

gtg ctg act cag cca ccc tca gcg tct ggg gcc ccc gga cag agg gtc      480
Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Ala Pro Gly Gln Arg Val
145          150          155          160

acc atc tct tgt tct gga agc aac tcc aac atc gga cgt aat tgg gta      528
Thr Ile Ser Cys Ser Gly Ser Asn Ser Asn Ile Gly Arg Asn Trp Val
          165          170          175

tac tgg tac cag caa ctc cca gga acg gcc ccc aaa ctc ctc atg ttt      576
Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Met Phe
          180          185          190

agg aat aat gaa cgg tcc tca ggg gtc cct gac cga ttc tct ggc tcc      624
Arg Asn Asn Glu Arg Ser Ser Gly Val Pro Asp Arg Phe Ser Gly Ser
          195          200          205

aag act ggc acc tca gcc tcc ctg gcc atc agt ggg ctc cgg tct gag      672
Lys Thr Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg Ser Glu
          210          215          220

gat gag ggt gat tac tac tgt gca tca tgg gat gac agt ctg cat gct      720
Asp Glu Gly Asp Tyr Tyr Cys Ala Ser Trp Asp Asp Ser Leu His Ala
225          230          235          240

tgg gtg ttc ggc ggg ggg acc cag ctc acc gtt tta ggt gcg gcc gca      768
Trp Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu Gly Ala Ala Ala
          245          250          255

```

```

<210> SEQ ID NO 47
<211> LENGTH: 256
<212> TYPE: PRT
<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 47

```

-continued

Glu Glu Val Gln Leu Leu Gln Ser Gly Ala Glu Val Lys Lys Pro Gly  
 1 5 10 15  
 Ala Ser Val Arg Val Ser Cys Gln Ala Ser Gly Tyr Thr Phe Ser Arg  
 20 25 30  
 Tyr His Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp  
 35 40 45  
 Met Gly Val Ile Asp Pro Asn Ser Gly Arg Val Ser Tyr Ser Gln Lys  
 50 55 60  
 Phe Gln Asp Arg Val Thr Met Thr Arg Asp Thr Phe Thr Ser Thr Val  
 65 70 75 80  
 Tyr Met Glu Leu Asn Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr  
 85 90 95  
 Cys Ala Arg Asp Arg Gly Tyr Cys Asn Gly Gly Arg Cys Phe Met Asp  
 100 105 110  
 Ala Phe Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly  
 115 120 125  
 Gly Gly Gly Ser Gly Gly Gly Gly Pro Gly Gly Gly Gly Ser Ser Tyr  
 130 135 140  
 Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Ala Pro Gly Gln Arg Val  
 145 150 155 160  
 Thr Ile Ser Cys Ser Gly Ser Asn Ser Asn Ile Gly Arg Asn Trp Val  
 165 170 175  
 Tyr Trp Tyr Gln Gln Leu Pro Gly Thr Ala Pro Lys Leu Leu Met Phe  
 180 185 190  
 Arg Asn Asn Glu Arg Ser Ser Gly Val Pro Asp Arg Phe Ser Gly Ser  
 195 200 205  
 Lys Thr Gly Thr Ser Ala Ser Leu Ala Ile Ser Gly Leu Arg Ser Glu  
 210 215 220  
 Asp Glu Gly Asp Tyr Tyr Cys Ala Ser Trp Asp Asp Ser Leu His Ala  
 225 230 235 240  
 Trp Val Phe Gly Gly Gly Thr Gln Leu Thr Val Leu Gly Ala Ala Ala  
 245 250 255

<210> SEQ ID NO 48  
 <211> LENGTH: 765  
 <212> TYPE: DNA  
 <213> ORGANISM: Escherichia coli  
 <220> FEATURE:  
 <221> NAME/KEY: CDS  
 <222> LOCATION: (1)..(765)

<400> SEQUENCE: 48

gag gag gtg cag ctg gtg gag tct ggg gga aac ttg gtt cag cct ggg 48  
 Glu Glu Val Gln Leu Val Glu Ser Gly Gly Asn Leu Val Gln Pro Gly  
 1 5 10 15  
 ggg tcc ctg aga ctc tcc tgt gca gcc tct gga ttc acc ttt agc agt 96  
 Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser  
 20 25 30  
 tat gcc atg agc tgg gtc cgc cag gct cca ggg aag ggg ctg gaa tgg 144  
 Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp  
 35 40 45  
 gtc tca gct att agt gct agt ggt ggc acc aca tac tac gca gat tcc 192  
 Val Ser Ala Ile Ser Ala Ser Gly Gly Thr Thr Tyr Tyr Ala Asp Ser  
 50 55 60  
 gtg aag ggc cgg ttc acc atc tcc aga gac aat tcc aag aac acg ctg 240  
 Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu  
 65 70 75 80

-continued

tat ctt caa atg aac agc ctg aga act gag gac acg gct gtg tat tac	288
Tyr Leu Gln Met Asn Ser Leu Arg Thr Glu Asp Thr Ala Val Tyr Tyr	
85 90 95	
tgt gcg aga gac agc cgt gca tac agc tat ggt tac ctc tac gtc ttt	336
Cys Ala Arg Asp Ser Arg Ala Tyr Ser Tyr Gly Tyr Leu Tyr Val Phe	
100 105 110	
gac tac tgg ggc cag ggc acc ctg gtc acc gtc tcc tca ggt gga ggc	384
Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly	
115 120 125	
ggt tca ggc gga ggt ggc tct ggc ggt ggc gga tcg cag tct gcc ctg	432
Gly Ser Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Ser Ala Leu	
130 135 140	
act cag cct gcc tcc gtg tct ggg tct cct gga cag tcg atc acc atc	480
Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile	
145 150 155 160	
tcc tgc act gga acc agc aat gat gtt ggg agt tat aac ctt gtc tcc	528
Ser Cys Thr Gly Thr Ser Asn Asp Val Gly Ser Tyr Asn Leu Val Ser	
165 170 175	
tgg tac caa caa cac cca ggc aaa gcc ccc aaa ctc ctg att tat gag	576
Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Glu	
180 185 190	
ggc agt aag cgg ccc tca ggg att tct aat cgc ttc tct ggc tcc aag	624
Gly Ser Lys Arg Pro Ser Gly Ile Ser Asn Arg Phe Ser Gly Ser Lys	
195 200 205	
tct ggc aac acg gcc tcc ctg acc atc tct ggg ctc cag gct gag gac	672
Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp	
210 215 220	
gag gct gat tat tac tgc atg tca tat acg agc agt ggc act cct tat	720
Glu Ala Asp Tyr Tyr Cys Met Ser Tyr Thr Ser Ser Gly Thr Pro Tyr	
225 230 235 240	
gtc ttc gga act ggg acc cag ctc acc gtt tta ggt gcg gcc gca	765
Val Phe Gly Thr Gly Thr Gln Leu Thr Val Leu Gly Ala Ala Ala	
245 250 255	

<210> SEQ ID NO 49  
 <211> LENGTH: 255  
 <212> TYPE: PRT  
 <213> ORGANISM: Escherichia coli

<400> SEQUENCE: 49

Glu Glu Val Gln Leu Val Glu Ser Gly Gly Asn Leu Val Gln Pro Gly	
1 5 10 15	
Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser Ser	
20 25 30	
Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp	
35 40 45	
Val Ser Ala Ile Ser Ala Ser Gly Gly Thr Thr Tyr Tyr Ala Asp Ser	
50 55 60	
Val Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu	
65 70 75 80	
Tyr Leu Gln Met Asn Ser Leu Arg Thr Glu Asp Thr Ala Val Tyr Tyr	
85 90 95	
Cys Ala Arg Asp Ser Arg Ala Tyr Ser Tyr Gly Tyr Leu Tyr Val Phe	
100 105 110	
Asp Tyr Trp Gly Gln Gly Thr Leu Val Thr Val Ser Ser Gly Gly Gly	
115 120 125	
Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Ser Ala Leu	
130 135 140	

-continued

Thr Gln Pro Ala Ser Val Ser Gly Ser Pro Gly Gln Ser Ile Thr Ile  
 145 150 155 160  
 Ser Cys Thr Gly Thr Ser Asn Asp Val Gly Ser Tyr Asn Leu Val Ser  
 165 170 175  
 Trp Tyr Gln Gln His Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Glu  
 180 185 190  
 Gly Ser Lys Arg Pro Ser Gly Ile Ser Asn Arg Phe Ser Gly Ser Lys  
 195 200 205  
 Ser Gly Asn Thr Ala Ser Leu Thr Ile Ser Gly Leu Gln Ala Glu Asp  
 210 215 220  
 Glu Ala Asp Tyr Tyr Cys Met Ser Tyr Thr Ser Ser Gly Thr Pro Tyr  
 225 230 235 240  
 Val Phe Gly Thr Gly Thr Gln Leu Thr Val Leu Gly Ala Ala Ala  
 245 250 255

<210> SEQ ID NO 50  
 <211> LENGTH: 768  
 <212> TYPE: DNA  
 <213> ORGANISM: Escherichia coli  
 <220> FEATURE:  
 <221> NAME/KEY: CDS  
 <222> LOCATION: (1)..(768)

<400> SEQUENCE: 50

gag gag gtg cag ctg gtg gag tct ggg gct gag gtg aag aag cct ggg 48  
 Glu Glu Val Gln Leu Val Glu Ser Gly Ala Glu Val Lys Lys Pro Gly  
 1 5 10 15  
 gcc tca gtg aga gtt tcc tgc cag gca tct gga tac aca ttc acc agg 96  
 Ala Ser Val Arg Val Ser Cys Gln Ala Ser Gly Tyr Thr Phe Thr Arg  
 20 25 30  
 tac cat ata cac tgg gtg cga cag gcc cct gga caa ggg ctt gag tgg 144  
 Tyr His Ile His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp  
 35 40 45  
 atg gga gtg atc gac ccc aat agt ggt aga ata agt tac tca cag aag 192  
 Met Gly Val Ile Asp Pro Asn Ser Gly Arg Ile Ser Tyr Ser Gln Lys  
 50 55 60  
 ttc cag gac aga gtc acc atg acc agg gac acg tcc acg agc aca gtc 240  
 Phe Gln Asp Arg Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val  
 65 70 75 80  
 tac atg gag ctg aac agc ctg aga tct gag gac aca gcc att tat tac 288  
 Tyr Met Glu Leu Asn Ser Leu Arg Ser Glu Asp Thr Ala Ile Tyr Tyr  
 85 90 95  
 tgt gcg aga gat cga gga tat tgt aat ggt ggc agg tgc ttt atg gat 336  
 Cys Ala Arg Asp Arg Gly Tyr Cys Asn Gly Gly Arg Cys Phe Met Asp  
 100 105 110  
 gca ttt gac tac tgg ggc cag ggg acc acg gtc acc gtc tcc tca ggt 384  
 Ala Phe Asp Tyr Trp Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly  
 115 120 125  
 gga ggc ggt tca ggc gga ggt ggc tct ggc ggt ggc gga tcg cag tct 432  
 Gly Gly Gly Ser Gly Gly Gly Gly Ser Gly Gly Gly Gly Ser Gln Ser  
 130 135 140  
 gtg ttg acg cag ccg ccc tca gcg tct ggg acc ccc ggg cag agg gtc 480  
 Val Leu Thr Gln Pro Pro Ser Ala Ser Gly Thr Pro Gly Gln Arg Val  
 145 150 155 160  
 acc atc gct tgt tct gga agc agc tcc aac atc gga att aat act gta 528  
 Thr Ile Ala Cys Ser Gly Ser Ser Ser Asn Ile Gly Ile Asn Thr Val  
 165 170 175  
 aac tgg tac cag cag atc cca gga acg gcc ccc aaa ctc ctc atc tat 576  
 Asn Trp Tyr Gln Gln Ile Pro Gly Thr Ala Pro Lys Leu Leu Ile Tyr





-continued

&lt;220&gt; FEATURE:

&lt;221&gt; NAME/KEY: CDS

&lt;222&gt; LOCATION: (1)..(744)

&lt;400&gt; SEQUENCE: 52

atg gag cag gtg cag ctg cag gag tct ggg gga ggc ttg gta cag cct 48  
 Met Glu Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Pro  
 1 5 10 15

ggg ggg tcc ctg aga ctc tcc tgt gca gcc tct gga ttc acc ttt agt 96  
 Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser  
 20 25 30

act tat gcc atg agc tgg gtc cgc cag gct cca ggg aag ggg ctg gag 144  
 Thr Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu  
 35 40 45

tgg gtc tca gtt att agt ggt agt ggt cat aca aca aac tac gcc gac 192  
 Trp Val Ser Val Ile Ser Gly Ser Gly His Thr Thr Asn Tyr Ala Asp  
 50 55 60

tcc gtg aag ggc cgc gtc acc ata tcc aga gac aat tcc aag aac aca 240  
 Ser Val Lys Gly Arg Val Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr  
 65 70 75 80

cta tat ctg caa atc aac agc ctg aga gcc gac gac acg gcc gtg tat 288  
 Leu Tyr Leu Gln Ile Asn Ser Leu Arg Ala Asp Asp Thr Ala Val Tyr  
 85 90 95

tac tgt gcg aga gat gtg tta gtc cta cag aat gct ttt gat atc tgg 336  
 Tyr Cys Ala Arg Asp Val Leu Val Leu Gln Asn Ala Phe Asp Ile Trp  
 100 105 110

ggc caa ggg acc acg gtc acc gtc tcc tca ggt gga ggt ggt tca ggc 384  
 Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly  
 115 120 125

gga ggt ggc tct ggc ggt ggc gga tcg gat gtt gtg atg acc cag tct 432  
 Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln Ser  
 130 135 140

cca tcc tca ctg tct gca tct gta gga gac aga gtc acc atc act tgt 480  
 Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys  
 145 150 155 160

cgg gcg agt cag ggt att agc agg tgg tta gcc tgg tat caa cag aaa 528  
 Arg Ala Ser Gln Gly Ile Ser Arg Trp Leu Ala Trp Tyr Gln Gln Lys  
 165 170 175

cca ggg aaa gcc cct aag ctc ctg atc tac gct gca tcc agt ttg caa 576  
 Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln  
 180 185 190

agt ggg gtc cca tca agg ttc agt ggc agt gga tct ggg aca gat ttc 624  
 Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe  
 195 200 205

act ctc acc atc agc agt ctg caa cct gaa gat ttt gca act tac atc 672  
 Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Ile  
 210 215 220

tgt caa cag agt tac agt agg ccg ctc act ttc ggc gga ggg acc aag 720  
 Cys Gln Gln Ser Tyr Ser Arg Pro Leu Thr Phe Gly Gly Gly Thr Lys  
 225 230 235 240

gtg gaa atc aaa cgt gcg gcc gca 744  
 Val Glu Ile Lys Arg Ala Ala Ala  
 245

&lt;210&gt; SEQ ID NO 53

&lt;211&gt; LENGTH: 248

&lt;212&gt; TYPE: PRT

&lt;213&gt; ORGANISM: Escherichia coli

&lt;400&gt; SEQUENCE: 53

Met Glu Gln Val Gln Leu Gln Glu Ser Gly Gly Gly Leu Val Gln Pro

-continued

1	5	10	15
Gly Gly Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Phe Thr Phe Ser	20	25	30
Thr Tyr Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu	35	40	45
Trp Val Ser Val Ile Ser Gly Ser Gly His Thr Thr Asn Tyr Ala Asp	50	55	60
Ser Val Lys Gly Arg Val Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr	65	70	75
Leu Tyr Leu Gln Ile Asn Ser Leu Arg Ala Asp Asp Thr Ala Val Tyr	85	90	95
Tyr Cys Ala Arg Asp Val Leu Val Leu Gln Asn Ala Phe Asp Ile Trp	100	105	110
Gly Gln Gly Thr Thr Val Thr Val Ser Ser Gly Gly Gly Gly Ser Gly	115	120	125
Gly Gly Gly Ser Gly Gly Gly Gly Ser Asp Val Val Met Thr Gln Ser	130	135	140
Pro Ser Ser Leu Ser Ala Ser Val Gly Asp Arg Val Thr Ile Thr Cys	145	150	155
Arg Ala Ser Gln Gly Ile Ser Arg Trp Leu Ala Trp Tyr Gln Gln Lys	165	170	175
Pro Gly Lys Ala Pro Lys Leu Leu Ile Tyr Ala Ala Ser Ser Leu Gln	180	185	190
Ser Gly Val Pro Ser Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe	195	200	205
Thr Leu Thr Ile Ser Ser Leu Gln Pro Glu Asp Phe Ala Thr Tyr Ile	210	215	220
Cys Gln Gln Ser Tyr Ser Arg Pro Leu Thr Phe Gly Gly Gly Thr Lys	225	230	235
Val Glu Ile Lys Arg Ala Ala Ala	245		

<210> SEQ ID NO 54  
 <211> LENGTH: 7  
 <212> TYPE: PRT  
 <213> ORGANISM: Escherichia coli

<400> SEQUENCE: 54

Ser Asn Ser Ala Ala Trp Ser  
 1 5

<210> SEQ ID NO 55  
 <211> LENGTH: 5  
 <212> TYPE: PRT  
 <213> ORGANISM: Escherichia coli

<400> SEQUENCE: 55

Ser Tyr Tyr Trp Ser  
 1 5

<210> SEQ ID NO 56  
 <211> LENGTH: 7  
 <212> TYPE: PRT  
 <213> ORGANISM: Escherichia coli

<400> SEQUENCE: 56

Gly Ser Ser Asn Tyr Trp Gly  
 1 5

-continued

<210> SEQ ID NO 57  
 <211> LENGTH: 18  
 <212> TYPE: PRT  
 <213> ORGANISM: Escherichia coli

<400> SEQUENCE: 57

Thr Arg Tyr Tyr Arg Ser Lys Trp Tyr Asn Asp Tyr Ala Leu Ser Val  
 1                   5                   10                   15

Lys Ser

<210> SEQ ID NO 58  
 <211> LENGTH: 16  
 <212> TYPE: PRT  
 <213> ORGANISM: Escherichia coli

<400> SEQUENCE: 58

Arg Ile Tyr Ala Ser Gly Arg Pro Lys Tyr Asn Pro Ser Leu Lys Ser  
 1                   5                   10                   15

<210> SEQ ID NO 59  
 <211> LENGTH: 16  
 <212> TYPE: PRT  
 <213> ORGANISM: Escherichia coli

<400> SEQUENCE: 59

Ser Ile His Tyr Ile Gly Thr Thr Tyr Tyr Asn Pro Ser Phe Lys Ser  
 1                   5                   10                   15

<210> SEQ ID NO 60  
 <211> LENGTH: 16  
 <212> TYPE: PRT  
 <213> ORGANISM: Escherichia coli

<400> SEQUENCE: 60

Ser Thr His Tyr Ile Gly Thr Thr Tyr Tyr Asn Pro Ser Phe Lys Ser  
 1                   5                   10                   15

<210> SEQ ID NO 61  
 <211> LENGTH: 18  
 <212> TYPE: PRT  
 <213> ORGANISM: Escherichia coli

<400> SEQUENCE: 61

Trp Lys Ala Phe Thr Ala Val Ala Gly Pro Asn Tyr Tyr Tyr Gly Met  
 1                   5                   10                   15

Asp Val

<210> SEQ ID NO 62  
 <211> LENGTH: 17  
 <212> TYPE: PRT  
 <213> ORGANISM: Escherichia coli

<400> SEQUENCE: 62

Val Tyr Ser Ser Ser Leu Thr Asp Phe Asp Tyr Tyr Tyr Gly Leu Asp  
 1                   5                   10                   15

Val

<210> SEQ ID NO 63  
 <211> LENGTH: 17  
 <212> TYPE: PRT  
 <213> ORGANISM: Escherichia coli

-continued

---

<400> SEQUENCE: 63

Val Cys Ser Ser Ser Leu Thr Asp Phe Asp Tyr Tyr Tyr Gly Leu Asp  
1 5 10 15

Val

<210> SEQ ID NO 64

<211> LENGTH: 9

<212> TYPE: PRT

<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 64

Arg Thr Arg Trp Cys Trp Phe Asp Pro  
1 5

<210> SEQ ID NO 65

<211> LENGTH: 5

<212> TYPE: PRT

<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 65

Asn Tyr Ser Leu Asn  
1 5

<210> SEQ ID NO 66

<211> LENGTH: 5

<212> TYPE: PRT

<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 66

Asn Tyr Ser Phe Asn  
1 5

<210> SEQ ID NO 67

<211> LENGTH: 5

<212> TYPE: PRT

<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 67

Ser Tyr Trp Ile Asp  
1 5

<210> SEQ ID NO 68

<211> LENGTH: 5

<212> TYPE: PRT

<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 68

Asn Tyr Trp Ile Asp  
1 5

<210> SEQ ID NO 69

<211> LENGTH: 5

<212> TYPE: PRT

<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 69

Ser Tyr Ala Met Asn  
1 5

<210> SEQ ID NO 70

<211> LENGTH: 17

<212> TYPE: PRT

<213> ORGANISM: Escherichia coli

-continued

---

<400> SEQUENCE: 70

Ala	Ile	Ser	Ser	Ser	Gly	Thr	Tyr	Arg	Phe	Tyr	Ala	Asp	Ser	Leu	Arg
1				5					10					15	

Gly

<210> SEQ ID NO 71

<211> LENGTH: 17

<212> TYPE: PRT

<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 71

Ala	Ile	Ser	Arg	Ser	Gly	Thr	Tyr	Arg	Phe	Tyr	Ala	Asp	Ser	Leu	Arg
1				5					10					15	

Gly

<210> SEQ ID NO 72

<211> LENGTH: 17

<212> TYPE: PRT

<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 72

Ile	Ile	Tyr	Pro	Asp	Asp	Ser	Asp	Thr	Arg	Tyr	Ser	Pro	Ser	Phe	Gln
1				5					10					15	

Gly

<210> SEQ ID NO 73

<211> LENGTH: 17

<212> TYPE: PRT

<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 73

Ser	Ile	Ser	Gly	Ser	Gly	Ile	Gly	Thr	Tyr	Tyr	Ala	Asn	Ser	Val	Gln
1				5					10					15	

Gly

<210> SEQ ID NO 74

<211> LENGTH: 13

<212> TYPE: PRT

<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 74

Asp	Leu	Gly	Asp	Leu	Glu	Trp	Leu	His	Ser	Pro	Asp	Pro
1				5					10			

<210> SEQ ID NO 75

<211> LENGTH: 13

<212> TYPE: PRT

<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 75

Asp	Leu	Gly	Asp	Leu	Asp	Trp	Leu	His	Ser	Pro	Asp	Pro
1				5					10			

<210> SEQ ID NO 76

<211> LENGTH: 10

<212> TYPE: PRT

<213> ORGANISM: Escherichia coli

<400> SEQUENCE: 76

Arg	Gly	Asp	Ser	Gly	Thr	Leu	Trp	Gly	Asp
1				5					10

-continued

<210> SEQ ID NO 77  
 <211> LENGTH: 13  
 <212> TYPE: PRT  
 <213> ORGANISM: Escherichia coli

<400> SEQUENCE: 77

Asp Glu Leu Asn Gln Leu Pro Gly Tyr Tyr Phe Asp Tyr  
 1                   5                           10

<210> SEQ ID NO 78  
 <211> LENGTH: 30  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: synthetic primer

<400> SEQUENCE: 78

gaggaagctt ccattaaacg ggtaaaatac 30

<210> SEQ ID NO 79  
 <211> LENGTH: 40  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: synthetic primer

<400> SEQUENCE: 79

tgcaatggcg gccgctaata ttgttctgga tattaccagc 40

<210> SEQ ID NO 80  
 <211> LENGTH: 72  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: synthetic primer

<400> SEQUENCE: 80

agcttctca tgtaggcggc cgcaggagac taaaagacg acgacgaaa acaccaccat 60

caccaccatt aa 72

<210> SEQ ID NO 81  
 <211> LENGTH: 72  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: synthetic primer

<400> SEQUENCE: 81

ggccttaatg gtggtgatgg tgggtgttgt cgtcgtcgtc tttgtagtct cctgcgggccg 60

cctacatgag ga 72

<210> SEQ ID NO 82  
 <211> LENGTH: 106  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: synthetic primer

<400> SEQUENCE: 82

agcttataaa ggaggaaatc ctcatgaaac agagcaccat cgcactggca ctggtaccgt 60

tactgttcac cccggttacc aaagcacgta ccatggtttc ccttgc 106

<210> SEQ ID NO 83

-continued

---

<211> LENGTH: 106  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: synthetic primer  
  
 <400> SEQUENCE: 83  
  
 ggccgcaagg gaaaccatgg tacgtgcttt ggtaaccggg gtgaacagta acggtaacag 60  
 tgccagtgcg atggtgctct gtttcatgag gatttcctcc tttata 106

<210> SEQ ID NO 84  
 <211> LENGTH: 39  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: synthetic primer  
  
 <400> SEQUENCE: 84  
  
 gtggtgatgg aattctttgt cgtcgctgtc tttgtagtc 39

<210> SEQ ID NO 85  
 <211> LENGTH: 40  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: synthetic primer  
  
 <400> SEQUENCE: 85  
  
 caccattaag gatcctaata ttgttctgga tattaccagc 40

<210> SEQ ID NO 86  
 <211> LENGTH: 40  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: primers  
  
 <400> SEQUENCE: 86  
  
 tctattctga attcgctgaa actggtgaaa gttgtttagc 40

<210> SEQ ID NO 87  
 <211> LENGTH: 38  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: primers  
  
 <400> SEQUENCE: 87  
  
 gccaatcgga attcctgcct caacctcctg tcaatgct 38

<210> SEQ ID NO 88  
 <211> LENGTH: 37  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: primer  
  
 <400> SEQUENCE: 88  
  
 gaactgggat ccttaagact ccttattacg cagtatg 37

<210> SEQ ID NO 89  
 <211> LENGTH: 50  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: primer



-continued

---

<400> SEQUENCE: 89  
 acccgtaagc ttataaagga ggaaatcctc atgaaataga gcaccatcgc 50

<210> SEQ ID NO 90  
 <211> LENGTH: 21  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: primer

<400> SEQUENCE: 90  
 tagccccctt attagcgttt g 21

<210> SEQ ID NO 91  
 <211> LENGTH: 24  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: primer

<400> SEQUENCE: 91  
 gtcacgtcgc gaatcgtcat ctgc 24

<210> SEQ ID NO 92  
 <211> LENGTH: 39  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: primer

<400> SEQUENCE: 92  
 tgtgcgaaaa gtaatgagtt tctttttgac tactggggc 39

<210> SEQ ID NO 93  
 <211> LENGTH: 24  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: primer

<400> SEQUENCE: 93  
 ctattgccta cggcagccgc tgga 24

<210> SEQ ID NO 94  
 <211> LENGTH: 58  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: primer

<400> SEQUENCE: 94  
 tccgccgaat accacatagg gcaaccacgg ataagaggag ttacagtaat agtcagcc 58

<210> SEQ ID NO 95  
 <211> LENGTH: 20  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: primer

<400> SEQUENCE: 95  
 tttcgcacag taatatacgg 20

<210> SEQ ID NO 96  
 <211> LENGTH: 18  
 <212> TYPE: DNA

-continued

---

<213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: primer  
  
 <400> SEQUENCE: 96  
  
 tatgtggtat tcggcgga 18  
  
 <210> SEQ ID NO 97  
 <211> LENGTH: 60  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: primer  
  
 <400> SEQUENCE: 97  
  
 acttcagctc cggacacccg tccggctccg ggttccaccg ctccgccggc tcacgggtgc 60  
  
 <210> SEQ ID NO 98  
 <211> LENGTH: 60  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: primer  
  
 <400> SEQUENCE: 98  
  
 cggagccgga cgggtgtccg gagctgaagt gacaccgtga gccggcggag cggtggaacc 60  
  
 <210> SEQ ID NO 99  
 <211> LENGTH: 23  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: primer  
  
 <400> SEQUENCE: 99  
  
 ctagttcgtc gggttcgtcg gga 23  
  
 <210> SEQ ID NO 100  
 <211> LENGTH: 19  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: primer  
  
 <400> SEQUENCE: 100  
  
 tcccgacgaa cccgacgaa 19  
  
 <210> SEQ ID NO 101  
 <211> LENGTH: 22  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: primer  
  
 <400> SEQUENCE: 101  
  
 ggacacggct gctgtattac tg 22  
  
 <210> SEQ ID NO 102  
 <211> LENGTH: 18  
 <212> TYPE: DNA  
 <213> ORGANISM: Artificial  
 <220> FEATURE:  
 <223> OTHER INFORMATION: primer  
  
 <400> SEQUENCE: 102  
  
 gctgaggaga cggtgacc 18

---

149

The invention claimed is:

1. An isolated or purified vector suitable for efficient selection and affinity maturation of a recombinant antibody[, the recombinant antibody having a leader peptide and being] encoded by a recombinant antibody coding sequence, 5 wherein

the vector comprises *a leader sequence encoding a leader peptide expressed with the recombinant antibody,*

*the vector further comprising at least one element able to reduce the expression level of said recombinant antibody,* the at least one element being selected from 10

a) a suppressed stop codon inside either the leader peptide or the recombinant antibody coding sequence;

b) a low-efficient promoter driving transcription of said recombinant antibody coding sequence; or

c) an inhibitor of the promoter driving transcription of said recombinant antibody coding sequence; and 15

wherein

the vector comprises a further element able to provide an efficient display of said recombinant antibody, the further element comprising: 20

a) a sequence coding for a carboxy-terminal part of a minor coat protein pill fused to the recombinant antibody coding sequence;

b) *a sequence coding for a leader peptide of the alkaline phosphatase of E. coli comprised as the leader [peptide of the recombinant antibody] sequence;* and 25

c) a coding sequence for the minor coat protein pill fused to the recombinant antibody coding sequence with no amber codon therebetween.

2. The vector according to claim 1 wherein the recombinant antibody includes: ScFv, active fragments of Abs, or humanized sequences of Abs.

3. The vector according to claim 1 wherein the vector is a plasmid, a phagemid or a phage.

4. The vector according to claim 1, said vector being a phagemid vector having the nucleotide sequence of SEQ ID NO: 1.

5. An in vitro host cell transformed with the vector according to claim 1.

6. A non-human host cell transformed with the vector according to claim 1.

7. The non-human host cell of claim 6, wherein the non-human host cell is a bacterial cell.

8. The vector of claim 1, wherein the vector is a DNA vector. 45

9. The in vitro host cell of claim 5, wherein the host cell is a bacterial cell.

10. *A method for improving selection and/or maturation of a recombinant antibody, the method comprising*

*cloning and expressing sequences encoding for recombinant antibodies with the vector according to claim 1; and*

150

*selecting a cloned and expressed recombinant antibody having an affinity for an antigen or target protein thus improving the selection and/or maturation of the recombinant antibody.*

11. *The method of claim 10, wherein the cloning and expressing comprises*

*constructing a phage display library for the recombinant antibody with the vector of claim 1 comprising the sequences encoding for the recombinant antibodies.*

12. *The method of claim 11, wherein the phage display library is selected from a synthetic or semi-synthetic antibody library, or a library mutated for affinity maturation of antibodies.*

13. *The method of claim 11, wherein the selecting comprises*

*performing affinity selection of the recombinant antibodies from the phage display library to obtain an affinity selected recombinant antibody having high affinity for the antigen or target protein.*

14. *The method of claim 11, wherein the phage display library -is a library mutated for affinity maturation of antibodies; and the selecting comprises*

*selecting a matured recombinant antibody from the library mutated for affinity maturation of antibodies, the matured recombinant antibody having an affinity for an antigen or target protein.*

15. *The method of claim 11, wherein the phage display library is a library mutated for affinity maturation of antibodies; and the selecting comprises*

*performing affinity selection of matured recombinant antibodies from the library mutated for affinity maturation of antibodies to obtain an affinity matured recombinant antibody having high affinity for an antigen or a target protein.*

16. *The method of claim 10, wherein the antigen or target protein is displayed on a cell.*

17. *The method of claim 10, wherein the sequences encoding for the recombinant antibodies comprise mutagenized sequences from an original sequence encoding for an original recombinant antibody.*

18. *The method of claim 10, wherein the sequences encoding for recombinant antibodies are derived from antibody producing cells.*

19. *The method of claim 18, wherein the antibody producing cells are Tumor Infiltrating Lymphocytes (TILs) or Peripheral Blood Lymphocytes (PBLs).*

20. *The method of claim 18, wherein the antibody producing cells are isolated from a tumor affected subject.*

21. *The method of claim 20, wherein the tumor affected subject is a breast cancer affected subject.*

\* \* \* \* \*